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Methods appendix to Measuring progress and projecting attainment 
based on past trends of the health-related Sustainable Development 
Goals in 188 countries: an analysis from the Global Burden of Disease 
Study 2016 
This appendix provides further methodological detail, supplemental figures, and more detailed 
results for the health-related Sustainable Development Goals. The appendix is organized into 
broad sections following the structure of the main paper. 
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Preamble 
This appendix provides methodological detail, supplemental figures and tables, and more detailed results 
for the health-related Sustainable Development Goals (SDGs). The appendix is organized into broad 
sections following the structure of the main paper. This study complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) recommendations, and this appendix is more 
comprehensive and encyclopedic than previous Global Burden of Disease appendices. It includes detailed 
tables, figures, indicator modeling write-ups and flowcharts, and information on data sourcing in an effort 
to maximize transparency in our estimation processes and provide a comprehensive account of analytical 
steps. Components of this document are the same as described in earlier GBD 2016 Capstone appendices 
but much more of this appendix are new text for the SDG Capstone. We intend this to be a living 
document, to be updated with each annual iteration of the Global Burden of Disease and in accordance 
with the 15 year timeline of the SDG cycle until their conclusion in 2030.  
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GATHER statement 
This study complies with the guidelines for Accurate and Transparent Health Estimates Reporting 
(GATHER) recommendations. We have documented the steps involved in our analytical procedures and 
detailed the data sources used in compliance with the Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER).  
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Methods Appendix Table 1. GATHER checklist of information that should be included in reports of global health estimates, with description of 
compliance and location of information for SDG Capstone 
# GATHER checklist item Description of compliance Reference 
Objectives and funding 
1 Define the indicators, populations, and time periods for which 
estimates were made. 
Narrative provided in paper and 
appendix describing indicators, 
definitions, and populations. 
Summary; Main text; Appendix Part 1. 
Sections 1-3; Supplementary Results 
2 List the funding sources for the work. Funding sources listed in paper. Main text 
Data Inputs 
For all data inputs from multiple sources that are synthesized as part of the study: 
3 Describe how the data were identified and how the data were 
accessed.  
Narrative description of data seeking 
methodology provided. 
Appendix Part 1. Sections 1-3 
4 Specify the inclusion and exclusion criteria. Identify all ad-hoc 
exclusions. 
Narrative about inclusion and exclusion 
criteria by data type provided. 
Appendix Part 1. Sections 1-3 
5 Provide information on all included data sources and their main 
characteristics. For each data source used, report reference 
information or contact name/institution, population represented, 
data collection method, year(s) of data collection, sex and age 
range, diagnostic criteria or measurement method, and sample 
size, as relevant.  
List of all data sources provided in 
submission materials; interactive, online 
data source tool that provides metadata 
for data sources by component, 
geography, cause, risk, or impairment has 
been developed. 
Appendix Part 3. Section 1. 
http://ghdx.healthdata.org/ 
There is a forthcoming custom data 
source tool with additional information 
on data sourcing for GBD and SDG 
capstone publications. 
6 Identify and describe any categories of input data that have 
potentially important biases (e.g., based on characteristics listed 
in item 5). 
Summary of known biases by cause 
included in methodological appendix. 
Appendix Part 1. Section 3 
For data inputs that contribute to the analysis but were not synthesized as part of the study: 
7 Describe and give sources for any other data inputs. Included in list of all data sources 
provided in submission materials, as well 
as online data source tool. 
http://ghdx.healthdata.org/ 
There is a forthcoming custom data 
source tool with additional information 
on data sourcing for GBD and SDG 
capstone publications. 
For all data inputs: 
8 Provide all data inputs in a file format from which data can be 
efficiently extracted (e.g., a spreadsheet as opposed to a PDF), 
including all relevant meta-data listed in item 5. For any data 
inputs that cannot be shared due to ethical or legal reasons, such 
Downloads of input data will be available 
through online tools, including data 
visualization tools and data query tools. 
Input data not available in tools will be 
made available upon request.  






as third-party ownership, provide a contact name or the name of 
the institution that retains the right to the data. 
Data analysis 
9 Provide a conceptual overview of the data analysis method. A 
diagram may be helpful.  
Flow diagrams of the overall 
methodological processes, as well as 
cause-specific modelling processes have 
been provided. 
Main text; Appendix Part 1. Section 3 
10 Provide a detailed description of all steps of the analysis, 
including mathematical formulae. This description should cover, 
as relevant, data cleaning, data pre-processing, data adjustments 
and weighting of data sources, and mathematical or statistical 
model(s).  
Flow diagrams and corresponding 
methodological write-ups for each cause 
and modelling processes have been 
provided. 
Appendix Part 1. Section 3 
11 Describe how candidate models were evaluated and how the final 
model(s) were selected. 
Provided in the methodological write-
ups.  
Appendix Part 1. Section 3 
12 Provide the results of an evaluation of model performance, if 
done, as well as the results of any relevant sensitivity analysis. 
Provided in the methodological write-
ups.  
Appendix Part 2 
13 Describe methods for calculating uncertainty of the estimates. 
State which sources of uncertainty were, and were not, 
accounted for in the uncertainty analysis. 
Provided in the methodological write-
ups.  
Appendix Part 1. Section 3 
14 State how analytic or statistical source code used to generate 
estimates can be accessed. 
Access statement provided. This will be available in an online 
repository that will be released upon 
publication of GBD 2016 Capstones. 
Results and Discussion 
15 Provide published estimates in a file format from which data can 
be efficiently extracted. 
GBD 2016 results will be made available 
through online data visualization tools, 
the Global Health Data Exchange, and the 
online data query tool. 
Supplementary Results 
16 Report a quantitative measure of the uncertainty of the estimates 
(e.g. uncertainty intervals). 
Uncertainty intervals are provided with 
all results. 
Main text; Supplementary Results 
17 Interpret results in light of existing evidence. If updating a 
previous set of estimates, describe the reasons for changes in 
estimates. 
Discussion of methodological changes 
between SDG rounds provided in the 
narrative of the paper and appendix. 
N/A 
18 Discuss limitations of the estimates. Include a discussion of any 
modelling assumptions or data limitations that affect 
interpretation of the estimates. 
Discussion of limitations provided in the 
narrative of the main paper as well as in 
the methodological write-ups in the 
appendix. 
Main text; Appendix Part 1. Section 3 
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Part 1. Health-related SDG indicators 
Section 1. Sustainable Development Goals overview  
In September 2015, the United Nations (UN) General Assembly established the Sustainable Development 
Goals (SDGs). The SDGs substantially broaden the development agenda beyond the MDGs and are 
expected to frame UN member state policies through 2030. In March 2017, the global SDG indicator 
framework was updated, now specifying 17 universal goals, 169 targets, and 232 indicators leading up to 
2030. Here we provide an analysis of 37 out of the 50 health-related SDG indicators based on data used 
and generated by the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016). 
Section 2. Health-related SDGs 
Health is a core dimension of the SDGs; the third SDG aims to “ensure healthy lives and promote 
wellbeing for all at all ages.” Health-related indicators are also present among ten of the other 16 goals. 
Across these 11 goals, there are 29 health-related targets with a total of 50 health-related indicators. 
Of the 50 health-related indicators included as part of the SDGs, estimates for 37 indicators, using 
consistent approaches built on systematic efforts to compile all available data, are included as part of the 
GBD study. In this paper, while acknowledging the continued debate about the structure and choices of 
SDG indicators, we use the GBD study to provide an assessment of the current status of these 37 health-
related SDG indicators, develop and compute a summary indicator of the health-related SDG indicators, 
and document historical trends. For GBD 2016, we produce projections based on past trends for the 
health-related SDGs through 2030 and examine projected attainment for defined SDG targets by 2030. 
The GBD study is an annual effort to measure the health of populations at national, and selected sub-
national levels, from 1990 to the most recent year (2016 for GBD 2016). The GBD study produces 
estimates of mortality and morbidity by cause, age and sex as well as that attributable burden to a 
selected set of major risk factors. Many of the 50 health-related SDG indicators are produced as part of 
the GBD. Elsewhere in this appendix, we outline the 10 SDGs, corresponding 24 health-related targets, 
and 37 health-related indicators included in this iteration of the GBD. Part 1. Section 3 of this appendix 
also further outlines the definition of each indicator used in analysis, as well as the estimation method 
and data sources.  
Direct outputs of the GBD study that are health-related SDG indicators include mortality rates 
disaggregated by age (under-5 and neonatal) and cause (maternal, cardiovascular diseases, cancers, 
diabetes, chronic respiratory diseases, road injuries, self-harm, unintentional poisonings, exposure to 
forces of nature, interpersonal violence, and conflict and terrorism) as well as measures of disease 
incidence (HIV, malaria, tuberculosis [TB], hepatitis B) and prevalence (neglected tropical diseases 
[NTDs]). The GBD risk factor analysis includes measurement of exposure prevalence included as health-
related SDG indicators (under-5 stunting, wasting and overweight; tobacco smoking; harmful alcohol use; 
intimate partner violence; unsafe water, sanitation, and hygiene [WaSH]; household air pollution; and 
ambient particulate matter) as well as deaths or disease burden attributable to risk factors selected as 
health-related SDG indicators (WaSH, household and ambient air pollution, and occupational risks). In 
addition, a number of measures of intervention coverage, including skilled birth attendance, antenatal 
care, in-facility delivery rates, met need for family planning with modern methods, antiretroviral therapy, 
and coverage of several vaccines are produced within the GBD study. 
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As noted in Table 1 in the main manuscript, for selected SDG indicators, we made modifications to the 
definition for clarity and/or based on the definition used in GBD. For example, Indicator 2.2.2 proposes to 
measure of malnutrition that combined prevalence of wasting and overweight among children under 5. 
As childhood wasting and overweight have very different determinants, effects on health outcomes, and 
interventions, we have selected to report them separately. For childhood overweight, we report 
prevalence among children aged 2 to 4 years, the definition used in GBD based on thresholds set by the 
International Obesity Task Force (IOTF). 
 
Four indicators have been added for the GBD 2016 analysis: vaccine coverage (Indicator 3.b.1); two 
violence indicators (prevalence of physical or sexual violence [16.1.3] and childhood sexual abuse 
[16.2.3]); and well-certified death registration (17.19.2c). Further, we have expanded the measurement 
of the universal health coverage (UHC) indicator (3.8.1) to represent a broader range of essential health 
services. This was achieved by including risk-standardized death rates from 32 causes considered 
amenable to personal healthcare – that is, deaths from these causes should not occur in the presence of 
high-quality healthcare. 
 
Further details on the estimation used for all indicators, compliant with Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER), are included in Appendix Part 1. Section 3. Indicator-
specific estimation. 
 
Section 3. Indicator-specific estimation 
The indicator-specific modeling write-ups follow the order of the SDG goals, targets, and indicators 
established by the UN. In some cases, multiple indicators were addressed in a single write-up, for 
example mortality due to natural disasters (SDG indicators 1.5.1, 11.5.1, and 13.1.1) are included in a 
single write-up along with mortality due to conflict and terrorism (16.1.2). In other cases, particular 
measures may be present in multiple indicators (e.g., mortality due to cardiovascular diseases are 
included in SDG indicators 3.4.1 and 3.8.1); in these cases, we refer include these model write-ups for one 
indicator, and reference that indicator write-up as needed elsewhere. 
 
The organization of this section is as follows: 
 
Natural disaster mortality (1.5.1, 11.5.1, 13.1.1), conflict and terrorism mortality (16.1.2) 
Child stunting (2.2.1) and child wasting (2.2.2a) 
Child overweight (2.2.2b) 
Maternal mortality ratio (3.1.1.) 
Skilled birth attendance (3.1.2, also in the UHC index [3.8.1]) 
Under-5 mortality (3.2.1), neonatal mortality (3.2.2) 
HIV incidence (3.3.1) 
TB incidence (3.3.2) 
Malaria incidence (3.3.3) 
Hepatitis B incidence (3.3.4) 
NTD prevalence (3.3.5) – includes 15 individual NTDs 
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NCD mortality (3.4.1) - includes cardiovascular diseases, cancers, diabetes, and chronic respiratory 
diseases 
Self-harm mortality (3.4.2), road injury mortality (3.6.1), unintentional poisonings mortality (3.9.3), 
interpersonal violence mortality (homicide) (16.1.1) 
Alcohol use (3.5.2) 
Met need for family planning with modern methods (3.7.1, also in the UHC index [3.8.1]) 
Adolescent birth rate (3.7.2) 
Universal health coverage (UHC) index (3.8.1) –  includes coverage of three childhood vaccines, 
antenatal care (1 and 4 visits), in-facility delivery rate, antiretroviral therapy coverage, and risk-
standardized death rates from causes amenable to healthcare (3.8.1) 
Mortality attributable to household air pollution and ambient air pollution (3.9.1), household air 
pollution (7.1.2), and mean PM2.5 (11.6.2) 
Mortality attributable to WaSH (3.9.2), water (6.1.1), sanitation (6.2.1a), access to handwashing facility 
(6.2.1b) 
Smoking prevalence (3.a.1) 
Vaccine coverage (3.b.1) 
Prevalence of intimate partner violence (5.2.1) 
DALY rates attributable to occupational risks (8.8.1) 
Prevalence of physical or sexual violence (16.1.3) 
Child sexual abuse (16.2.3) 
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This modeling strategy encompasses indicators associated with mortality due to exposure to forces of 
nature (natural disasters): 1.5.1, 11.5.1, 13.1.1; and mortality due to conflict and terrorism: 16.1.2. 
Indicator 1.5.1 
As a component of SDG Goal 1. End poverty in all its forms everywhere, SDG Target 1.5., by 2030, build 
the resilience of the poor and those in vulnerable situations and reduce their exposure and vulnerability 
to climate-related extreme events and other economic, social and environmental shocks and disasters, 
is measured using SDG Indicator 1.5.1, deaths due to exposure to forces of nature per 100,000. 
Indicator 11.5.1 
As a component of SDG Goal 11. Make cities and human settlements inclusive, safe, resilient and 
sustainable, SDG Target 11.5, by 2030, significantly reduce the number of deaths and the number of 
people affected and substantially decrease the direct economic losses relative to global gross domestic 
product caused by disasters, including water-related disasters, with a focus on protecting the poor and 
people in vulnerable situations, is measured using SDG Indicator 11.5.1, deaths due to exposure to 
forces of nature per 100,000. 
Indicator 13.1.1 
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As a component of SDG Goal 13. Take urgent action to combat climate change and its impacts, SDG 
Target 13.1, strengthen resilience and adaptive capacity to climate-related hazards and natural 
disasters in all countries, is measured using SDG Health Index Indicator 13.1.1, deaths due to exposure 
to forces of nature per 100,000. 
Indicator 16.1.2 
As a component of SDG Goal 16. Promote peaceful and inclusive societies for sustainable development, 
provide access to justice for all and build effective, accountable and inclusive institutions at all levels, 
SDG Target 16.1, significantly reduce all forms of violence and related death rates everywhere, is 
measured using SDG Indicator 16.1.2, deaths due to conflict and terrorism per 100,000. 
Overall 
Input data for fatal discontinuities are compiled a range of sources, including country vital registration 
(VR) data; international databases that capture several cause-specific fatal discontinuities; and 
supplemental data in the presence of known issues with data quality or representativeness, or time lags 
in reporting. A systematic literature review was not used to identify input data for fatal discontinuities, 
though some literature sources were identified through online supplemental research. Below we 
provide more detail on the different input data sources by sub-causes of fatal discontinuities. 
Subnational locations and population splitting 
In locations where we produced estimates at the subnational level for GBD 2016, deaths due to all fatal 
discontinuity causes were assigned to the relevant subnational location(s) when that information could 
be obtained either through country data sources (e.g., VR) or through additional online research. If no 
subnational location could be found, the deaths were split proportionally by population across all 
subnational locations.  
In locations that have experienced boundary changes or split from other locations that we currently 
estimate (e.g., the former Yugoslavia, Czechoslovakia, the Soviet Union, Sudan and South Sudan), we 
split deaths due to events that occurred prior to boundary changes proportionally based on the 
populations residing within the boundaries of present-day locations unless we found documentation 
that clearly indicated whether the event and corresponding deaths occurred in one of the present-day 
GBD 2016 locations. 
Locations with 4- or 5-star data quality ratings 
For countries and territories assigned 4- or 5-star data quality ratings (see Section 2 of the appendix for 
details), we prioritized data from country-specific vital registration. VR data for fatal discontinuities was 
exclusively used in 4- and 5-star locations unless there was well-known data quality issues or 
discrepancies in the cause of death data reporting related to a particular event (e.g., supplemental 
death data for Louisiana was used for Hurricane Katrina because of established data reporting issues). 
The process for identification of location-year fatal discontinuities is described more in the Modelling 
strategy below. 
Locations with less than 4-star data quality ratings 
For countries and territories assigned data quality ratings below 4 stars, we compared VR with data 
available from alternative sources for Exposure to forces of nature, taking the highest death estimate 
11
available from all sources. For other fatal discontinuity causes, we disregarded lower quality VR and 
used well-established databases by type of fatal discontinuity. Whenever specific events were identified 
that did not have corresponding data points within these databases, we used supplemental data 
sources, including scientific literature.  
Major data sources other than country VR for each fatal discontinuity cause follow. 
Conflict and terrorism. Data for conflict and terrorism come from the Uppsala Conflict Data Program 
(UCDP), International Institute for Strategic Studies, and Robert S. Strauss Center for International 
Security and Law. The table below provides details about the various datasets we utilized from these 
sources, the dates they were last accessed, and the years for which we used the data provided. 
Supplemental online research was conducted for recent conflicts where the databases above were not 
up-to-date. In addition, deaths due to conflict and terrorism in Iraq from 2003 to present were 
estimated using a combination of supplemental sources. The source found with the lowest number of 
Data source name Date 
accessed 
Years of data 
downloaded 
Type of data included 
Uppsala Conflict Data Program1 
Battles 10/6/16 1989-2015 Armed conflict: incompatibility that concerns 
government and/or territory over which the use of 
armed force between the military forces of two 
parties, of which at least one is the government of a 
state, which resulted in deaths 
Non-state 10/6/16 1989-2015 The use of armed force between two organized 
armed groups, neither of which is the government of 
a state, which results in deaths 
One-sided 10/6/16 1989-2015 The use of armed force by the government of a state 
or by a formally organized group against civilians 
which results in deaths 
Georeferenced Event 
Dataset 
10/6/16 1989-2015 UCDP battles, non-state, and one-sided conflict 
deaths with the most disaggregated location 
information available 
PRIO Battles Deaths 
Dataset 
10/6/16 1970-1988 Armed conflict (civil wars, etc.) 
International Institute for Strategic Studies 
Armed Conflict Dataset 10/6/16 1997-Present Insurgency, Inter-state, Intra-state conflict deaths 
Robert S. Strauss Center For International Security And Law 
Armed Conflict Location 
and Event Dataset (ACLED) 
10/6/16 1997-2016 Actions of opposition groups, governments, and 
militias in selected locations in Africa and Asia, 
specifying the exact location and date of battle 
events, transfers of military control, headquarter 
establishment, civilian violence, and rioting 
Social Conflict Analysis 
Database (SCAD) 
10/6/16 1990-2016 Protests, riots, strikes, inter-communal conflict, 
government violence against civilians, and other 
forms of social conflict (covers Africa and Latin 
America) 
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deaths, Iraq Body Count2, was used as the lower bound of the uncertainty interval from 2003 to 2016. 
Estimates from the Iraq Mortality Study by Hagopian et al3 from 2003 to 2006, the deadliest years of the 
war, were used to scale deaths to generate the upper uncertainty interval limits using the following 
formula:  
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑ℎ𝑠𝑠𝐺𝐺𝐺𝐺𝐺𝐺 2016,   ℎ𝑖𝑖𝑖𝑖ℎ =  𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑ℎ𝑠𝑠𝐼𝐼𝐺𝐺𝐼𝐼 ∙ �𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑ℎ𝑠𝑠𝐼𝐼𝐼𝐼𝐼𝐼𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑ℎ𝑠𝑠𝐼𝐼𝐼𝐼𝐼𝐼�2003−2006  
We used the average ratio between IMS and IBC reported deaths between 2003 and 2006, multiplied by 
the number of deaths reported by the IBC. This high estimate is carried forward through 2016 under the 
assumption that the Iraq Body Count similarly undercounts the number of deaths due to the ongoing 
civil war in Iraq. The final, best estimate for conflict and terrorism deaths in Iraq from 2003 to 2016 is 
the midpoint of the high and low estimates given above. 
We identified four major conflicts that were not represented in these databases: 1997 civil conflict in 
Albania4; 1971 genocide in Bangladesh5; 1972 genocide in Burundi6; and 1993 genocide in Burundi6. In 
these cases, we used literature sources in order to account for these fatal discontinuities.  
For country-years where multiple sources provided estimates, we prioritized sources in the following 
order: (1) country VR data, if death estimates were highest of all sources; (2) UCDP; (3) IISS; (4) country 
VR if death estimates were not the highest of all sources; (5) Robert Strauss Center; (6) online 
supplemental research. 
Exposure to forces of nature, other injury causes, and protein-energy malnutrition. The Centre for 
Research on the Epidemiology of Disasters’ International Disaster Database (EM-DAT) served as the 
primary non-VR source of fatal discontinuities due to exposure to forces of nature (i.e., natural 
disasters); other transport injuries (e.g., plane, train, and boat accidents); poisonings; fire, heat, and hot 
substances; other exposure to mechanical forces (eg, building collapse); and protein-energy malnutrition 
(ie, famine or severe drought). Data from EM-DAT were last accessed March 29, 2017. Supplemental 
online research was conducted for events where EM-DAT was not up-to-date. 
For country-years where multiple sources provided estimates, we prioritized sources in the following 
order: (1) country VR data, if data quality rating is 4 or 5 stars; (2) country VR data if data quality rating is 
less than 4 stars and death estimates were highest of all sources; (3) EM-DAT; (4) online supplemental 
research. Exceptions were made where it was clear that VR systems had been compromised by the 
event being measured.  
Meningococcal meningitis and diarrheal diseases. New to GBD 2016, we sought to include fatal 
discontinuities due to a subset of infectious diseases: meningococcal meningitis (or meningococcal 
infection) and diarrheal disease caused by cholera. These two infectious diseases were included on the 
fatal discontinuity cause list for GBD 2016 because (1) their current modelling strategies with the Cause 
of Death Ensemble model (CODEm) does not optimally capture the potentially highly variable – or 
epidemic – mortality levels and trends characteristic of these two causes; and (2) they can contribute to 
significant total fatalities in a given location-year. Other infectious diseases for which the latter is true – 
high death rates in the presence of an outbreak or epidemic – are currently modelled with alternative 
cause of death methods (eg, natural history models for measles and yellow fever), which allow for 
greater variation year-over-year if or when outbreaks occur. In future iterations of the GBD, we plan to 
revisit the inclusion criteria for infectious diseases as fatal discontinuities and develop more of an 
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ensemble approach to modelling causes that can be both endemic (and thus result in more uniform 
levels and trends over time) and epidemic (and subsequently lead to rapid increases – and decreases – 
in deaths for a given location-year).  
The Global Infectious Diseases and Epidemiology Network (GIDEON) served as the primary data source 
for collating cholera and meningococcal meningitis or meningococcal infection death reports.7,8 For any 
year in which cholera or meningococcal meningitis deaths were recorded in a country or territory 
covered by the GBD, we directly extracted reported deaths from 1970 to 2016. When there were 
reporting gaps in cholera or meningococcal meningitis deaths over this period of time and the World 
Health Organization (WHO) annual cholera or meningitis reports had death reports for those years, we 
used the WHO reports. The primary exception were two major cholera outbreaks in Bangladesh – 1982-
1983 and 1991 – which were not captured by either GIDEON or WHO. As result, we used the EM-DAT 
records for the 1982-1983 outbreak and literature for the 1991 outbreak.9  
Ebola. Since GBD 2015, outbreaks due to Ebola virus disease have been estimated using the data and 
methods described in the Ebola write-up of this appendix and included in GBD death estimates in the 
same way as other fatal discontinuity causes.  
 
Modelling strategy  
All input data for fatal discontinuity causes were run through the causes of death data formatting and 
mapping process.  
VR de-duplication 
For country-years where deaths due to fatal discontinuity causes were recorded in both VR and other 
utilized data sources, the higher of the two estimates were taken in the case of deaths due to conflict 
and terrorism and exposure to forces of nature.  
For the other injury causes that also have a CODEm model, a process was established to avoid 
duplication of fatal discontinuity deaths in the two models. First, location-years with death data from 
non-VR sources were identified. If these location-cause-years also had VR death estimates that were 
greater than 40% higher than the immediately surrounding years and could be linked to a specific fatal 
discontinuity event, these years were marked as outliers in the VR data and the difference between the 
outlier year and the average of the surrounding years was included in the relevant cause in the fatal 
discontinuities database. The deaths from the identified events were subtracted from the all-cause VR 
estimates used in the all-cause mortality estimation process.  
Uncertainty analysis for input and draw-level input to age-sex splitting 
Uncertainty intervals for deaths due to conflict and terrorism were generated using UCDP high and low 
death estimates, except in the case of Iraq 2003-2016, as explained above. In cases where low and high 
estimates were not included in the available data, the regional average uncertainty interval was applied 
to the available death estimate across all fatal discontinuity causes.  
We assumed a normal distribution using the mean deaths and standard deviation based on high and low 
estimates. The standard deviation was capped at the mean divided by 1.96 in order to ensure that 95% 
of the 3,000 draws generated were greater than zero. Non-positive draws were dropped, and 1,000 
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draws were sampled from the remaining set of positive draws. These 1,000 positive draws were used for 
final calculations of means and uncertainty intervals. 
Age-sex splitting 
All compiled data were run through the causes of death age-sex splitting process. 
Changes from GBD 2015 
GBD 2016 saw an effort to systematize the collection of up-to-date fatal discontinuity data through 
supplemental online research. New tools included expanded use of web scraping and online media 
tracking. This process resulted in a more comprehensive set of conflict and terrorism data for 2016, as 
well as large natural disasters not contained in EM-DAT or VR.  
In previous rounds of GBD, deaths due to executions and police conflict were included with conflict and 
terrorism. In GBD 2016, these causes were separated and estimated separately from the overarching 
war and conflict cause group using a CODEm model, as described in this appendix. 
We added two epidemic infectious diseases, cholera and meningococcal meningitis, to the list of fatal 
discontinuities in an effort to better capture the large variations in mortality that these causes can incur.  
We removed the absolute death threshold for fatal discontinuities and limited our inclusion criteria to 
an event exceeding a mortality rate threshold per location-year. We view this revision as an 
improvement for estimating the effects of fatal discontinuities in subnational locations and countries 
with smaller populations, as an absolute threshold of 10, 20, or 50 deaths would ultimately omit events 
in these places. 
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݉௖ሺݐሻ ൌ ܺߚ ൅ ݄ሺݎ௖,௧ሻ 
where ܺߚ is a linear model and ݄ሺݎ௖,௧ሻ is a smoothing function for the residuals; and ݎ௖,௧ is derived from 
the linear model. The following linear model was used for estimating SBA: 



























































































































































































































































































ହ݉଴௖௬௦ ൌ expሾሺߚଵ ൅	ߛଵ௖ሻ ∗ log൫ܮܦܫ௖௬൯ ൅ ሺߚଶ ൅	ߛଶ௖ሻ ∗ ݁݀ݑܿܽݐ݅݋݊௖௬ ൅ ߛ௖ ൅ ߛ௖௦ 	൅ ߙ௧ሿ ൅





























݆ܽ݀ݑݏݐ݁݀ହ݉଴,௖௬௦ ൌ expሾሺߚଵ ൅	ߛଵ௖ሻ ∗ log൫ܮܦܫ௖௬൯ ൅ ሺߚଶ ൅	ߛଶ௖ሻ ∗ ݁݀ݑܿܽݐ݅݋݊௖௬ ൅ ߛ௖ ൅ ߛ௥௘௙,௖ ൅












































μ୲ ൌ fሺtሻ ൅ S୲ 






















































































































































































	ቀ ୑ୟ୪ୣ	 ௤బఱ	୊ୣ୫ୟ୪ୣ	 ௤బఱ	 ቁ୨୧୲ ൌ β
෠ ൅ γᇱ ௤బఱ	 	ୠ୧୬ ቀ ݍ଴ହ	 ୨୧୲ቁ ൅ γො୨ ൅ γො୧	
The male and female 5q0 values are found using the system of equations that includes the model above 
and equation below, where rbirth is the sex‐ratio at birth. 
ݍ଴ହ	 ൌ ቀ ଵଵା୰ౘ౟౨౪౞ቁ ∗ ሺfemale ݍ଴ହ















logሺPrሺdeath	at	age	y|u5	deathሻ୨୧୲ሻ ൌ βଵ ൅ βଶ ∗ ܪܫ ௜ܸ௧ ൅ βଷ ∗ ܯܽݐ. ܧ݀.௜௧൅ βସ ∗ ܥ݋݉݌݈݁ݐ݁݊݁ݏݏ௦௜௧ ൅




on 5q0 bin (γො′ ௤బఱ	 	ୠ୧୬ሺ ݍ଴ହ	 ୨୧୲ሻ), a coefficient on the under‐5 crude death rate from HIV (β෠ଶ), a coefficient on
maternal education (β෠ଷ), and a coefficient on completeness (β෠ସ): 








































ݍ௘௡௡ ൌ Prሺ݀݁ܽݐ݄	݅݊	݁݊݊	| ݑ5	݀݁ܽݐ݄ሻ ∗ 5ݍ0 























































































































































































































































































































































































































































































݊ୟୢ୨୳ୱ୲ୣୢ௧ି௜ ൌ ߙ௧ି௜ ∗ ݊௧ି௜ 
ܸܴ௧ is the number of HIV/AIDS deaths in year ݐ from ST‐GPR, and ܦݐ is the number of HIV/AIDS deaths 
from the first run of Spectrum. In the second equation, ݀ݐݐെ݅ is the number of HIV/AIDS deaths among 








































































































































































































































































































































































































































































































































































Covariate  Parameter  Beta (95% CI)  Exponentiated beta (95% 
CI) 
Smear positive TB  Prevalence  ‐0.75    0.47 (0.47 — 0.47) 
Sex (male)  Prevalence  0.51  1.66 (1.55 — 1.79) 

















HAQ (log‐transformed)  Excess mortality  ‐1.58  0.21 (0.19 — 0.22) 


























ܲ݊݋ܪܫ ௖ܸ,௬,௔,௦ ൌ ܯܦܴ௖,௬
ቆ1 ൅ ൬ܴܴ ܪܫܸܶܤ௖,௬,௔,௦ܶܤ݊݋ܪܫ ௖ܸ,௬,௔,௦൰ቇ	ܶܤ݊݋ܪܫ ௖ܸ,௬,௔,௦
 
 
where ܯܦܴ௖,௬	is  the  number  of  all MDR‐TB  cases  among HIV‐positive  and HIV‐negative  individuals  by 












































































































































































































































































































































ܲሺܿܽݎݎ݅݁ݎ	|	ܽ݃݁ ൑ 6	݉݋݊ݐ݄ݏሻ ൌ 	0.885 
 
ܲሺܿܽݎݎ݅݁ݎ	|	6	݉݋݊ݐ݄ݏ	 ൑ ܽ݃݁ ൏ 25	ݕ݁ܽݎݏሻ ൌ 	 ݁ି଴.଺ସହ	ൈ௔௚௘బ.రఱఱ  
 






























































Reported cases + 
undetected cases
Disease duration from literature:
6 months treated
3 years untreated





























Input Data & Methodological Summary 
Case Definition 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a vector-borne disease which 
is transmitted by the bite of the tsetse fly. It is caused by the parasite Trypanosoma brucei with two 
subspecies, namely T.b. rhodesience (makes up less than 5% of total HAT cases) and T.b. gambiense. 
Cases are diagnosed through laboratory methods which rest on finding the parasite in body fluid or 
tissue by microscopy. In highly endemic or epidemic areas where the likelihood of false positives in 
serological tests is deemed lower, a seropositive individual is considered affected even in the absence of 
parasitological confirmation. The ICD-10 codes for HAT are B56.0, B56.1 and B56.9. 
Input data 
Model inputs 
The input data for GBD 2016 included a) population at risk estimates from GBD 2010 ArcGIS analysis 
using geocoded case notifications for 2000 to 2009 [1] and population Count Grid estimates from 
Gridded Population of the World 3 [2, 3], b) population screened from 1997 to 2004 [4], c) historical 
data from GBD 2010 on total number of HAT cases reported [1, 4, 5], and d) cases reported annually to 
WHO [6] – for Kenya, a study on cases reported subnationally [7] was used to split the national cases 
into five counties (HomaBay, Migori, Busia, Bungoma, Kakamega). A systematic review of literature was 
conducted in PubMed on 8/10/2016 using the following search string:  
((African trypanosomiasis[Title/Abstract] AND incidence[Title/Abstract]) AND (“2009”[Date – 
Publication] : “2013”[Date – Publication])).  
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 This yielded 72 studies of which only four met the inclusion criteria and were extracted. The inclusion 
criteria were: 
1. Studies representative of the national population 
2. Population-based studies 
3. Studies with primary data on incidence 
4. Studies of human African trypanosomiasis only (excluded studies on animal African 
trypanosomiasis) 
 
The four studies extracted had national incidence data similar to the ones extracted from WHO [6]. 
Therefore, three studies with age-specific incidence data from active screening undertaken in the 
Democratic Republic of Congo [8] and Uganda [9, 10] were used to inform age pattern for incidence and 
prevalence. Location-years with missing reported cases were excluded and five subnational locations for 
Kenya were added. The table below shows the number of studies included, and the number of countries 
or subnational units and GBD world regions represented. 
 incidence  
Studies 2 
Countries/subnationals 34 
GBD world regions 4 
 
Severity splits/sequelae 
The basis of the GBD disability weight (DW) survey assessments are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights 
for sequelae due to HAT are shown below. 
Sequela Lay description DW (95% CI) 
Skin 
disfigurement, 
level 1   
Has a slight, visible physical deformity that is sometimes 
sore or itchy. Others notice the deformity, which causes 







Cannot move around without help, and cannot lift or 
hold objects, get dressed or sit upright. The person also 
has very low intelligence, speaks few words, and needs 




The non-fatal model for HAT involved estimating prevalence from incidence. First, a multi-level mixed-
effects linear regression of natural log-transformed incidence rate (ratio of HAT cases reported to 
population at risk) on natural log-transformed screening coverage (ratio of number screened for HAT to 
population at risk), with country random effects, was performed. Gaps were then filled using 
exponential interpolation between years and extrapolation from 2014 to 2015 for reported cases; for 
screening coverage only extrapolation from 2014 to 2015 was done. Then 1,000 draws of mortality 
among treated cases were generated, assuming that 0.7%–6.0% of all treated (reported) cases die [11, 
12, 13]. 
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Using the mean and variance-covariance matrix from the regression as parameters, a multivariate 
normal distribution was used to generate 1,000 draws of case detection rate (CDR), given the expected 
screening coverage. Undetected deaths were then estimated as the difference between the ratio of 
reported cases to CDR and reported cases (reported cases/CDR – reported cases). Estimates of incidence 
were obtained by adding the reported cases to the undetected cases. Without information on sex-
specific incidence, equal incidence rates between both sexes was assumed. Finally, an age-pattern was 
applied to the incidence estimates using the incidence studies from DRC and Uganda [8, 9, 10]. 
Assuming the same proportion in treated and untreated cases, the incidence estimates were then split 
into the two sequelae, skin disfigurement and sleeping disorder. This was done by generating 1,000 
draws of the splitting proportion for the sequelae (70%–74% with sleeping disorder) based on a study 
that reported presence of symptoms at admission of patients in treatment centers [14] – draws were 
generated from a beta distribution with alpha parameter = 1884 and beta parameter = 649. 
To compute prevalence of HAT, 1,000 draws of total duration of symptoms in untreated cases was 
generated from a normal distribution with mean = {ln(3) – 0.5 * sigma^2}, and standard deviation = 
sigma, where sigma = {ln(4.39)-ln(1.92))/(invnormal(0.975)*2)} – these parameters were based on a 
study of T.b. gambiense [14] which estimated an average duration of three years to untreated cases. An 
estimated duration of six months was applied to cases that received treatment, based on findings from a 
paper about T.b. rhodesiense in Uganda [12]. Prevalence was then estimated from the incident cases 
before applying age pattern. Prevalence of treated and untreated cases was summed up, assuming that 
untreated cases have been prevalent up to their death for a certain duration. For untreated cases, it was 
assumed that half the duration is spent with sleeping disorder (severe motor and cognitive impairment) 
and disfigurement [14]. Treated (ie, reported) cases are assumed to have been prevalent for 0.5 years, 
and for the fraction of treated cases that present with sleeping disorder, it was assumed that this is 
present for half the total duration and that the rest of the duration is spent suffering from disfiguring 
skin disease. Treated cases that don’t present with sleeping disorder were assigned disfigurement for 
the entire duration. Lastly, an age-pattern using a cubic spline was applied to the prevalence estimates 
using the incidence studies from DRC and Uganda [8, 9]. 
Results from the model were assessed by visualizing time trends of incident and prevalent cases across 
locations and age (similar trends were applied in both sexes). Maps of the global distribution of HAT and 
the two sequelae were also generated. In addition, the estimated incident cases were compared with 
the cases reported to the WHO across time – as expected, the estimates from GBD 2015 were higher 
than the WHO numbers because we accounted for undetected cases. 
Changes from GBD 2013 included: a) inclusion of new data on reported cases from WHO [6] (years 2013 
and 2014 for 23 locations), b) inclusion of the following country (years) based on available historical data 
post-1980: Botswana (1983), Ethiopia (1980–1983), Guinea-Bissau (1980–1983, 1985–1987), Rwanda 
(1980, 1982–1988), and Sierra Leone (1981–1982), c) adding five subnational locations (out of 49) for 
Kenya, thus correcting the age-split proportion such that a 0.32/0.68 proportion was used for 
adults/children – in GBD 2013, this proportion was 0.25/0.75 for adults/children. 
Changes from GBD 2015 to GBD 2016 
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Chagas disease is defined by infection with the protozoa Trypanosoma cruzi, which is transmitted by 
Triatominae insect vectors (most common), blood transfusion, organ transplant, and congenital 
transmission. It includes an acute phase corresponding with the time of infection, and is typically 
asymptomatic. Chronic infection may be latent (ie, asymptomatic), or result in cardiovascular or 
digestive sequelae. It includes all ICD-10 codes under the heading B57 (Chagas disease), with codes 
B57.0-B75.1 corresponding to the acute phase, B57.2 corresponding to chronic cardiovascular sequelae, 
and B57.3 corresponding to chronic digestive sequelae.  
Input data 
Model inputs 
For GBD 2016 estimation, we used seroprevalence data to model Chagas. The table below illustrates the 
geographic distribution of model input data for the estimation process.  
Table 1. Geographies 
Level  Prevalence 




We also use CSMR estimates in the modeling process, which will be addressed in further detail below. 
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Modelling strategy  
We modeled Chagas disease using a full DisMod-MR 2.1 Bayesian meta-regression model incorporating 
seroprevalence data, as above, and CSMR estimates. We assume no remission. We eliminate all new 
infections, except those via vertical transmission, in Chile and Uruguay for years after the interruption of 
vector-based transmission (Abad-Franch F, Diotaiuti L, Gurgel-Gonçalves R, Gürtler RE. Certifying the 
interruption of Chagas disease transmission by native vectors: cui bono? Mem Inst Oswaldo Cruz 
2013;108:251–4.; Coura JR. Chagas disease: control, elimination and eradication. Is it possible? Mem 
Inst Oswaldo Cruz 2013;108:962–7.). For non-endemic countries, we estimate the prevalence of 
imported chronic infections based on migration. For each non-endemic country, we estimate the total 
number of people infected with Chagas as the sum of the number of immigrants from each endemic 
country multiplied by the corresponding prevalence of Chagas in that endemic country.  
 
We estimate five sequelae: symptomatic acute infection from incidence; and megaviscera, heart failure, 
atrial fibrillation, and chronic asymptomatic infection from prevalence. We assume that 5% of acute 
infections will be symptomatic (Teixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA. Chagas 
disease. Postgrad Med J 2006;82:788–98.). The proportion of chronic infections resulting in a given 
sequela varies by sex and age: the prevalence of megaviscera among those infected with Chagas ranges 
from 0% in children to nearly 10% among older adults (Coura JR, Naranjo MA, Willcox HP. Chagas’ 
disease in the Brazilian Amazon: II. A serological survey. Rev Inst Med Trop São Paulo 1995; 37:103–7.); 
the prevalence of atrial fibrillation attributable to Chagas ranges from 0% among children to 
approximately 10% in men over 80 years of age (Ribeiro AL, Marcolino MS, Prineas RJ, Lima-Costa MF. 
Electrocardiographic abnormalities in elderly Chagas disease patients: 10-year follow-up of the Bambuí 
Cohort Study of Aging. J Am Heart Assoc 2014;3:e000632.); and the prevalence of heart failure 
attributable to Chagas among those who are infected ranges from 0% among young children, to a 
maximum of 23% among men over 80 years of age (Sabino EC, Ribeiro AL, Salemi VM, et al., for the 
National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (REDS-II), International 
Component. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-
seropositive former blood donors. Circulation 2013;127:1105–15.). 
 
Severity splits and disability weights 
 
The table below illustrates the sequelae, lay descriptions, and DWs for Chagas disease.  
 
Table 2. Sequelae, lay description and DWs 
 
Sequelae Description Disability Weight 
Atrial fibrillation and 
flutter due to Chagas 
disease 
 






Mild heart failure due 
to Chagas disease 
Is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 





Moderate heart failure 
due to Chagas disease 
Is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 





Severe heart failure 
due to Chagas disease 
Is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 





Mild chronic digestive 
disease due to Chagas 
disease 
 
Has some pain in the belly that causes nausea but does not 





digestive disease due 
to Chagas disease 
 
Has pain in the belly and feels nauseated. The person has 





Acute Chagas disease Has a fever and aches, and feels weak, which causes some 












Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy for endemic countries from GBD 2015 
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Input Data & Methodological Summary 
Case definition 
Cystic echinococcosis is a parasitic disease caused by infection with the Echinococcus granulosis 
tapeworm. It is a natural parasite of canines, with sheep being the most common intermediate host in 
the two-stage lifecycle, but can be spread to humans through ingestion of soil, water, or food 
contaminated with the fecal matter of an infected dog containing infective eggs. Diagnosis is made by 
clinical findings, imaging, serology, and tissue pathology. The ICD-9 and ICD-10 codes for echinococcosis 
are 122.0-122.9 and B67-B67.9, respectively. 
Input data 
Model inputs 
The nonfatal estimation for cystic echinococcosis (CE) focused on estimating incidence and prevalence 
of CE and its sequelae. A systematic review of literature was conducted in PubMed for GBD 2015 using 
the following search string:  
("echinococcosis"[Title/Abstract] OR "hydatid disease"[Title/Abstract] OR 
"hydatidosis"[Title/Abstract] OR "echinococcal disease"[Title/Abstract] OR "Echinococcus 
granulosus infection"[Title/Abstract]) AND (“1990”[Date – Publication] : “2015”[Date – 
Publication]) AND (epidemiology OR incidence OR prevalence).  
This yielded 1,619 studies of which 279 were included during the title/abstract screening. Following the 
full-text screening, 77 studies (32 incidence, 43 prevalence and 2 both) were included and extracted – 
studies were excluded because of one or more of the following reasons: 
1. study not population-based
2. study does not have primary data on prevalence and/or incidence
3. study not in humans
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4. study on sub-populations 
5. review study 
 
Data from these extracted studies were combined with data from studies extracted during GBD 2013 
and hospital data prepared by the GBD team. 
Since we were interested in modelling symptomatic CE cases, we only used data on incidence of patients 
diagnosed by imaging techniques (mainly ultrasonography). Therefore, we excluded prevalence data 
which were mostly from serological studies. 
The table below shows the number of studies finally included, and the number of countries or 




GBD world regions 16 
 
Sequelae due to cystic echinoccocosis 
The table below shows the sequelae due to echinococcosis and their associated disability weights. 
Sequela Lay description DW (95% CI) 
Chronic respiratory disease has cough and shortness of breath after heavy 
physical activity, but is able to walk long 
distances and climb stairs. 
0.019 (0.011–0.033) 
Abdominal problems has pain in the belly and feels nauseated. The 
person has difficulties with daily activities. 
0.114 (0.078–0.159) 
Epilepsy (Combined DW) NA 
 
Modelling strategy 
DisMod MR was used to model the nonfatal burden of symptomatic cystic echinococcosis (CE) using 
incidence data. The covariates included were sheep per capita; proportion of the population with access 
to sanitation; log-transformed lag-distributed income; and clinic or hospital data type. 
Mortality estimates from the custom mortality model were used to inform the excess mortality 
parameter (CODEm estimates used as cause-specific mortality rate data). Estimates of excess mortality 
rate were obtained and used to estimate prevalence (CSMR/EMR). A remission of 0.15–0.25 per case 
per year (duration 2–6.7 years, average 5 years) was assumed. The following steps were followed to 
estimate excess mortality rate: 1) create custom age groups for CE deaths at the 1,000-draw level; 2) 
calculate CSMR as CSMR=deaths/population at the 1,000-draw level – calculate mean CSMR, uncertainty 
interval, and standard error; and 3) calculate EMR as EMR=CSMR/(prevalence), where prevalence = 
(incidence*5) – standard error of EMR was calculated taking into consideration the standard errors of 
both prevalence and CSMR. 
After running DisMod, a thousand draws of proportions for abdominal, respiratory, and epileptic 
symptoms among echinococcosis cases, that add up to 1, were generated. Uncertainty in the splitting 
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proportions was captured by drawing them from a Dirichlet distribution, informed by published data on 
cysts localization [1]. On average, the proportions of abdominal, respiratory, and epileptic symptoms 
due to echinococcosis were 0.8, 0.19, and 0.01, respectively. These proportions were used to split the 
prevalence and incidence from DisMod into the three sequelae. 
Model evaluation was done by separately assessing the fit of the DisMod MR model and checking the 
estimates produced after estimating incidence and prevalence of sequelae due to cystic echinococcosis. 
Plots of time trends of incidence and prevalence across locations and age were used to evaluate the 
results. In addition, maps of the global distribution of incidence and prevalence were assessed across 
time. 
Changes from GBD 2015 to GBD 2016 






1. Eckert J, Deplazes P. Biological, Epidemiological, and Clinical Aspects of Echinococcosis, a 
Zoonosis of Increasing Concern. Clin Microbiol Rev, 2004; 17(1): 107-35 
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Input Data & Methodological Summary 
Case Definition 
Cysticercosis, or Neurocysticercosis (NCC), is a parasitic disease caused by the pig tapeworm, Taenia 
solium. It is transmitted via ingestion of eggs or gravid proglottids shed by a human or non-human host 
with an intestinal infection of the same helminth known as Taeniasis. In rare cases, auto-infection is also 
possible among people with intestinal infections. Diagnosis is made by magnetic resonance imaging 




The nonfatal estimation for cysticercosis focused on estimating prevalence of NCC among epileptics at 
risk as well as the prevalence of NCC with epilepsy. A systematic review of literature was conducted in 
PubMed for GBD 2015 using the following search string:  
("cysticercosis"[Title/Abstract] OR "neurocysticercosis"[Title/Abstract] OR 
"cysticerciasis"[Title/Abstract] OR "Taenia solium"[Title/Abstract]) AND (“1990”[Date – 
Publication] : “2015”[Date – Publication]) AND (epidemiology OR prevalence)).  
This yielded 1,038 studies of which 166 were included during the title/abstract screening. Following the 
full-text screening, 17 studies were included and extracted – studies were excluded because of one or 
more of the following reasons: 
1. study not in epileptics
2. study not population-based
3. study does not have primary data on prevalence of NCC among epileptics at risk
4. study not in humans (some studies were on cysticercosis in pigs)
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5. study on comorbidities with NCC (other than epilepsy) 
6. study on sub-population, eg, patients with neurological disorders 
7. review study 
 
We combined the newly extracted studies with studies extracted during GBD 2013. The table below 
shows the number of studies finally included, and the number of countries or subnational units and GBD 
world regions represented. 
 prevalence  
Studies 31 
Countries/subnationals 23 
GBD world regions 8 
 
A study-level covariate was also created in GBD 2015 to indicate the type of diagnosis for each study, ie, 
definitive or probable. Of the 77 rows of country-year-age-sex data, there were 15 rows with definitive 
diagnosis and 62 rows with probable diagnosis. 
Three additional data sources that were used included 1) epilepsy envelope prevalence (from the 
epilepsy DisMod MR model), 2) proportion of the population with access to sanitation (from the GBD 
covariates database), and 3) proportion of the population that is Muslim (from the PEW Research Center 
[1].)(http://www.pewforum.org/2011/01/27/table-muslim-population-by-country/). 
Modelling strategy 
DisMod MR was used to model the prevalence of NCC among epileptics at risk. In the model, pigs per 
capita, the proportion of the population with access to sanitation and religion (binary, >50% Muslim) 
were used as country-level covariates. In addition, the prevalence of “definitive diagnosis” was 
transformed to that of “probable and definitive diagnosis” so as to not underestimate overall 
prevalence. 
After running DisMod, we adjusted the fraction of people with epilepsy attributable to cysticercosis in 
endemic countries for the population at risk based on the proportion of the population without access 
to sanitation and the proportion of the population that is Muslim. Predicted NCC prevalence among 
epileptics at risk was calculated such that Prevalence=P×(NM-N)/(NM-1), where P = prevalence of all-
cause epilepsy in total population, N = proportion of NCC among epileptics at risk (non-Muslims without 
access to sanitation), and M = proportion of population not at risk of contracting NCC. It was assumed 
that the prevalence of epilepsy due to causes other than NCC is the same regardless of whether a 
population is at risk or not. It was also assumed that Muslims and non-Muslims have equal access to 
sanitation. 
Model evaluation was done by separately assessing the fit of the DisMod MR model and checking the 
estimates produced after estimating prevalence of NCC with epilepsy. Plots of time trends of prevalence 
across locations and age were used to evaluate the results. In addition, maps of the global distribution of 
prevalence of NCC among epileptics at risk and prevalence of NCC with epilepsy were also assessed 
across time. 
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Other than using additional data extracted from literature, we updated the proportion of population 
with Muslim data by filling in subnational locations with national proportions – this was done due to lack 
of data on this covariate at the subnational level. 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy from GBD 2015 to GBD 2016. 
 
References: 























Estimates of Dengue 































Dengue is mosquito-borne viral infection that causes febrile illness and, in severe cases, jaundice, 
hemorrhage, and death. It includes all ICD-10 codes under the heading A90 (Dengue fever [classical 
dengue]) and A91 (Dengue hemorrhagic fever). 
Input data 
Model inputs 
For GBD 2016, we modelled dengue incidence based on officially reported cases. The table below 
illustrates the geographic distribution of data points used in our analysis. 
Table 1. Geographies 
Level Incidence 




Updates to systematic reviews are performed on an ongoing schedule across all GBD causes, and an 
update for dengue fever will be performed in the next one to two iterations. While no systematic update 
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was conducted, we did incorporate new expansion factor data that were provided by collaborators and 
have updated to the latest available case reports for GBD 2016. 
 
Modelling strategy  
The methods used to model dengue incidence remain unchanged from GBD 2015, and are an improved 
variant of the methods used for GBD 2013 that were described by Stanaway et al. Briefly, we derive two 
dengue-specific covariates: first a variable to define the expected spatial distribution of the disease 
based on principal components analysis of dengue CSMR estimates and dengue transmission probability 
and, second, a variable to define the country-specific trends, based on a mixed-effects model of 
reported cases. We then estimate a mixed-effects negative binomial model with number of reported 
cases as the dependent variable, fixed effects on the aforementioned spatial and temporal covariates, 
and random effects on location. These random effects are assumed to correspond to deviations in 
reporting completeness and, calibrating against published expansion factor data (ie, estimates of the 
degree of underreporting), they are inflated to adjust for underreporting estimates. The resulting 
incidence estimates are split into moderate (94.5%) and severe (5.5%) sequelae, based on the 
proportion of reported cases that were severe. We assume that 8.4% of symptomatic infections will 
produce post-acute chronic fatigue lasting an average of six months (Teixeira L de AS, Lopes JSM, 
Martins AG da C, Campos FAB, Miranzi S de SC, Nascentes GAN. Persistence of dengue symptoms in 
patients in Uberaba, Minas Gerais State, Brazil. Cad Saúde Pública 2010; 26: 624–30.). 
 Severity splits and disability weights 
Table 2. Sequelae, lay descriptions, and DWs 
Sequela Lay description Disability Weight (DW) 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032–0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088–0.19) 
Asymptomatic Infection with no apparent illness. NA 
 
Changes from GBD 2015 to GBD 2016 




1. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of 
dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases 
[Internet]. 2016 Feb [cited 2016 May 23]. 
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and 
burden of dengue. Nature. 2013 Apr 25;496(7446):504–7. 
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Input Data & Methodological Summary 
Case definition 
Human foodborne trematodiases (FBT) is defined as the infection with parasitic worms of the class trematoda, 
which are also known as flukes. Trematodes are transmitted via contaminated food and infection is highly 
related to food habits. Definitive hosts, including humans, become infected when ingesting viable metacercariae 
by consuming contaminated aquatic products (eg, watercress). In the ICD-10, FBT are listed under code B66 [1]. 
 
FBT is subdivided into six types of FBT (see Table 1): 
• Clonorchiasis 
• Fascioliasis 
• Intestinal fluke 
• Opisthorchiasis 
• Paragonimiasis (normal and cerebral infections) 
 
Table 1. Subtypes of FBT 
 Species of FBT Also known as: Carcinogen 
1 Chlonorchiasis (Chinese) Liver fluke Associated with choliangiocarcinoma 
2 Opisthorchiasis 
(O viverrini & O felineus) 
Liver fluke Associated with choliangiocarcinoma 
(O viverrini) 
3 Fascioliasis Liver fluke No available evidence 
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4 Intenstinal fluke Liver fluke No available evidence 
5 Paragonimiasis Lung fluke   
 
Thresholds for heavy infection and duration by species of FBT 
The majority of people infected with FBTs are asymptomatic. When symptoms do occur they are often non-
specific. Among the clinical symptomatic group, severity is associated with worm burden, typically measured by 
fecal egg counts, and the duration of infection. The thresholds for heavy infection and duration by species of FBT 
are shown in Table 2. The clinical presentation of FBT depends on the target organs (liver, lung, or intestines). 
Clonorchiasis and opisthorchiasis patients may suffer from loss of appetite, fullness, indigestion, diarrhoea, pain 
in the right upper quadrant, lassitude, weight loss, ascites, and oedema.[2, 3] Cholangitis, obstructive jaundice, 
intra-abdominal mass, cholecystitis, and gallbladder or intrahepatic stones may occur as complications.[3, 4] 
 
Table 2. Thresholds for heavy infection and duration by species of FBT 
 Species of FBT Case thresholds for heavy infection Duration 
1 Chlonorchiasis 10,000 eggs per g of feces lifelong 
2 Opisthorchiasis 10,000 eggs per g of feces lifelong 
3 Fascioliasis 1,000 eggs per g of faces lifelong 
4 Intenstinal fluke 1,000 eggs per g of faces lifelong 
5 Paragonimiasis 100 eggs per 5 ml sputum lifelong 






For GBD 2010, the data came from the expert group and is the result of their analysis. The expert group analysis 
used the results of a systematic literature review performed by Furst et al. as a starting point for the analysis.[5] 
Furst et al. searched PubMed, WHOLIS, FAOBIB, Embase, CAB Abstracts, Literatura Latino Americana e do Caribe 
em Ciências de Saùde (LILACS), ISI Web of Science, BIOSIS preview, Science Direct, African Journals OnLine 
(AJOL), and the System for Information on Grey Literature in Europe (SIGLE), period Jan 1, 1980, to 
Dec 31, 2008. The initial number of studies identified through the literature review was ~34,000 references. The 
literature review included extracted data from 181 studies. For GBD 2013 and GBD 2015 the search strategy was 
replicated to capture epidemiological studies published between 2008 and 2015. Due to the cyclical nature of 
103
systematic review for GBD causes, no data collection was scheduled for GBD 2016. As such, foodborne 
trematodiases will be a priority for the next iteration of the study. 
Input data for the assessment of the total national number of infected people  
Only studies that used countrywide surveys to estimate the national prevalence rates were included (or for 
China, province-wide surveys). Reason for choosing only national studies is that FBT shows a highly focal spatial 
distribution and local cross-sectional surveys would profoundly under- or overestimate true national 
prevalences. We decided not to model national and subnational together and get a coefficient on subnational, 
because there is not a one-fits-all relationship across the world. Infection is highly related to food habits and 
there are highly varying differences between national and subnational prevalence rates. The final GBD 2016 
dataset contained 29 prevalence studies from 17 countries. We used raw data from the selected studies as input 
for DisMod. 
Prevalence intestinal fluke infection 
Intestinal fluke is different from the other types of FBT, because there are several pathogens that fall under 
intestinal fluke infection. It can be caused by pathogens, such as Metagonimus spp., Echinostoma spp., 
Neodiplostomatidae.[6] When assessing the prevalence of intestinal fluke infection, we added the identified 
prevalence for each parasite species in order to obtain the overall prevalence of intestinal fluke infections. This 
approach may lead to a certain overestimation of the true prevalence, because people may be co-infected with 
more than one intestinal fluke species. There is no sufficient evidence about the proportion of co-infections, but 
the resulting overestimation of the true prevalence may be more than offset by the assumptions made in our 
previous modelling approach and the many challenges in generating the underlying epidemiological parameters 
(eg, diagnostic inaccuracy in the detection of infections with the more than 50 intestinal fluke species). Also of 
note: the transmission source of intestinal fluke infections are species-specific and therefore vary. For instance, 
Fasciolopsis buski is usually transmitted by eating raw water plants with the infective parasite stage attached to 
the water plants, whereas Neodiplostomatidae are transmitted by eating undercooked and infested frogs, 
snakes, and tadpoles. Because of these different transmission pathways, the rate of co-infection might in fact be 
smaller than expected. 
Input data to differentiate between asymptomatic and heavy infections 
We estimated the proportion of heavily infected among all infected in all available national and regional cross-
sectional surveys. It is expected that heavy infection increases with age and there are data available on heavy 
infection by age group. We therefore decided to include age-dependent rates of heavy infection for 
clonorchiasis, opisthorchiasis, and intenstinal fluke infection. For (cerebral) paragonimiasis and fascioliasis there 
were not sufficient age-dependent data on high intensity FBT infection.  
 
Modelling strategy 
We used a three-step process for the disease modelling of FBT. In the first step we used DisMod-MR 2.0 to 
estimate assess the prevalence of FBT by age, sex, year, and country. In the second we differentiated between 
asymptomatic and heavy infections. MetaXL (a meta-analysis add in for Microsoft Excel) was used to estimate 
the proportion of heavy infected among all infected by age group for clonorchiasis, opisthorchiasis, and 
intenstinal fluke infection (see Table 3 and 4). These proportions were used to estimate the prevalence of heavy 
FBT infection.  
The third step consisted of deselecting countries that have no autochtonous case reports of FBT (input 34,000 
references from literature review).  
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Clonorchiasis Opisthorchiasis Intestinal fluke infection 
Mean Low High Mean Low High Mean Low High 
0-9 30% 17% 44% 10% 0% 29% 8% 3% 14% 
10-19 15% 0% 43% 15% 0% 69% 11% 8% 14% 
20-29 18% 10% 29% 16% 0% 52% 18% 15% 21% 
30-39 17% 5% 34% 21% 0% 56% 22% 17% 28% 
40-49 22% 13% 32% 28% 1% 68% 22% 13% 32% 
50-59 18% 0% 49% 29% 0% 75% 17% 9% 28% 
60+ 32% 18% 47% 25% 0% 64% 15% 8% 23% 
 
 
Table 4. Percentage of high-intensity infection by type of FBT (based on 4 FBT prevalence studies) 
Type of FBT 
 
Mean Low High 
Paragonimiasis 23% 0% 59% 
Fascioliasis 19% 3% 41% 
 
Cerebral paragonimiasis 
It was assumed that 0.8% of paragonimiasis cases have cerebral involvement. This proportion was used to 
estimate the prevalence of cerebral paragonimiasis. This proportion is based on one study. The data are from Oh 
SJ. The rate of cerebral involvement in paragonimiasis: an epidemiologic study. Jpn J Parasitol 1969;18:211-14. 
The study was performed in Paju, South Korea. This is an area with 6,738 inhabitants and according to the 
survey, it was estimated that 29.6% of all individuals would react to intradermal test (= an immunological 
reaction indicating previous or current contact to the parasite). 25% of all “positive reactors” may have eggs in 
their sputum (= active infection with the parasite currently present in the human host). If these rates are applied 
to the community as a whole, the number of patients with active paragonimiasis would be at least 498 
(=6,738*0.296*0.250). Furthermore, four cases of cerebral paragonimiasis were found in this community. 
Therefore, four out of 498 individuals with active paragonimus infection suffered from cerebral infection 
(=0.80%; 95% confidence interval 0.019%-1.587%).  
Severity splits and disability weights 
For GBD 2016, FBT was not split into health states with different severities. The table below shows the GBD 2016 
disability weights that were used to calculate the burden of FBT in YLDs. 
  
Table 5. Disability weights that were used to calculate FBT YLDs 
Sequelae  Severity description Health state name Disability weight 
Asymptomatic 
clonorchiasis 
Clonorchiasis, currently without 
symptoms 











Opisthorchiasis,  currently without 
symptoms 
N/A 0.000 (0.000–0.000) 
Heavy 
opisthorchiasis 







Fascioliasis, currently without 
symptoms 
N/A 0.000 (0.000–0.000) 
Heavy 
fascioliasis 








Intestinal fluke infection, currently 
without symptoms 
N/A 0.000 (0.000–0.000) 
Heavy intestinal 
fluke infection 







Paragonimiasis, currently without 
symptoms 
N/A 0.000 (0.000–0.000) 
Heavy 
paragonimiasis 
Cough, fever, and weight loss Tuberculosis, not HIV-infected 0.333 (0.224–0.454) 
Cerebral 
paragonimiasis 
Epilepsy due to cerebral paragonimiasis Epilepsy, less severe (seizures 
< once per month) 
0.263 (0.173–0.367) 
  Epilepsy, severe (seizures >= 
once per month 
0.552 (0.375–0.710) 
Note. N/A: not applicable 
 
Changes from GBD 2015 to GBD 2016 
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3.3.5 Dracunculiasis (Guinea worm) SDG Capstone Appendix
Flowchart 
Total number of Guinea worm disease cases 
Systematic literature review data on age and sex 
distribution
Run DisMod model to 
produce estimates of 
incidence and prevalence by 




















by location for all 
years
Incidence PrevalenceAssign duration of disability
Background 
Guinea-worm disease is caused by the parasitic worm Dracunculus medinensis. The transmission cycle 
begins when Guinea worm larvae are released in water (shallow ponds or open wells) where they are 
ingested by copepod Cyclops (water fleas) [1]. When a person consumes contaminated water, the 
copepod is dissolved by gastric acids and the larvae are released. Larvae then migrate through the 
intestinal wall; the male and female mate. Shortly thereafter, the male dies and the female worm moves 
through the victim’s subcutaneous tissues. A year post-infection, the adult worm emerges through the 
skin, usually from the feet or lower limbs. Worm emergence causes an intensely painful edema, blister 
and an ulcer accompanied by fever, nausea, and vomiting. To relieve the pain associated with the 
worm’s emergence, infected persons immerse the infected part of their body in local water sources such 
as ponds. Upon entering the water, the female worm will expulse her larvae into drinking water where 
the cycle can begin again [1,2].  
To break the cycle of transmission, ministries of health in endemic countries implement a suite of 
interventions: case detection and containment; provision of safe water sources; distribution of filter 
cloths and pipe filters; water source treatment with Abate® (a larvacide); and health education.   
By design, the Guinea worm eradication programmatic infrastructure covers the entire at-risk 
population. Since case containment [3] is a key intervention designed to not only interrupt transmission 
but also monitor progress toward eradication, incident cases of guinea worm disease are nationally 
representative. To implement case containment as an intervention, all cases of Guinea worm disease are 
identified. Containment is defined as detection within 24 hours of the worm’s emergence; the patient 
did not contaminate any water source; the patient received proper wound care and health education on 
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not entering any water source; and a supervisor verified the case as dracunculiasis within seven 
days. Case reporting occurs at the village level on a monthly basis; case data are then aggregated within 
the national Guinea worm eradication program and reported to the World Health Organization. In 
settings where annual case reports are low (suggesting no transmission) or transmission has been 
interrupted, cash rewards are promoted to enhance surveillance activities.  
 
Input Data & Methodological Summary 
Case Definition 
A Guinea worm case is defined as an individual with Guinea worm disease (a single case could have 
more than one worm emerge at one time). These cases are confirmed through the Guinea worm 





Only the following countries were identified as guinea-worm endemic as of 1990 (4): Benin, Burkina 
Faso, Cameroon, Central African Republic, Chad, Côte d’Ivoire, Ethiopia, Ghana, India, Kenya, Mali, 
Mauritania, Niger, Nigeria, Pakistan, Senegal, Sudan, South Sudan, Togo, Uganda, and Yemen [4]. Any 
country not reporting Guinea worm in 1990 is not included in the GBD model.  
Geographic restrictions by year were also implemented to account for the period post-transmission to 
reflect the accomplishments of the Guinea worm eradication campaign. Geographic restriction for 
countries that were endemic in 1990 was defined based on data reported post-interruption of 
transmission. In the GBD analysis, Guinea worm disease was no longer modelled for the year that 
followed the last reported case (imported or indigenous) provided that the subsequent years through 
2015 also had no case reports. To ensure that cases were attributed to burden in the country in which 
the case was detected, both indigenous and imported cases were included. For example, if Kenya 
reported its last case in 2005 (imported), and as no other cases were reported through 2015, the 
geographic restriction began in 2006. For Ethiopia and Chad, countries that had re-introduction of 
transmission, no geographic restriction was implemented for the period 1990–2015. 
Data sources  
1) Case data by geography, by year 
2) Literature review of age/sex distribution 
3) Literature review for sequelae (type, duration, and proportion) 
Case data: Annual case data were reported by WHO in the Weekly Epidemiological Record. For years or 
geographies for which WER reports were not published, the following sources were also used to extract 
case counts: 
1) CDC’s MMWR reports 
2) 1990–1999 total country reports from Hopkins et. al. [4]:  A summary of case totals from 
1990–1999, as these are not reported in WER for every year 
3) India subnational estimates: India MOH report (1984–1999) 
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4) The Carter Center’s Guinea worm wrap-up: disaggregation of case totals for Sudan and 
South Sudan pre-2011 (independence) to ensure case totals from 1990–2010 are consistent 
with current national boundaries.  
The number of cases annually was compared to official total numbers to ensure accuracy. WER data 
were used in the analysis in the event of a discrepancy.   
Subnational data 
India: Subnational data for India were obtained from the Ministry of Health for the period 1984–1999, 
cases were reported by year and state: http://www.ncdc.gov.in/index2.asp?slid=329&sublinkid=216. 
Kenya: Subnational data from Kenya were requested from the MOH but not obtained. To split cases by 
subnational unit, the Carter Center Guinea Worm Wrap-Up was reviewed to identify districts with 
endemic villages. A national survey conducted 1993/1994 found cases in Turkana and West Pokot 
counties, but case totals were not reported by county. Indigenous transmission was interrupted in 1995, 
with imported cases reported until 2005. All cases in Kenya are currently analyzed in GBD as occurring in 
Turkana County as we are unable to disaggregate the data. WER reports from 1999–2006 document that 
all imported cases from 1998–2005 occurred in Turkana County. 
Age/sex distribution 
Generally, the risk of Guinea worm infection varies according to sex- or age-specific differences in access 
to safe drinking water. A study in Ethiopia found women were more likely to experience Guinea worm 
disease than men; in India, men experienced greater risk of infection [1].  Exposure to unsafe water 
sources varies largely on mobility patterns and type of water sources: communities in which infested 
water is carried in for consumption are more likely to see more Guinea worm disease in children and 
older adults [5]. Communities in which infection results from drinking contaminated water due to 
human movement patterns (such as cattle grazing, travel) demonstrate a slightly greater risk in adults, 
particularly those of working age. Once interventions to control the spread of Guinea worm infection are 
implemented, the age and sex distribution likely changes to reflect variation in access to safe water 
sources and case-containment practices, but age/sex case data are currently not available.   
The evidence base available to describe risk of infection by age is as follows: 
1) Studies from Nigeria: 
a. Adeyeba et al [6]: Guinea worm disease not common among children <1 year of age; 
increase in risk by age 
b. Kale et al [7]: More boys ages 5-9 years than girls were infected (11.9% v. 6.8%); Women 
ages 20-29 higher prevalence of infection than men (13.4% v. 4.7%); Overall, the 
prevalence in both men and women was highest in ages 10-14 and 30 years or older.   
2) Other countries: 
a. Sudan [8]: No significant age trend among lower-endemicity villages; higher-endemicity 
villages (n=4) had higher prevalence in children and older adults. Attributes the 
difference in age trends to community-level water source.  
b. Ghana [9]: The trend in age of first infection reported was similar for males and females, 
with more females experiencing first infection between 15 and 19 years and males 
between 20 and 24 years of age. The proportion of men with guinea worm disease was 
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much higher than women among ages 25-54 years. Adults (>15 years of age) were more 
likely to be infected than children.  
The evidence base available to describe the risk of infection by gender is as follows: 
1) Studies from Nigeria: 
a. Adeyeba et al [6]: No difference among males and female 
b. Kale et al [7]: No overall gender difference comparing total males infected to total 
females infected, although gender differences for certain age groups (see notes above). 
For the GBD analysis, no difference in incidence based on gender was modelled due to conflicting 
evidence related to sex-specific risk of infection. While there is limited evidence to suggest that risk 
varies by sex, it is also modified by age; however, evidence for this modification also suggests that such 
age- and sex-specific risk may vary by endemic community within a given geography (in some settings, 
women at higher risk, in others men, but not for all age strata).   
To model age-specific variation, we assumed a limited increase in risk among adults aged 15 years and 
older and assumed no Guinea worm disease in infants less than 1 year of age.  
Severity splits/sequelae 
Sequelae associated with Guinea worm relate to the wound at the site of the worm’s emergence, which 
can include abscesses and chronic ulcerations. Joint and tissue damage can occur, as well as secondary 
infection in connective tissues[10]. During the worm’s emergence, which takes approximately one 
month to exit the body, the ulcer is painful and itchy[1]. The wound is subject to secondary infection and 
scarring. While an individual experiences Guinea worm disease, they are generally unable to work and 
have limited mobility at the time of emergence and during the period in which they are healing. 
Although most worms emerge in the feet and lower legs, there are reports of worms exiting at other 
locations[10], which could cause other disability not accounted for here. A study in Nigeria found that 
98% of worms emerged in the lower limbs[11]. Therefore, all disability associated with Guinea worm 
disease is attributed to lower limb conditions, pain and lack of mobility with no distinction made for 
number of worms emerging at any single time.  
The following evidence base was reviewed to determine the proportion of cases attributed to each 
sequela, as well as duration of sequelae.  
Duration of disability and type of disability: 
Studies from Nigeria: 
1) Adeyeba et al [6]: 93.4% incapacitated for an average of 26 days. 
2) Smith et al [12]: Average disability duration 12.7 weeks; 58% unable to leave the home for a 
mean duration of 4.2 weeks; duration of disability greater among those older than 50 years 
compared to those younger than 50 years. 
3) Okoye et al [11]: 21% of cases were totally incapacitated due to their infection (not permanently 
disabled). 
4) Kate et al [7]: A survey of 17 villages from 1971 to 1975 found that duration of disability was 
approximately 100 days. 
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Other countries: 
5) Benin [13]: From two villages in highly endemic areas, estimated 39-59 days of disability 
experienced after worm emergence. 
6) Ghana [14]: 28.2% experienced pain 12-18 months post emergence; 5% unable to carry out at 
least one daily activity, 0.5% permanently impaired. 
7) Ghana [9]: Complete disability experienced among males with Guinea worm disease lasted 
approximately 5 weeks among those untreated. Among cases provided supportive care (wound 
management), the duration of disability was 2.5 weeks.  
We therefore assume that each case of Guinea worm disease identified from 1990 onward likely 
received some degree of case management through national Guinea worm eradication programs; this 
assumption likely holds better in the period post-1995 after case-containment was widely adopted. For 
cases identified prior to 1995, we extend the period of disability due to worm emergence to two 
months, followed by two months of motor impairment. 
For cases reported after 1995, we assume every case experiences pain and disfigurement, Level 3, and 
motor impairment (severe) for a period of one month, followed by two months of motor impairment 
(moderate).   
For all years, we assume that 30% of all cases will then experience disfigurement level 2 with itch/pain 
and motor impairment (moderate) for an additional 9 months (approximately a year of disability). A 
total of 0.5% of all cases will experience permanent disability defined as musculoskeletal problems, 
lower limbs, severe, experienced after the initial period of pain/disfigurement and motor impairment 
associated with worm emergence.  
Sequela Lay description DW (95% CI) 
Disfigurement, 
level 3, with 
itch/pain 
has an obvious physical deformity that is very painful and itchy. 
The physical deformity makes others uncomfortable, which 
causes the person to avoid social contact, feel worried, sleep 




level 2, with 
itch/pain 
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 







has severe pain in the leg, which makes the person limp and 
causes a lot of difficulty walking, standing, lifting and carrying 






is unable to move around without help, and is not able to lift or 






has some difficulty in moving around, and difficulty in lifting and 






The incidence of Guinea worm disease is modeled using DisMod. Duration of Guinea worm disease is 
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Input data and methodological summary 
Case definition 
Ascariasis is a helminth diseases caused by the parasitic roundworm Ascaris lumbricoides. It is one of the 
three intestinal nematode infections (INI), or soil-transmitted helminthiasis (STH), that we model in GBD. 
Diagnosis is made by microscopic exam of stool with or without concentration procedures 
(recommended as eggs may be difficult to see). The ICD-10 codes for ascariasis are B77-B77.9. 
Input data 
Model inputs 
Four different input data were used in the ascariasis nonfatal model. The first was prevalence data 
prepared by the expert group (EG) during GBD 2010 [1, 2]. They provided the data (mean, upper, lower) 
by location, year (1990, 2005, 2010), age (0-4, 5-9, 10-14, 15+ years), helminth type (ascariasis, 
hookworm disease, trichuriasis) and intensity of infection (light, medium, heavy, all). For the model, light 
infestation was not attributed any disability. The second data, also from the EG, was on reductions in 
prevalence in 2010, provided by location, age, helminth type, and coverage (community/school). The 
table below shows the number of countries or subnational units and GBD world regions represented in 
the data. 
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Table 1a. Geographic spread of data 
 prevalence 
Countries/subnationals 163 
GBD world regions 16 
 
The third input data was from the WHO PCT Databank [3]. This data was downloaded from the source 
website and represented 121 locations and six GBD world regions. The last input data was 1,000 draws of 
wasting envelope prevalence among children under 5 years – the methods used to generate estimates of 
wasting prevalence are detailed elsewhere (part of risk factors documentation). The table below shows 
the number of countries or subnational units and GBD world regions represented in the data. 
Table 1b. Geographic spread of data  
 prevalence 
Countries/subnationals 561 
GBD world regions 21 
 
 Severity splits/sequelae 
The table below shows the list of sequelae due to ascariasis and the associated disability weights (DW). 
The sequelae were based on prevalence of medium and heavy infestation – medium infestation was 
assigned mild abdominopelvic problems; heavy infestation was assigned symptomatic worm infection; 
and light infestation was not attributed any disability. 
Table 2. Sequelae, lay descriptions, and disability weights (DWs) 
Sequela Lay description DW 
Mild abdominopelvic problems  has some pain in the belly that causes nausea but 
does not interfere with daily activities 
0.011 (0.005–0.021) 
Heavy infestation has cramping pain and a bloated feeling in the belly 0.027 (0.015–0.043) 
Severe wasting is extremely skinny and has no energy 0.128 (0.082–0.183) 
Asymptomatic ascariasis N/A N/A 
 
Modelling strategy 
In the estimation of morbidity due to ascariasis, the EG data were first prepared by formatting the 
location names to be consistent with the GBD 2016 location names and applying the 2010 prevalence to 
1990 and 2005 for sub-Saharan Africa countries – estimates for these two years were missing. This was 
followed by using the data on reductions in 2010 prevalence to adjust the prevalence for locations with 
coverage data. After this adjustment, only data for medium infection, heavy infection, and all infection 
were retained. 
Using the mean prevalence and the upper and lower bounds of the mean provided by the EG, 1,000 
draws of prevalence were generated. This was done by multiplying the mean estimates by the exponent 
of random draws from a normal distribution with mean = 0 and standard deviation = sd, where sd = 
abs(abs(ln(upper)-ln(lower))/(invnormal(0.975)*2). These draws were created for all GBD age-groups, 
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assuming the same prevalence in ages 15+ and same prevalence in males and females. Since the draws 
were only at the national level, subnational locations were filled with national figures where applicable 
(Brazil, China, India, Indonesia, Kenya, Mexico, Saudi Arabia, and South Africa). 
To get 1995 and 2000 estimates, exponential interpolation of estimates between 1990 and 2005 was 
performed. The draws for 2016 were produced based on 2010 estimates corrected for PCT control 
activities between 2010 and 2014 – this was done by extrapolating the 2005–2010 trend to 2016, given 
cumulative number of treatments per person calculated using data from the WHO PCT Databank [3]. The 
2005-2010 trend was applied to all intensities of infection. Prevalence was assumed to be zero for the 
countries with missing input data and also in children younger than 28 days. The resulting estimates were 
1,000 draws of ascariasis prevalence by GBD location, year, age, sex, and intensity level (mild, heavy, 
overall infection). To estimate the prevalence of asymptomatic ascariasis, prevalence of mild and heavy 
infestation was subtracted from the overall ascariasis prevalence. 
The final step in the modelling process was to estimate the prevalence of severe wasting due to ascariasis 
in age groups 28–364 days and 1–4 years. This was done separately using 1,000 draws of prevalence of 
heavy infestation due to ascariasis and the wasting envelope prevalence. The initial step in determining 
prevalence of severe wasting due to ascariasis was generating 1,000 draws of change in weight-for-height 
z-score per heavy prevalent case from a random normal distribution with mean = 0.493826493 and 
standard deviation = 0.04972834 (calculated from upper and lower bounds of the mean estimate). The 
mean, upper, and lower bounds were provided by a GBD collaborator who calculated them based on a 
published article [4]. The prevalence of severe wasting due to ascariasis was then obtained as a function 
of change in weight-for-height z-score (z_change) such that prevalence = p_wasting_env – 
Phi(Phi_inv(p_wasting_env) – z_change*p), where p_wasting_env = wasting envelope prevalence, Phi_inv 
is the inverse standard normal cumulative distribution function (cdf), and p = prevalence of heavy 
ascariasis infestation. 
Model evaluation was done by plotting prevalence of overall ascariasis and that of each sequela against 
year for each location and age group. Maps of the global distribution of total ascariasis prevalence and 
prevalence of sequelae due to ascariasis were also assessed across time and age.  
The only change made from GBD 2015 modelling strategy was the incorporation of updated data from 
the WHO PCT databank [3] in the correction of estimates for MDA activities. 
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Input Data and Methodological Summary  
Case Definition 
Cutaneous leishmaniasis (CL) is the most common manifestation of disease caused by the Leishmania 
parasite, transmitted through the bite of phlebotomine sand flies. It causes the appearance of skin 
lesions, often beginning as papules or nodules and developing into ulcers, on parts of the body exposed 
to the bite of the sand fly. Mucocutaneous leishmaniasis (MCL) is a much more exceptional – and severe 
– presentation. Primarily isolated to Latin America, MCL infections can result in degradation of the 
mucous membranes, typically following an ulcerative sore from CL infection. Transmission varies by 
geographic region, as approximately 70 animal species have been identified as potential reservoir hosts 
of the parasite. 
Input data 
No systematic review of literature in the PubMed database was done for Cutaneous and 
Mucocutaneous Leishmaniasis for GBD 2016; however WHO country profile datasets were updated 
from their original 2010 year of reference, and subnational data from India and Brazil were included. 
Modelling strategy 
In general, there were few updates to the CL modelling strategy. The minimal amount of prevalence 
data conflicted with incidence where available, and thus was excluded from the model. No study-level 
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covariates were used. The Sociodemographic Index (SDI) was used as a country-level covariate on the 
incidence data, with a floor of exp(-1) – as to allow a degree of regional and subnational variation while 
constraining the predictive power such that predictions in hypo-endemic countries with low SDI values 
and no data would not be unduly high. 
In order to control for DisMod fitting values to locations known to be devoid of CL, we replace estimates 
in these locations with zeros. Then for locations with confirmed CL presence, we apply an 
underreporting factor reported in Alvar et al. In order to distinguish prevalence of acute cases and those 
that endure lifelong disability, we used a normalized version of the health system access (HSA) covariate 
such that 47.6% of cases with poor access to health care – defined as (cases * (1 - norm(HSA)]) – would 
progress to the lifelong stage. All acute cases were assumed a six-month duration. 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy from GBD 2015 to GBD 2016. 
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3.3.5 Lymphatic Filariasis SDG Capstone Appendix
Flowchart  
Input Data and Methodological Summary 
Case Definition 
Lymphatic filariasis (LF) is a neglected tropical disease spread in which threadlike nematodes invade the 
lymphatic system. The worms responsible – Wuchereria bancrofti, Brugia malayi, and Brugia timori – 
are spread from human to human via mosquitoes. The most prominent clinical manifestations of LF are 
lymphedema (a swelling of the legs, also known in its more extreme manifestation as elephantiasis) 
and hydrocele (a collection of fluid in the sac around the testicles).  
Input data 
A systematic review of literature for GBD 2016 in the PubMed database was done on October 14, 2016, 
for prevalence and incidence data using the search (Lymphatic filariasis AND prevalence) OR (Lymphatic 
filariasis AND (prevalence OR incidence OR "mass drug administration" OR MDA OR coverage)) OR 
(Lymphedema, hydrocele) OR (Transmission Assessment Survey (TAS)) OR (Lymphatic filariasis AND 
mapping).  
Population at risk and MDA coverage data come from the WHO PCT Databank [1]. 
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Modelling strategy  
Data on prevalence of microfilaria is modelled using Dismod-MR 2.1. Due to the focal nature of 
lymphatic filariasis, we make the assumption that data collected are from endemic locations unless 
specifically specified in literature or survey methods. If the data are nationally representative, we adjust 
the data points by multiplying by the inverse of the proportion of the population at risk. Due to the fact 
that data is collected in endemic locations or we adjust it so that it is within the population at risk, we 
then scaled the DisMod-MR 2.1 estimates according to at-risk population in order to attain nationally 
representative values. We developed a new MDA location-level covariate that is used in the DisMod 
model based off WHO PCT Databank data, informing prevalence estimates.   
For lymphedema and hydrocele, we incorporate survey data from the Global LF Atlas in a non-linear 
error-in-variables regression that determines the prevalence of lymphedema and hydrocele as 
functions of microfilaria prevalence, which is then applied to the total microfilaria DisMod model in 
order to attain an envelope of cases by location-year. Separately, all available prevalence data for these 
conditions is modeled in DisMod in order to determine an age-sex pattern.  
In the estimation of lymphedema and hydrocele prevalence, we perform the same population at-risk 
correction that is done on microfilaria prevalence. For hydrocele prevalence after treatment, we take 
the value before MDA rollout in 2000 and reduce that by the same treatment efficacy function 
described for microfilaria prevalence, using dosage-reduction data specific to hydrocele along with the 
location-year specific MDA coverage. For lymphedema, we assume no new cases appear among 
treated individuals. As such, we reduce lymphedema prevalence in post-treatment years in accordance 
with MDA coverage.  
Sequela  Data points  Regions   Countries   Subnational units  
Prevalence of detectable 




40  28  
Lymphedema due to lymphatic 




25  15  
Hydrocele due to lymphatic  




22  12  
  
Changes from GBD 2015 to GBD 2016 
We conducted a new literature review, and utilized data from recent years and the MDA covariate to 
predict the time trend rather than last year’s non-linear regression to estimate the reduction of 
microfilaria as a function of treatments per person.  
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3.3.5 Visceral Leishmaniasis SDG Capstone Appendix 
Flowchart 
 
Input data and methodological summary  
Case definition 
Visceral leishmaniasis (VL) is the most serious manifestation of disease caused by the Leishmania 
parasite, transmitted through the bite of phlebotomine sand flies. Those infected typically present with 
fever, weight loss, anaemia, leukopenia, thrombocytopenia, and enlargement of the spleen and liver. If 
left untreated, it can be fatal. Transmission varies by geographic region, as approximately 70 animal 
species have been identified as potential reservoir hosts of the parasite. The ICD9 code related to 
visceral leishmaniasis is 085.0, and the ICD10 code is B55.0. 
Input data 
No systematic review of literature in the PubMed database was undertaken for GBD 2016; however, 
updates of case notification, primarily from WHO country reports, were included. 
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We updated estimates of country-year-specific MI ratios by running a linear regression of the logit of the 
MI ratio on the log of income per capita using vital registration and inpatient hospital data from Brazil 
and Spain, two countries in which we had both reliable mortality and incidence data at the national 
level. This ratio was used in two ways; first, in assuming a duration of three months, we were able to 
derive excess mortality for use in DisMod. Second, the product of the M:I ratio and cases then estimated 
by DisMod, based upon incidence data, were used as death estimates for CoDCorrect. 
 
Modelling strategy 
The minimal amount of prevalence data available conflicted with the relationship between incidence 
and excess mortality data, as well as the remission prior (set to 4 based on duration assumptions), and 
thus was excluded from the model. No study-level covariates were used. The Socio-demographic Index 
(SDI) was used as a country-level covariate on the incidence data, with a floor of exp(-1) – as to allow a 
degree of regional and subnational variation while constraining the predictive power such that 
predictions in hypo-endemic countries with low SDI values and no data would not be unduly high. 
In order to best represent the documented distribution of VL in India, we used the national fit from the 
DisMod model and redistributed it among the Indian states based on data from Bhunia, et al. Further, in 
order to control for DisMod fitting values to locations known to be devoid of VL, we replaced estimates 
in these locations with zeros. Then for locations with confirmed VL presence, we applied an 
underreporting factor reported in Alvar et al. Resultant incidence draws are then assumed to have a 
duration of three months, from which prevalence is calculated. Of those three months, three weeks are 
assumed to be spend with severe infection, and nine with moderate infection. 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy for endemic countries from GBD 2015 
to GBD 2016. 
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3.3.5 Leprosy SDG Capstone Appendix 
Flowchart 
WHO Weekly Epidemiologic Reports: case 
notification data
Location/age/sex/
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Input Data and Methodological Summary 
Case definition 
Leprosy is a chronic bacterial infection caused by Mycobacterium leprae, primarily affecting the nervous 
system, skin, respiratory tract, and eyes. Transmission is facilitated through contact with fluid from the 
nose and mouth of an infected individual. The ICD-10 codes for leprosy are A30.9.  
Input data  
To model nonfatal outcomes due to leprosy, WHO Weekly Epidemiological Record (WER) case 
notification data were used from 1987 to 2012 to capture incident cases of leprosy. This is the same 
database that was used to model GBD 2015 estimates, and due to the cyclical nature of systematic 
reviews for GBD causes, no data collection was scheduled for GBD 2016. As such, leprosy will be a 
priority for the next iteration of the study. Stage-specific incidence data for grade 1 and grade 2 leprosy 
that are used to define age-sex patterns came from Brazil case notification data.  
Modelling strategy 
We used a multi-step process for the disease modeling of leprosy. In the first step, we ran a single-
parameter model using DisMod-MR 2.0 to estimate the leprosy incidence age pattern by age, sex, year, 
and country. Then, we scaled the incidence outputs to the WHO WER cases, and used the ordinary 
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differential equations (ODE) solver to calculate prevalence from the scaled DisMod-MR 2.0 incidence 
outputs.  
Severity data were prepared by running a generalized ordered logistic regression using Brazil case 
notification data to get the relationship between leprosy incidence and grade 1 and grade 2 incidence by 
age and sex. We then used this relationship to split the parent DisMod-MR 2.0 model, and again scaled 
to WHO WER severity-specific cases. For disfigurement grade 1, we apply a duration of six months to get 
prevalence estimates. For disfigurement grade 2, we again use the ODE solver to get prevalence 
estimates.  
Model evaluation was done by separately assessing the fit of the parent DisMod model and checking the 
final estimates produced after age-sex splits. Plots of time trends of prevalence across locations and age 
were used to evaluate the results. In addition, maps of the global distribution of leprosy prevalence and 
prevalence of sequelae due to leprosy were also assessed across time. 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy from GBD 2015 to GBD 2016. 
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3.3.5 Onchocerciasis SDG Capstone Appendix
Flowchart 
Input data & methodological summary 
Case definition 
Onchocerciasis, also known as river blindness, is a parasitic disease caused by the helminth Onchocerca 
volvulus. It is transmitted via the bite of one of several species of Similium blackflies that have 
historically bred in fast-moving freshwater rivers and tributaries throughout sub-Saharan Africa, Central 
America, and South America. Diagnosis can be made by skin snip biopsy to identify larvae, surgical 
removal of nodules and exam for adult worms, slit lamp exam of anterior part of the eye where larvae 
or lesions caused by them are visible, and antibody tests (mostly useful to visitors to areas with 
parasites). The ICD-10 code for onchocerciasis is B73. 
Input data 
Model inputs 
Prevalence data prepared by the GBD 2010 expert group (EG) was used for modelling the nonfatal 
outcomes resulting from onchocerciasis in Africa. This included 1,000 draws of infection and morbidity 
(visual impairment, blindness, and skin conditions) cases with confidence intervals categorized by 
country, age, and sex for years 1990, 1995, 2000, 2005, and 2010. Details about the materials and 
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methods used by the EG to generate these draws can be found elsewhere [1-5]. These data represented 
all African countries included in the African Programme for Onchocerciasis Control (APOC) and the 
Onchocerciasis Control Programme (OCP) for which initial Rapid Epidemiological Mapping of 
Onchocerciasis (REMO) assessments demonstrated a need for Community-Directed Treatment with 
Ivermectin (CDTI) (defined as having a prevalence of skin nodules greater than 20%). Four countries – 
Rwanda, Mozambique, Kenya and Gabon – were designated as hypo-endemic countries after initial 
REMO assessments and not included due to sparsity of cases and paucity of data. Estimates for Sudan 
from GBD 2010 were reassigned to South Sudan in GBD 2013 after its independence in 2011 since REMO 
assessments indicated that the vast majority of cases occurred in that area of the former Sudan. The 
tables below show the countries included in each program and the number of corresponding GBD 
locations they represent.  
 APOC Countries OCP Countries 
Countries included Angola, Burundi, Cameroon, 
Central African Republic, Chad, 
Congo, Democratic Republic of 
Congo, Ethiopia, Equatorial Guinea, 
Liberia, Malawi, Nigeria, South 
Sudan, Tanzania, and Uganda 
Benin, Burkina Faso, Côte d'Ivoire, 
Ghana, Guinea Bissau, Guinea, Mali, 




Rwanda, Mozambique, Kenya, 
Gabon, Sudan 
 
GBD countries & 
subnationals 
15 11 
GBD world regions 3 1 
 
Prevalence data for modelling non-fatal outcomes resulting from onchocerciasis in the Americas was 
extracted via a systematic literature review. Web of Science, Scopus, and PubMed were searched with 
the following search strings: 
Database Search string Yield 
PubMed (oncho*[Title/Abstract] OR "river blindness"[Title/Abstract] OR "O. 
volvulus"[Title/Abstract] OR "robles disease"[Title/Abstract] OR "blinding 
filariasis"[Title/Abstract] OR "coast erysipelas"[Title/Abstract] OR “sowda” [Title/Abstract] 
OR “nodding syndrome”[Title/Abstract]) AND (“1980”[Date – Publication] : “2016”[Date – 
Publication]) AND (epidemiology[Title/Abstract] OR prevalence[Title/Abstract] OR 
incidence[Title/Abstract] OR surveillance[Title/Abstract] OR”MDA”[Title/Abstract] OR 
“Mass Drug Administration”[Title/Abstract] OR “Community-directed treatment with 
ivermectin”[Title/Abstract] OR “CDTI”[Title/Abstract] OR “mass treatment”[Title/Abstract] 
OR “multiple ivermectin treatments”[Title/Abstract] OR “monthly doses of 
ivermectin”[Title/Abstract] OR “large scale treatment”[Title/Abstract] OR 
REMO[Title/Abstract] OR “Rapid epidemiological mapping of 
onchocerciasis”[Title/Abstract] OR APOC[Title/Abstract] OR “African Programme for 
Onchocerciasis Control”[Title/Abstract] OR OCP[Title/Abstract] OR “Onchocerciasis Control 




TS=(oncho* OR "river blindness" OR "O. volvulus" OR "robles disease" OR "blinding 
filariasis" OR "coast erysipelas" OR sowda OR “nodding syndrome”) AND TS=(epidemiology 
OR prevalence  OR incidence  OR surveillance OR MDA OR “Mass Drug Administration” OR 
“Community-directed treatment with ivermectin” OR CDTI OR “mass treatment” OR 
1,144 
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“multiple ivermectin treatments” OR “monthly doses of ivermectin” OR “large scale 
treatment” OR REMO OR “Rapid epidemiological mapping of onchocerciasis” OR APOC OR 
“African Programme for Onchocerciasis Control” OR OCP OR “Onchocerciasis Control 
Programme”) NOT TS=((Animals NOT Humans)) 
SCOPUS (TITLE-ABS-KEY(oncho* OR "river blindness" OR "O. volvulus" OR "robles disease" OR 
"blinding filariasis" OR "coast erysipelas")) AND TITLE-ABS-KEY(epidemiology OR 
prevalence OR incidence OR surveillance OR MDA OR "Mass Drug Administration" OR 
"Community-directed treatment with ivermectin" OR CDTI OR "mass treatment" OR 
"multiple ivermectin treatments" OR "monthly doses of ivermectin" OR "large scale 
treatment" OR REMO OR "Rapid epidemiological mapping of onchocerciasis" OR APOC OR 
"African Programme for Onchocerciasis Control" OR OCP OR "Onchocerciasis Control 
Programme") AND NOT KEY(Animals NOT Humans) AND PUBYEAR > 1979 
2,000 
 
This yielded 4,130 results in total which was reduced to 2,502 after removing duplicates. The title and 
abstracts were screened for inclusion or exclusion with the following criteria: 
Exclusion Criteria: 
• Pre-1980 
• Non-original source 
• Non-representative population 
o Vulnerable populations (eg, slum-dwellers, prisoners, orphans, high-risk jobs, etc.) 
o Hospital-based samples (including saved stool samples) 
o Non-native peoples (eg, migrants, expats, nomads, etc.) 
o Immunosuppression/illness (eg, HIV, TB, CA, RA, asthma, malaria, handicap, etc.) 
• Non-human population 
• Does not meet case definition 
• Case-control study 
 
Sixty-one articles were identified for full text screening and extraction from the historically endemic 
American countries: Guatemala, Brazil, Ecuador, Venezuela, Mexico, and Colombia. 
Severity splits/sequelae 
The table below shows the list of common clinical manifestations of onchocerciasis and the sequelae to 
which they have been mapped along with the lay description and the associated disability weight (DW) 
of each sequela. 
Clinical manifestation Sequela name Lay description DW 
Uveitis; Punctate 





has vision problems that make it difficult to 











has severe vision loss, which causes difficulty 
in daily activities, some emotional impact (for 
example worry), and some difficulty going 





Blindness Blindness is completely blind, which causes great 
difficulty in some daily activities, worry and 
anxiety, and great difficulty going outside the 











has a slight, visible physical deformity that is 
sometimes sore or itchy. Others notice the 














has a slight, visible physical deformity that 










has a visible physical deformity that is sore 
and itchy. Other people stare and comment, 
which causes the person to worry. The 










has an obvious physical deformity that makes 
others uncomfortable, which causes the 
person to avoid social contact, feel worried, 









The nonfatal modelling for onchocerciasis included three major steps. In the first step, GBD 2010 
prevalence was extrapolated to obtain GBD 2016 estimates. Uncertainty was quantified and provided by 
the EG for all estimates except those of moderate skin disease. In this case acute skin disease level 2 and 
chronic skin disease level 2 were summed to create the moderate skin disease sequela, and within each 
of the OCP draws the number of cases with visual impairment and blindness were multiplied by a 
random value (the exponent of a normally distributed variable with mean zero and standard deviation 
0.1) in order to add uncertainty. Within each draw, the same randomly drawn value was applied to all 
country-year-age-sex estimates. Visual impairment was split into moderate and severe vision 
impairment by first multiplying the visual impairment estimates by a random value (from a normal 
distribution with mean 0.84 and standard deviation 0.0031) to generate moderate vision impairment, 
and then subtracting the resulting estimates from visual impairment to obtain estimates of severe vision 
impairment. Prevalence of sequelae was calculated by dividing the cases by the population. 
The second step in modelling morbidity due to onchocerciasis was the adjustment of uncertainty in the 
conversion of nodule prevalence to microfilaria (mf) prevalence and in the effects of mass drug 
administration (MDA). To adjust for uncertainty in translation of nodule prevalence to mf prevalence, 
the final OCP draws from the first step were logit transformed uncertainty was added from a random 
value drawn from a normal distribution to the transformed estimates. The resulting estimates were then 
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normalized and scaled using estimates published elsewhere [1]. To adjust for uncertainty due to MDA, 
the year when MDA with Ivermectin started was set according to the table below. 
Country MDA start year 
Angola, Burundi, South Sudan 2005 
Congo, Ethiopia, DRC 2001 
Cameroon, Central African Republic, Equatorial Guinea, Liberia, Nigeria, Uganda 1999 
Chad, Niger, Tanzania 1998 
Malawi 1997 
All others 1990 
 
The uncertainty in the time trend was then multiplied by the normalized prevalence estimates and the 
final prevalence was obtained by re-expanding the scaled normalized draws and adjusting the scale back 
from logit scale. 
To estimate the prevalence of asymptomatic onchocerciasis, prevalence of morbidity (vision loss, 
blindness and skin conditions) was subtracted from the overall onchocerciasis prevalence – moderate 
vision impairment, severe vision impairment and blindness estimates were each multiplied by a factor of 
8/33 before subtraction to account for cases that have concurring symptoms. 
Model evaluation was done by separately assessing plots of time trends of prevalence across locations 
and age for each sequela. In addition, maps of the global distribution of total onchocerciasis prevalence 
and prevalence of sequelae due to onchocerciasis were also assessed across time. 
In the final step, estimates for onchocerciasis in the Americas were modelled using Gompertz functions. 
Uncertainty was obtained by simulating across the deceleration parameter. The proportion of disease 
manifesting in each of the mapped sequela was derived from the proportion of sequela in the GBD 2010 
estimates and uncertainty was added. 
 
Changes from GBD 2015 to GBD 2016 
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Input data and methodological summary 
Case definition 
Rabies is a fatal viral infection, transmitted by animal bites. Without prophylactic vaccination the disease 
is almost universally fatal. The disease has a long incubation period (1-3 months), and early intervention 
with prophylactic vaccination is nearly 100% effective in preventing symptomatic disease. It is considered 
a neglected tropical disease (NTD). We model symptomatic infections, not including those infections in 
which intervention prevented the onset of symptomatic disease, corresponding to the ICD10 code A82. 
Input data 
Model inputs 
As we derive our estimate of cases from our estimate of deaths, no incidence data are used in the model. 
For GBD 2016, we modelled rabies mortality using all available data in the cause of death database. Data 
points were outliered if they reported an improbable number of rabies deaths (eg, zero rabies deaths in a 
hyperendemic country) or if their inclusion in the model yielded distorted trends. In some cases multiple 
data sources for the same location differed dramatically both in their quality and reported rabies 
mortality (eg, a verbal autopsy and vital registration source). In these cases the lower-quality data source 
was outliered. 
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Modelling strategy  
We derive estimates of the number of symptomatic rabies infections (ie, those not averted through 
prophylactic vaccination) based on rabies mortality estimates, assuming 99% case fatality. All cases are 
assumed to be severe. 
 
We modelled rabies mortality using a two-model hybrid approach 1) a global CODEm model of all 
locations, using all data in the CoD database; and 2) a CODEm model restricted to data-rich countries.     
We have made two substantive changes in the modelling strategy from GBD 2013. First, we have changed 
from a single global model to the hybrid global/data-rich model approach. Second, we conducted an 
exploratory analysis to determine the most predictive covariates for rabies and have updated the 
covariates used in the CODEm model accordingly. 
 
 Sequela description and DW 
 
There is only one sequela and associated disability weight for rabies, which is severe. The lay description 
is included in the table below. 
 






Severe Has a high fever and pain, and feels very weak, which 





Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy for rabies from GBD 2015.  
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calculate prev of 
sequelae, split by sex 
and age
Bounds for std deviation of 
prevalence of infection
Effects of treatment with 
praziquantel
Household survey from lit.
Calculate conversion factor for 
splitting species-specific infection in 
N. Africa/Middle East
Literature data
Calculate transformation factors (TF) 
to convert  prevalence in <20 years 
old to total population
Calculate TF to convert total 
infection prevalence to species-
specific prevalence in sub-Saharan 
Africa
Species-specific (mansoni, 
haematobium) and overall  






Convert prev in under 20 to 
prev in total pop
Split total prev into 
mutually exclusive species-
specific prev
Convert total prev of 
infection to prev of 
species-specific infection
Calculate pre-control 
(1990-2005) prev of 
sequelae using Dismod 
global age pattern








Schisto stage 2 (hepatic dis, 
dysuria, hydronephrosis) lit data 
from EG
Schisto stage 1 (diarrhea, 
bladder) lit data from EG
Schisto stage 3 (hematemesis, 











(2010 & 2015 prev):
take 2005 results and 




Calculate prev of overall schisto 
infection for 1990-2015:
• For both sexes, assume linear
increase in prev until age 15, 
then stable over age













DALYsMild, moderate and 







Schistosomiasis, also known as bilharzia or “snail fever,” is a helminth disease caused by infection with 
five species of the parasite Schistosoma, namely, S. mansoni, S. japonicum, S. haematobium, S. mekongi, 
and S. intercalatuma. It is considered a neglected tropical disease (NTD). The first three species cause 
the most infection and the last two rarely cause disease. Diagnosis is made by microscopic exam of stool 
or urine for parasite eggs. For less advanced infections, serologic techniques are used. The ICD-10 codes 
for schistosomiasis are B65-B65.9. 
Input data 
Model inputs 
To model nonfatal outcomes due to schistosomiasis, we conducted a systematic literature review, 
extracting prevalence data from 1980 to 2016 for the five species of schistosomiasis listed above. The 
search string used in the systematic review is (schistosom*[Title/Abstract] OR bilharzia*[Title/Abstract] 
OR "snail fever"[Title/Abstract]) AND ("1990"[Date - Publication] : "3000"[Date - Publication]) AND 
(epidemiolog* OR inciden* OR prevalen* OR seroprevalen*) NOT (animals[mesh] NOT humans[mesh]). 
Additionally, we used data compiled by the Global Atlas of Helminth Infections (GAHI), which includes 
grey literature and unpublished data.    
Population at risk/mass drug administration data 
Population at risk estimates and MDA data were taken from the WHO PCT Databank [1]. 
Severity splits/sequelae 
The table below shows the list of clinical sequelae (including mild, moderate, and severe anaemia) due 
to schistosomiasis, their lay descriptions, and the associated disease stages and disability weights. Using 
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literature [1], a list of eight possible clinical sequelae and anaemia sequelae were defined (mild 
infection, mild diarrhoea, haematemesis (vomiting blood), hepatomegaly, ascites (buildup of fluid in the 
peritoneal cavity), dysuria (painful urination), bladder pathology, hydronephrosis (swelling of kidney due 
to buildup of urine in the kidney), mild anaemia, moderate anaemia, and severe anaemia).  
Table 2. Clinical sequela, lay descriptions, disease stages, and DWs 




Mild infection has a low fever and mild discomfort , but no 
difficulty with daily activities 
1 0.006 (0.002–
0.012) 
Mild diarrhoea  1 0.056 
Hepatomegaly has some pain in the belly that causes nausea but 
does not interfere with daily activities 
2 0.011 (0.005–
0.021) 
Dysuria has some pain in the belly that causes nausea but 
does not interfere with daily activities 
2 0.011 (0.005–
0.021) 
Hydronephrosis has some pain in the belly that causes nausea but 
does not interfere with daily activities 
2 0.011 (0.005–
0.021) 
Haematemesis vomits blood and feels nauseated 3 0.325 (0.209–
0.463) 
Ascites has pain in the belly and feels nauseated. The 
person has difficulties with daily activities 
3 0.114 (0.078–
0.159) 
Bladder pathology has some pain in the belly that causes nausea but 
does not interfere with daily activities 
3 0.011 (0.005–
0.021) 
Mild anaemia feels slightly tired and weak at times, but this 





feels moderate fatigue, weakness, and shortness 




Severe anaemia feels very weak, tired, and short of breath, and 
has problems with activities that require physical 





The morbidity model for schistosomiasis involved a multi-step process. First, we ran a single-parameter 
prevalence model in DisMod-MR 2.0 using the prevalence data extracted in the systematic review and 
from the GAHI database. We make the assumption that all of our data are measured within a population 
at risk – therefore, the estimates from the DisMod model represent prevalence estimates among the 
population at risk for schistosomiasis. Additionally, we included the MDA treatment data from the WHO 
as a country-level covariate in the DisMod model. Second, we then scaled the prevalence estimates to 
the population at risk estimates from the WHO PCT Databank to get age/sex/location/year all-
schistosomiasis prevalence envelopes. 3) We ran a generalized linear model to get species-specific 
proportional prevalence on data from literature that reported both S. haematobium and S. mansoni 
infection, and 4) literature-informed parameters (a, b, c) for translating infection (x) to morbidity (y): y = 
(a + bx^c)/(1 + bx^c) – a [2-4]. We used the species-specific conversion factors calculated in step (3) to 
split the all-schistosomiasis envelope into species-specific schistosomiasis. We then used the parameters 
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determined in step (4) to translate infection into morbidity to get age/sex/year/location-specific 
prevalence of sequelae. The burden of anemia due to schistosomiasis was estimated (see anaemia 
documentation for details). 
Model evaluation was done by separately assessing the fit of the single-parameter DisMod models and 
checking the final estimates produced after age-sex splits. Plots of time trends of prevalence across 
locations and age were used to evaluate the results. In addition, maps of the global distribution of total 
schistosomiasis prevalence and prevalence of sequelae due to schistosomiasis were also assessed across 
time. 
 
Changes from GBD 2015 to GBD 2016 
The main change made from GBD 2015 was the systematic review and using extracted data in a DisMod 
model to estimate prevalence within the population at risk. In addition, newly updated data from the 
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We model vision impairment as visual acuity <6/18 according to the Snellen chart. The following 
impairments are modeled:  
Condition Case definition 
Blindness Visual acuity of <3/60 or 
<10% visual field around 
central fixation 
Severe vision impairment  ≥3/60 and <6/60 
Moderate vision impairment  ≥6/60 and <6/18 
Near vision impairment envelope  Near visual acuity of <6/18 
distance equivalent 
  
Near vision impairment describes the progressive inability to focus on near objects as individuals age, and 
is also called presbyopia. This impairs the ability to read. The majority of presbyopia can be corrected by 
the use of reading glasses, contact lenses, or refractive surgery.  
We model vision impairment due to the following causes: uncorrected refractive error, cataract, 
glaucoma, macular degeneration, diabetic retinopathy, trachoma, Vitamin A deficiency, retinopathy of 
prematurity, meningitis, encephalitis, onchocerciasis, and other vision loss. Vision loss due to vitamin A 
deficiency, retinopathy of prematurity, meningitis, encephalitis, and onchocerciasis are modelled as part 
of their underlying cause as described in their respective sections.  
Refractive error is blurry vision due to the lens’s inability to focus. The blurriness caused by refractive 
error can be addressed through the use of contact lenses, glasses, or refractive surgery. Cataract is 
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clouding of the lens of the eye due to protein buildup that impairs vision. Glaucoma is a condition with 
increased intraocular pressure which can lead to damage of the optic nerve. Macular degeneration is a 
deterioration of the macula, leading to central vision loss. Diabetic retinopathy is damage to the retina 
caused by damaged blood vessels that can leak blood into the retina and cause scarring of the retina. 
Trachoma results from a conjunctival bacterial infection (Chlamydia trachomatis) that produces 
inflammation and scarring which leads to an inversion of the eyelids and eyelashes scratching the cornea, 
which eventually leads to scarring of the cornea and vision impairment or blindness. 
 
Input data 
 Model inputs 
Data on overall vision impairment come from surveys measuring visual acuity in representative 
population-based studies, either from publications in peer-reviewed and grey literature or surveys for 
which we had the unit record data. Data were excluded if no test was used of visual acuity that can be 
converted to the Snellen scale, and if a study did not assess “presenting” or “best-corrected” vision. A 
subset of these studies that reported vision loss by cause were used to estimate the prevalence of vision 
loss due to cataract, glaucoma, macular degeneration, diabetic retinopathy, and other causes.  
 
For GBD 2015, we conducted a systematic review for new sources since GBD 2013 (covering 1/1/2013 – 
5/20/2015), using the following search string:  
((((glaucoma[Title/Abstract] OR cataract[Title/Abstract] OR macular[Title/Abstract] OR 'refractive 
error'[Title/Abstract] OR presbyopia[Title/Abstract]) OR (('blindness'[MeSH Terms] OR 'blindness'[All 
Fields]) OR 'vision, low'[MeSH Terms])) AND ('2013'[PDAT] : '3000'[PDAT])) AND 'humans'[MeSH Terms]) 
AND (prevalence[Title/Abstract] OR incidence[Title/Abstract] OR epidemiology[Title/Abstract])   
 
This yielded 1,169 results, of which we extracted 20 sources. Furthermore, we extracted from the 
following nationally representative surveys measuring visual acuity: the WHO Studies on Global Ageing 
and Adult Health (SAGE) and the United States National Health and Examination Surveys (NHANES).  
For GBD 2016, we did a comprehensive extraction of the Rapid Assessment of Avoidable Blindness (RAAB) 
repository (http://raabdata.info/), a database of vision impairment studies in developing settings across 
the world. There are 266 site-years of data, the majority of which have publicly available reports or 
publications of the data. A standardized methodology was used by all sources in the repository, allowing 
inclusion of all available reports. In addition, we added two state-level national surveys from India.  
Due to the sparse literature reporting measured near-vision visual acuity, we also extracted data from the 
following nationally representative studies measuring self-reported near vision loss: SAGE; NHANES; the 
Surveys of Health, Ageing, and Retirement in Europe (SHARE); the Multi-Country Survey Study on Health 
and Responsiveness (MCSS); and the World Health Surveys (WHS).  
Several adjustments were made to raw data.  
1) Where studies reported visual acuity spanning multiple thresholds (eg, <6/60, rather than 
separate severe and blind estimates), we crosswalked using ratios predicted by a linear 
regression on age, using data from studies reporting vision loss by each severity.  
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2) Some studies reported best-corrected vision impairment, but not presenting vision impairment 
(PVI). We crosswalked these data points using a linear regression of logit-transformed PVI 
prevalence with fixed effects on best-corrected VI, healthcare quality and access index (HAQI) 
and Socio-demographic Index (SDI) and super-region random effects. This gave us a predicted PVI 
data points for these studies not explicitly reporting PVI. These crosswalked data points were 
flagged with a study-level covariate that increased standard error in DisMod.  
3) Where data points spanned more than 20 years of age, we age-split using an algorithm that 
applies the age-pattern of the super-region to split the data to five-year age groups.  
 
Whereas other vision impairment aetiologies are modelled based on prevalence data, vision impairment 
due to trachoma is modelled as a proportion of the overall vision impairment envelope, a strategy that 
was chosen based on the nature of available data. 
 
Health states and disability weights 
 
Health state name Health state description Disability weight 
Distance vision, severe 
impairment 
This person has severe vision loss, which causes difficulty in daily activities, some emotional impact (for 









This person is completely blind, which causes great difficulty in some daily activities, worry and anxiety, 




This person has difficulty seeing things that are nearer than 3 feet, but has no difficulty with seeing 




Modelling strategy  
We modelled the prevalence of vision loss in two steps. In the first step, we estimated the total 
prevalence estimates of presenting vision loss: moderate vision impairment, severe vision impairment, 
blindness, and near vision impairment (presbyopia). We directly derived prevalence of near vision 
impairment from this step, whereas the remaining three models that reflect different severity levels of 
distance vision loss continued to the next step.  
1) Estimate severity-specific vision impairment (the “envelopes”) 
First, we ran five DisMod-MR 2.1 models to estimate the total prevalence estimates of presenting vision 
loss: moderate vision impairment, severe vision impairment, blindness, near vision impairment 
(presbyopia), and presenting vision impairment (moderate + severe + blindness). The presenting vision 
impairment model was used as a covariate in the severity-specific models to improve consistency across 
severities.  
Betas and exponentiated values, which can be interpreted as an odds ratio, are shown in the table below 
for each covariate. The best-corrected covariate indicates whether the test measures visual acuity with 
the level of correction the patient presents with (best_corrected = 0) or the ophthalmologist provides 
additional correction via pinhole (best_corrected = 1). Rapid-assessment corrects for potential biases in 
cause-specific vision loss from studies using expedited visual acuity measurement. Socio-demographic 
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Index (SDI) and healthcare access and quality index (HAQI) are used as location covariates as a proxy 
measure of access to eye care such as cataract surgery. Non-representative studies are those not 
representative at the level they are used to model (eg, a state-level survey assigned to a country), 
including a z-cov adjusts for potential bias. Data points that were crosswalked from best-corrected visual 
acuity are flagged with a z-cov to adjust uncertainty in the crosswalk process. Non-standard severity 
definition is used to crosswalk between the self-report questionnaire of SHARE (nonstandard) and the 
other surveys, including SAGE and NHANES, which are crosswalked to examination data using the self-
reported covariate.  
 
2) Estimate cause-specific vision impairment  
In the second step, we estimated the prevalence of vision loss due to multiple causes: refractive error, 
cataract, glaucoma, macular degeneration, diabetic retinopathy, retinopathy due to prematurity, 
trachoma, vitamin A deficiency, onchocerciasis, meningitis, and other causes not classified elsewhere. The 
vision loss due to retinopathy of prematurity, vitamin A deficiency, onchocerciasis, meningitis, tetanus, 
and neonatal conditions was modeled as part of these underlying causes. Vision loss due to trachoma is 
modelled as a proportion of the envelope, with separate proportion models for vision impairment and 
blindness. For each of cataract, glaucoma, macular degeneration, diabetic retinopathy, and other vision 
loss, we ran two DisMod-MR 2.1 models: one for the combined category of moderate and severe vision 
loss due to the cause, and one for blindness due to the cause. Moderate and severe vision loss were 
modelled together because input data were mostly available for the aggregate. Refractive error was 
modelled in three models, one for each severity. We used the following age restrictions:  
Cause Minimum age  
Cataracts 20 
Glaucoma 45 
Macular degeneration 45 
Diabetic retinopathy 20 
Trachoma 15 
Other vision loss 0 
 
For the cataract model, we used known risk factors – hypertension, smoking, air pollution, and elevation.  
For cataract and refractive error, we used presenting vision impairment as a covariate, as these are the 
main causes of vision impairment and are treatable and thus should have greater covariance with overall 
vision impairment than less common causes such as glaucoma or macular degeneration.  
We estimated the proportions of low vision and blindness due to trachoma using custom mixed-effects 
models. For consistency, the two models (blindness and low vision) were parameterized identically and 
differ only in their input data. Our model included fixed effects on age (using cubic splines with knots at 0, 
40, and 100 years of age), sex, and a covariate derived from a principal components analysis of the 
proportion of the population at risk for trachoma and the proportion of the population with access to 
sanitation. We included nested random effects on super-region, region, and country. Finally, we applied 
geographic and age restrictions to ensure that we estimate zero proportions in non-endemic locations 
and among those younger than 15 year of age (as scarring of the cornea due to trachoma takes decades 
to develop). The prevalence of trachoma at each severity level was calculated by multiplying the 
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proportion of vision loss (vision impairment or blindness) due to trachoma by the corresponding best-
corrected vision loss envelope.  
We split the moderate plus severe vision loss estimates for each cause into moderate and severe using 
the ratio of best-corrected moderate and severe vision loss envelopes. As exceptions, onchocerciasis and 
retinopathy of prematurity were modelled for moderate and severe vision loss as part of the estimation 
process of these causes.  
We scaled the cause-specific vision loss prevalence to the total prevalence of the best-corrected vision 
loss envelopes for each of the three severity levels. The final result is prevalence of vision loss due to each 
cause by severity.  
 
The following changes have been implemented since GBD 2015: 
- DisMod is not designed to handle wide-age data points – by age-splitting the input data we 
improve model fits.  
- In the severity-specific vision impairment models, we use overall presenting vision impairment as 
a covariate, ensuring greater consistency between severities.  
- In GBD 2013 vision impairment models, best-corrected vision data were crosswalked within 
DisMod using a single beta for all ages and locations. By crosswalking the input data, we allow the 
ratio between presenting and best-corrected vision impairment to vary with age and location.   
- In GBD 2013, we estimated the ratio of vision impairment due to refractive error. In 2016, we are 
estimating the prevalence of refractive error, as it shows greater covariance with predictors such 
as SDI and HAQI. This allows the second step (squeezing causes to the envelopes) to include 
refractive error as an input.  
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3.4.1 Non-communicable Disease (NCD) Mortality SDG Capstone Appendix 
Cardiovascular diseases, cancers, diabetes mellitus, and chronic respiratory diseases
Indicator definition 
This modeling strategy encompasses the indicator associated with non-communicable disease mortality 
(3.4.1). 
Indicator 3.4.1 
As a component of SDG Goal 3. Ensure healthy lives and promote well-being for all at all ages, SDG Target 
3.4, by 2030, reduce by one third premature mortality from NCDs through prevention and treatment and 
promote mental health and well-being, is measured using SDG Indicator 3.4.1, deaths due to 
cardiovascular disease, cancer, diabetes, and chronic respiratory disease among populations aged 30 to 
70 per 100,000. 
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3.4.1 Cardiovascular Diseases SDG Capstone Appendix 




































Vital registration, verbal autopsy, and surveillance data were used to model this cause. We outliered 
non-representative subnational verbal autopsies from a number of Indian states. We also outliered 
verbal autopsy data sources that were implausibly low in all age groups and ICD8 and ICD9 BTL data 
points that were inconsistent with the rest of the data and created implausible time trends. 
Modelling strategy  
We used a standard CODEm approach to model deaths from cardiovascular diseases. We have updated 
the covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
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Table: Selected covariates for CODEm models, cardiovascular diseases 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Trans fatty acid None 1 1 
Mean BMI None 2 1 
Elevation over 1500m (proportion) None 2 -1 
Fasting plasma glucose (mmol/L) None 2 1 
Outdoor pollution (PM2.5) None 2 1 
Indoor air pollution (all fuel types) None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 
Alcohol (litres per capita) None 3 0 
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Rheumatic Heart Disease  
 




































Vital registration and surveillance data were used to model rheumatic heart disease. We outliered ICD8 
and ICD9 BTL data points which were inconsistent with the rest of the data and created implausible time 
trends. We also outliered data points which were too high after the redistribution process in a number 
of age groups. 
 
Modelling strategy  
We used a standard CODEm approach to model deaths from rheumatic heart disease. We have updated 
the covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
 
Table: Selected covariates for CODEm models, rheumatic heart disease 
Covariate Transformation Level Direction 
SEV None 1 1 
Improved water (proportion) None 1 -1 
Malnutrition None 1 1 
Sanitation (proportion with access) None 1 -1 
Healthcare access and quality index None 2 -1 
LDI Log 3 -1 
SDI None 3 -1 
Education (years per capita) None 3 -1 
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Ischemic Heart Disease 
 





































Vital registration, verbal autopsy, and surveillance data were used to model ischemic heart disease. We 
outliered verbal autopsy data in countries and subnational locations where high-quality vital registration 
data were also available. We also outliered non-representative subnational verbal autopsy data points, 
ICD8 and ICD9 BTL data points which were inconsistent with the rest of the data and created implausible 
time trends, and data in a number of Indian states identified by experts as poor-quality. 
 
Modelling strategy  
We used a standard CODEm approach to model deaths from ischemic heart disease. We have updated 
the covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
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Table: Selected covariates for CODEm models, ischemic heart disease 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Trans fatty acid None 1 1 
Mean BMI None 2 1 
Elevation over 1500m (proportion) None 2 -1 
Fasting plasma glucose None 2 1 
Outdoor pollution (PM2.5) None 2 1 
Indoor air pollution None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 










































Verbal autopsy and vital registration data were used to model cerebrovascular disease. We outliered 
non-representative subnational verbal autopsy data points. We reassigned deaths from verbal autopsy 
reports for cerebrovascular disease to the parent cardiovascular disease for both sexes for those under 
20 years of age. We also outliered ICD8, ICD9 BTL, and ICD10 Tabulated data points which were 
inconsistent with the rest of the data and created implausible time trends. Data points from sources 
which were implausibly low in all age groups and data points that were causing the regional estimates to 
be improbably high were outliered. 
 
Modelling strategy  
We used a standard CODEm approach to model deaths from cerebrovascular disease. The most 
significant update to the cerebrovascular method was the addition of a correction for miscoding of 
Alzheimer and other dementias and Parkinson disease to the post-CODEm adjustments to generate 
corrected cause-specific death estimates for final burden estimation. We have also updated the 
covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
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Table: Selected covariates for CODEm models, cerebrovascular disease 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Trans fatty acid None 1 1 
Mean BMI None 2 1 
Elevation over 1500m (proportion) None 2 -1 
Fasting plasma glucose None 2 1 
Outdoor pollution (PM2.5) None 2 1 
Indoor air pollution None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 







































Vital registration and surveillance data were used to model ischemic stroke. We reassigned deaths from 
verbal autopsy reports for ischemic stroke to the parent cardiovascular disease for both sexes for those 
under 20 years of age. We outliered ICD8 data points which were inconsistent with the rest of the data 
and created implausible time trends. 
Modelling strategy  
We used a standard CODEm approach to model deaths from ischemic stroke. In locations with limited 
data on ischemic stroke, the subtype-specific deaths were estimated by squeezing both ischemic and 
hemorrhagic stroke to the overall cerebrovascular envelope. We have updated the covariates included 
in the ensemble modelling process (see Table). Otherwise, there have been no substantive changes from 
the approach used in GBD 2015. 
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Table: Selected covariates for CODEm models, ischemic stroke 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Trans fatty acid None 1 1 
Mean BMI None 2 1 
Elevation over 1500m (proportion) None 2 -1 
Fasting plasma glucose None 2 1 
Outdoor pollution (PM2.5) None 2 1 
Indoor air pollution None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 












































Vital registration and surveillance data were used to model hemorrhagic stroke. We reassigned deaths 
from verbal autopsy reports for hemorrhagic stroke to the parent cardiovascular disease for both sexes 
for those under 20 years of age. We outliered ICD8 data points which were inconsistent with the rest of 
the data and created implausible time trends. 
Modelling strategy  
We used a standard CODEm approach to model deaths from hemorrhagic stroke. In locations with 
limited data on hemorrhagic stroke, the subtype-specific deaths were estimated by squeezing both 
ischemic and hemorrhagic stroke to the overall cerebrovascular envelope. We have updated the 
covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
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Table: Selected covariates for CODEm models, hemorrhagic stroke 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 0 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Trans fatty acid None 1 1 
Mean BMI None 2 1 
Elevation over 1500m (proportion) None 2 -1 
Fasting plasma glucose None 2 1 
Outdoor pollution (PM2.5) None 2 1 
Indoor air pollution None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 
Alcohol (litres per capita) None 3 0 
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Hypertensive Heart Disease 
 




































Vital registration and surveillance data were used to model hypertensive heart disease. We outliered 
ICD9 BTL data points, which were inconsistent with the rest of the data and created implausible time 
trends. 
Modelling strategy  
We used a standard CODEm approach to model deaths from cardiovascular diseases. We have updated 
the covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
 
Table: Selected covariates for CODEm models, hypertensive heart disease 
Covariate Transformation Level Direction 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Mean BMI None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 







































Vital registration data were used to model deaths due to myocarditis.  
Modelling strategy  
We used a standard CODEm approach to model deaths from myocarditis. This is one of three new sub-
causes under the cardiomyopathy and myocarditis parent cause for GBD 2016. The covariates selected 
for inclusion in the CODEm modelling process can be found in the table below. 
 
Table: Selected covariates for CODEm models, myocarditis 
Covariate Transformation Level Direction 
Summary exposure variable, CMP none 1 1 
Systolic blood pressure (mm Hg) none 1 1 
Healthcare access and quality index none 2 -1 
Lag distributed income per capita (I$) log 3 0 













































Vital registration and verbal autopsy data were used to model deaths due to alcoholic cardiomyopathy. 
We outliered ICD9 data points in Cyprus that were implausibly high and discontinuous with the rest of 
the time series. 
Modelling strategy  
We used a standard CODEm approach to model deaths from alcoholic cardiomyopathy. This is one of 
three new sub-causes under the cardiomyopathy and myocarditis parent cause for GBD 2016. The 
covariates selected for inclusion in the CODEm modelling process can be found in the table below. As 
local differences in coding practices may explain some of the geographic variation that we see for deaths 
due to cardiomyopathy and myocarditis, we plan to explore how this issue may affect the alcoholic 
cardiomyopathy sub-cause further in future iterations of GBD. 
 
Table: Selected covariates for CODEm models, alcoholic cardiomyopathy 
Covariate Transformation Level Direction 
Summary exposure variable, CMP none 1 1 
Smoking prevalence none 1 1 
Alcohol (litres per capita) none 1 1 
Healthcare access and quality index none 2 -1 
Lag distributed income per capita (I$) log 3 0 












































Vital registration data were used to model deaths due to other cardiomyopathy. We outliered data 
points in Central Asia and Central and Eastern Europe due to implausibly high values which we 
attributed to variation in local coding practices after review with experts. 
Modelling strategy  
We used a standard CODEm approach to model deaths from other cardiomyopathy. This is one of three 
new sub-causes under the cardiomyopathy and myocarditis parent cause for GBD 2016. The covariates 
selected for inclusion in the CODEm modelling process can be found in the table below. As local 
differences in coding practices may explain some of the geographic variation that we see for deaths due 
to cardiomyopathy and myocarditis, we plan to explore how this issue may affect the other 
cardiomyopathy sub-cause further in future iterations of GBD. 
 
Table: Selected covariates for CODEm models, other cardiomyopathy  
Covariate Transformation Level Direction 
Summary exposure variable, CMP none 1 1 
Systolic blood pressure (mmHg) none 1 1 
Smoking prevalence none 1 1 
Body mass index (kg/m2) none 2 1 
Healthcare access and quality index none 2 -1 
Lag distributed income per capita (I$) log 3 0 
Socio-demographic Index none 3 0 
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Vital registration data: We outliered ICD8 and ICD9 data points that were discontinuous from other data 
in the time series and created an unlikely time trend. We also outliered data points that were 
implausibly low in multiple age groups.  
Modelling strategy  
In order to address changes in coding practices for atrial fibrillation, we used an integrated approach 
that combined DisMod-MR and CODEm models to estimate deaths from atrial fibrillation and flutter. 
This approach allowed us to adjust estimates to more accurately reflect the number of deaths for which 
atrial fibrillation was the true underlying cause of death. 
 
The modelling steps are illustrated in the above flowchart. Covariates included in both the DisMod-MR 
2.1 and CODEm models can be found in the table below. In Step 1, we estimated deaths for atrial 
fibrillation using a standard CODEm approach. In Step 2, we estimated prevalence rates in DisMod-MR 
2.1 using data from published reports of cross-sectional and cohort surveys, as well as primary care 
facility data.  We also used claims data covering inpatient and outpatient visits for the United States 
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along with inpatient hospital data from 163 locations in 15 countries. For GBD 2016, inpatient hospital 
data were adjusted using age- and sex-specific information from US claims data for: 1) readmission 
within one year; 2) primary diagnosis code to secondary codes; and, 3) the ratio of inpatient to 
outpatient visits. We set priors of no remission and no excess mortality prior to age 30.  
 
In Step 3, we calculated the excess mortality rate (EMR) for 2016 (defined as the cause-specific mortality 
rate (CSMR) estimated from CODEm divided by the prevalence rate from DisMod-MR 2.1). We then 
selected 17 countries based on four conditions: 1) ranking of 4 or 5 stars on the newly developed system 
for assessing the quality of VR data; 2) prevalence data available from the literature was included in the 
DisMod-MR 2.1 estimation; 3) prevalence rate ≥ 0.005; and, 4) CSMR ≥ 0.00002. Using information from 
these countries as input data, we ran a linear mixed-effects regression of logEMR on sex, age, and 
location. Sex and age were treated as fixed effects for the regression, while location was considered a 
random effect. We then predicted age- and sex-specific EMR using the results of this regression for all 
non-selected countries. Countries included in the regression were assigned their directly calculated 
values. These EMR data points were assigned to the time period 1990–2016 and uploaded into the 
nonfatal database in order to be used in modelling.  
 
In Step 4, we reran DisMod-MR 2.1 including the EMR estimated in Step 3 as input data using the same 
priors as in Step 2. The CSMR from the DisMod-MR model in Step 4 was used as the finalized output. As 
DisMod-MR 2.1 only generates estimates for six years (1990, 1995, 2000, 2005, 2010, 2016), we 
interpolated the missing years to generate death estimates for all years (1980–2016). These results were 
then uploaded into the Cause of Death database. Finally, in Step 5, the unadjusted death estimates were 
run through the CoDCorrect process to generate adjusted deaths, and YLLs were generated by the 




Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Mean BMI None 2 1 
Elevation over 1500m (proportion) None 2 -1 
Fasting plasma glucose None 2 1 
Outdoor pollution (PM2.5) None 2 1 
Indoor air pollution None 2 1 
Healthcare Access and Quality Index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 
Alcohol (litres per capita) None 3 0 
Trans fatty acid None 1 1 
 
DisMod Covariates – Step 2 
Study covariate Parameter Beta Exponentiated beta 
Hospital data Prevalence -0.000086 (-0.19 – 0.097) 1.0 (0.82 – 1.10) 
All MarketScan, year 2000 Prevalence -0.47 (-0.5 – -0.44) 0.63 (0.61 – 0.64) 
All MarketScan, year 2010 Prevalence -0.003 (-0.024 – -0.014) 1.0 (0.98 – 1.01) 
Log-transformed age-
standardized SEV scalar: A 
Fib 
Prevalence 0.75 (0.75 – 0.75) 2.12 (2.12 – 2.12) 
LDI (I$ per capita) Excess mortality rate -0.48 (-0.5 – -0.43) 0.62 (0.61 – 0.65) 
 
DisMod Covariates – Step 4 
Study covariate Parameter Beta Exponentiated beta 
All MarketScan, year 2000 Prevalence -0.46 (-0.49 – -0.43) 0.63 (0.62 – 0.65) 
All MarketScan, year 2010 Prevalence -0.0021 (-0.025 – -0.021) 1.0 (0.98 – 1.02) 
Log-transformed age-
standardized SEV scalar: A 
Fib 
Prevalence 0.75 (0.75 – 0.75) 2.12 (2.12 – 2.12) 








































Vital registration and surveillance data were used to model this cause. We outliered data in Oman as 
they were improbably high in comparison with the rest of the region. We also outliered ICD8 data that 
were discontinuous with the rest of the time series and created implausible time trends. 
Modelling strategy  
We used a standard CODEm approach to model deaths from cardiovascular diseases. We have updated 
the covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
  
163
Table: Selected covariates for CODEm models, cardiovascular diseases 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Cumulative cigarettes (10 yrs) None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Trans fatty acid (percent) None 1 1 
Mean BMI None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 
Alcohol (litres per capita) None 3 0 
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Peripheral Artery Disease 







































Vital registration data were used to model peripheral artery disease. We outliered all data points with 
<1 death in Egypt per expert review. 
 
Modelling strategy  
We used a standard CODEm approach to model deaths from peripheral artery disease. We have 
updated the covariates included in the ensemble modelling process (see Table). Otherwise, there have 
been no substantive changes from the approach used in GBD 2015. 
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Table: Selected covariates for CODEm models, peripheral artery disease 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Mean body mass index (kg/m2) None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 
Trans fatty acid (percent) None 3 1 








































Vital registration and surveillance data were used to model endocarditis. We outliered vital registration 
data in Mozambique as these were non-representative for sub-Saharan Africa and were causing regional 
estimates to be implausibly low. We also outliered ICD8 data that were discontinuous from the rest of 
the data series and created an implausible time trend. 
 
Modelling strategy  
We used a standard CODEm approach to model deaths from endocarditis. We have updated the 
covariates included in the ensemble modelling process (see Table). Otherwise, there have been no 
substantive changes from the approach used in GBD 2015. 
Table: Selected covariates for CODEm models, endocarditis 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Improved water (proportion) None 1 -1 
Sanitation (proportion with access) None 1 -1 
Healthcare access and quality index None 1 -1 
Lag distributed income per capita (I$) Log 3 -1 





Other Cardiovascular and Circulatory Diseases 







































Vital registration, verbal autopsy, and surveillance data were used to model other cardiovascular and 
circulatory diseases. We outliered ICD8 and ICD9 BTL data points that were inconsistent with the rest of 
the data and created implausible time trends. We also outliered ICD8 data points which were not 
nationally representative. 
Modelling strategy  
We used a standard CODEm approach to model deaths from other circulatory and cardiovascular 
diseases. We have updated the covariates included in the ensemble modelling process (see Table). 
Otherwise, there have been no substantive changes from the approach used in GBD 2015. 
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Table: Selected covariates for CODEm models, cardiovascular diseases 
Covariate Transformation Level Direction 
Summary exposure variable None 1 1 
Cholesterol (total, mean per capita) None 1 1 
Smoking prevalence None 1 1 
Systolic blood pressure (mmHg) None 1 1 
Trans fatty acid (percent) None 1 1 
Mean BMI None 2 1 
Elevation over 1500m (proportion) None 2 -1 
Fasting plasma glucose (mmol/L) None 2 1 
Indoor air pollution (all fuel types) None 2 1 
Outdoor air pollution (PM2.5) None 2 1 
Healthcare access and quality index None 2 -1 
Lag distributed income per capita (I$) Log 3 -1 
Socio-demographic Index None 3 0 
Omega-3 (kcal/capita, adjusted) Log 3 -1 
Fruits (kcal/capita, adjusted) None 3 -1 
Vegetables (kcal/capita, adjusted) None 3 -1 
Nuts and seeds (kcal/capita, adjusted) None 3 -1 
Whole grains (kcal/capita, adjusted) None 3 -1 
Pulses/legumes (kcal/capita, adjusted) None 3 -1 
PUFA adjusted (percent) None 3 -1 
Alcohol (litres per capita) None 3 0 
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3.4.1 Cancers SDG Capstone Appendix
Input data and methodological summary for all cancers except for non-melanoma skin cancer 
Data 
The cause of death (COD) database contains multiple sources of cancer mortality data. These sources 
include vital registration, verbal autopsy, and cancer registry data. The cancer registry mortality 
estimates that are uploaded into the COD database stem from cancer registry incidence data that have 
been transformed to mortality estimates through the use of mortality-to-incidence ratios (MIR). 
Data seeking processes 
Cancer mortality data in the cause of death database other than cancer registry data 
Sources for cancer mortality data other than cancer registry data are described in the COD database 
description (Section 2).  
Cancer registry data 
Cancer registry data were used from publicly available sources or provided by collaborators. We 
attempted to collect data from all registries that are members of the International Association of Cancer 
Registries (IACR) by either downloading publicly available data or contacting the registries. We also used 
cancer registry databases like Cancer Incidence in Five Continents (CI5), EUREG, and NORDCAN.1–9  
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Most cancer registries only report cancer incidence. However, if a cancer registry also reported cancer 
mortality, mortality data were also extracted from the source to be used in the MIR estimation. 
Inclusion and exclusion criteria 
Only population-based cancer registries were included, and only those that included all cancers (no 
specialty registries), data for all age groups, and data for both sexes. Pathology-based cancer registries 
were included if they had a defined population. Hospital-based cancer registries were excluded.  
Cancer registry data were excluded from either the final incidence data input or the MI model input if a 
more detailed source (e.g., providing more detailed age or diagnostic groups) was available for the same 
population. Preference was given to registries with national coverage over those with only local 
coverage, except those from countries where the GBD study provides subnational estimates. 
Data were excluded if the coverage population was unknown.  
Bias of categories of input data 
Cancer registry data can be biased in multiple ways. A high proportion of ill-defined cancer cases in the 
registry data requires redistribution of these cases to other cancers, which introduces a potential for 
bias. Changes between coding systems can lead to artificial differences in disease estimates; however, 
we adjust for this bias by mapping the different coding systems to the GBD causes. Underreporting of 
cancers that require advanced diagnostic techniques (e.g., leukemia and brain, pancreatic, and liver 
cancer) can be an issue in cancer registries from low-income countries. On the other hand, 
misclassification of metastatic sites as primary cancer can lead to overestimation of cancer sites that are 
common sites for metastases, like brain or liver. Since many cancer registries are located in urban areas, 
the representativeness of the registry for the general population can also be problematic. The accuracy 
of mortality data reported in cancer registries usually depends on the quality of the vital registration 
system. If the vital registration system is incomplete or of poor quality, the mortality-to-incidence ratio 
can be biased to lower ratios. 
Data for liver cancer etiology splits 
To find the proportion of liver cancer cases due to the four etiology groups included in GBD (1. Liver 
cancer due to hepatitis B, 2. Liver cancer due to hepatitis C, 3. Liver cancer due to alcohol, 4. Liver cancer 
due to other causes), a systematic literature search was performed in PubMed. Studies were included if 
the study population was representative of liver cancer population for the respective location. For each 
study the proportions of liver cancer due to the three specific risk factors were calculated. Remaining 
risk factors were included under a combined “other” group. Cryptogenic cases were only included if 
other etiologies like viral hepatitis or alcoholic cirrhosis had been excluded. If multiple risk factors were 
reported for an individual patient these were apportioned proportionally to the individual risk factors. 
Methods 
Steps of analysis and data transformation processes 
Cancer registry data went through multiple processing steps before integration with the COD database. 
First, the original data were transformed into standardized files, which included standardization of 
format, categorization, and registry names (#1 in flowchart).  
Second, some cancer registries report individual codes as well as aggregated totals (e.g., C18, C19, and 
C20 are reported individually but the aggregated group of C18-C20 [colorectal cancer] is also reported in 
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the registry data). The data processing step “subtotal recalculation” (#2 in flowchart) verifies these 
totals and subtracts the values of any individual codes from the aggregates. 
In the third step (#3 in the flowchart), cancer registry incidence data and cancer registry mortality data 
are mapped to GBD causes. A different map is used for incidence and for mortality data because of the 
assumption that there are no deaths for certain cancers. One example is basal cell carcinoma of the skin. 
In the cancer registry incidence data, basal cell carcinoma is mapped to non-melanoma skin cancer 
(basal cell carcinoma). However, if basal cell skin cancer is recorded in the cancer registry mortality data, 
the deaths are instead mapped to non-melanoma skin cancer (squamous cell carcinoma) under the 
assumption that they were indeed misclassified squamous cell skin cancers. Other examples are benign 
or in situ neoplasms. Benign or in situ neoplasms found in the cancer registry incidence dataset were 
simply dropped from that dataset. The same neoplasms reported in a cancer registry mortality dataset 
were mapped to the respective invasive cancer (e.g., melanoma in situ in the cancer registry incidence 
dataset was dropped from the dataset; melanoma in situ in the cancer registry mortality dataset was 
mapped to melanoma). 
In the fourth data processing step (#4 in the flowchart) cancer registry data were standardized to the 
GBD age groups. Age-specific incidence rates were generated using CI5, SEER, and NORDCAN data, while 
age-specific mortality rates were generated from the CoD data through a method described in Part 2. 
Age-specific proportions were then generated by applying the age-specific rates to a given registry 
population that required age-splitting to produce the expected number of cases/deaths for that registry 
by age. The expected number of cases/deaths for each sex, age, and cancer were then normalized to 1, 
creating final, age-specific proportions. These proportions were then applied to the total number of 
cases/deaths by sex and cancer to get the age-specific number of cases/deaths.  
In the rare case that the cancer registry only contained data for both sexes combined, the now-age-
specific cases/deaths were split and re-assigned to separate sexes using the same weights that are used 
for the age-splitting process. Starting from the expected number of deaths, proportions were generated 
by sex for each age (e.g., if for ages 15 to 19 years old there are six expected deaths for males and four 
expected deaths for females, then 60% of the combined-sex deaths for ages 15-19 years would be 
assigned to males and the remaining 40% would be assigned to females).  
In the fifth step (#5 in the flowchart) data for cause entries that are aggregates of GBD causes were 
redistributed. Examples of these aggregated causes include some registries reporting ICD10 codes C00-
C14 together as, “lip, oral cavity, and pharyngeal cancer.” These groups were broken down into sub-
causes that could be mapped to single GBD causes. In this example, those include lip and oral cavity 
cancer (C00-C08), nasopharyngeal cancer (C11), cancer of other parts of the pharynx (C09-C10, C12-
C13), and “Malignant neoplasm of other and ill-defined sites in the lip, oral cavity, and pharynx” (C14).  
To redistribute the data, weights were created using the same “rate-applied-to-population” method 
employed in age-sex splitting (see step four above). For the undefined code (C14 in the example) an 
“average all cancer” weight was used, which was generated by adding all cases from 
SEER/NORDCAN/CI5 and dividing the total by the combined population. Then, proportions were 
generated by sub-cause for each aggregate cause as in the sex-splitting example above (see step four). 
The total number of cases from the aggregated group (C00-C14) was then recalculated for each 
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subgroup and the undefined code (C14). C14 was then redistributed as a “garbage code” in step six. 
Distinct proportions were used for C44 (non-melanoma skin cancer) and C46 (Kaposi’s sarcoma). Non-
melanoma skin cancer processing is described under section “Input data and methodological summary 
for non-melanoma skin cancer (squamous-cell carcinoma).” C46 entries were redistributed as “other 
cancer,” HIV, and C80 (other and unknown cancers) using proportions described in Part 2. 
In the sixth step (#6 in the flowchart) unspecified codes (“garbage codes”) were redistributed. 
Redistribution of cancer registry incidence and mortality data mirrored the process of the redistribution 
used in the cause of death database (Part 2).  
In the seventh step (#7 in the flowchart) duplicate or redundant sources were removed from the 
processed cancer registry dataset. Duplicate sources were present if, for example, the cancer registry 
was part of the CI5 database but we also had data from the registry directly. Redundancies occurred and 
were removed as described in “Inclusion and Exclusion Criteria,” where more detailed data were 
available, or when national registry data could replace regionally representative data. From here, two 
parallel selection processes were run to generate input data for the MI models and to generate 
incidence for final mortality estimation. Higher priority was given to registry data from the most 
standardized source when creating the final incidence input, whereas for the MI model input only 
sources that reported incidence and mortality were used. This is different to GBD 2015 where mortality 
and incidence could come from different sources as long as they covered the same population. 
In the eighth step (#8 in the flowchart) the processed incidence and mortality data from cancer 
registries were matched by cancer, age, sex, year, and location to generate MI ratios. These MI ratios 
were used as input for a three-step modelling approach using the general GBD ST-GPR approach with 
SDI as a covariate in the linear step mixed effects model using a logit link function. Predictions were 
made without the random effects. The ST-GPR model has three main hyper-parameters that control for 
smoothing across time, age, and geography. The time adjustment parameter (𝜆𝜆) was set to 2, which 
aims to borrow strength from neighboring time points (i.e. the exposure in this year is highly correlated 
with exposure in the previous year but less so further back in time). The age adjustment parameter ω 
was set to 0.5, which borrows strength from data in neighboring age groups. The space adjustment 
parameter 𝜉𝜉 was set to 0.95 in locations with data and to 0.5 in locations without data (the higher 𝜉𝜉 
was applied when at least one age-sex group in the country of estimation had at least five unique data 
points. The lower 𝜉𝜉 was applied when estimating data-scarce countries). Zeta aims to borrow strength 
across the hierarchy of geographical locations.10 For the amplitude parameter in the Gaussian process 
regression we used 2 and for the scale we used a value of 15. 
As in GBD 2015 we have modified the approach to estimate MI ratios. Since for GBD 2015 MI ratio 
predictions for some cancers yielded similar predictions for low-SDI countries without data as for high-
SDI countries we refined the estimation process. Inclusion criteria for the MI ratio input data were 
changed to only include mortality and incidence data if they were reported by the same source. We 
excluded MI ratios reported in the CI51,1–7 since mortality data used for the calculation of these MI ratios 
by definition has to be independent from the cancer registry. We also revised the outliering process and 
excluded data based on the SDI quintile categorization rather than on development status. For each 
cancer, MI ratios from locations in SDI quintiles 1-4 (low to high-middle SDI) were dropped if they were 
below the median of MI ratios from locations in SDI quintile 5 (high SDI). We also dropped MI ratios 
from locations in SDI quintiles 1-4 if the MI ratios were above the third quartile + 1.5 * IQR (inter-
quartile range). We dropped all MIR that were based on less than 25 cases to avoid noise due to small 
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numbers except for mesothelioma and acute lymphoid leukemia where we dropped MIR that were 
based on less than 10 cases because of lower data availability for these two cancers. We also aggregated 
incidence and mortality to the youngest 5-year age bin where we had at least 50 data points to avoid 
MIR predictions in young age groups that were based on few data points. The MIR in the age-bin that 
was used to aggregate MIR to, was used to backfill the MIR for younger age groups. 
Since MI ratios can be above 1, especially in older age groups and cancers with low cure rates, we used 
the 95th percentile of the cleaned dataset that only included MIR that were based on 50 or more cases, 
to cap the MIR input data. This “upper cap” was used to allow MIR over 1 but to constrain the MIR to a 
maximum level. To run the logit model, the input data was divided by the upper caps and model 
predictions after ST-GPR was rescaled by multiplying them by the upper caps.  
Upper caps used for GBD 2016 were the following: 


















To constrain the model at the lower end, we used the 5th percentile of the cancer specific cleaned MIR 
input data to replace all model predictions with this lower cap. 
Final MI ratios were matched with the cancer registry incidence dataset in the ninth step (#9 in the 
flowchart) to generate mortality estimates (Incidence * Mortality/Incidence = Mortality) (#10 in the 
flowchart). The final mortality estimates were then uploaded into the COD database (#11 in the 
flowchart). Cancer-specific mortality modelling then followed the general CODEm process. 
Liver cancer etiology split models 
The proportion data found through the systematic literature review were used as input for four separate 
DisMod-MR 2.1 models to determine the proportion of liver cancers due to the four subgroups for all 
locations, both sexes, and all age groups (step #16 in the flowchart). A study covariate was used for 
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publications that only assessed liver cancer in a cirrhotic population. The reference or “gold standard” 
that was used for crosswalking was the compilation of all studies that assessed the etiology of liver 
cancer in a general population. For liver cancer due to hepatitis C and hepatitis B, a prior value of 0 was 
set between age 0 and 0.01. For liver cancer due to alcohol a prior value of 0 was set for ages 0 to 5 
years. For liver cancer due to hepatitis C, hepatitis C (IgG) seroprevalence was used as a covariate as well 
as a covariate for alcohol (liters per capita) and hepatitis B prevalence (HBsAg seroprevalence), forcing a 
negative relationship between the alcohol and hepatitis B covariate and the outcome of liver cancer due 
to hepatitis C proportion. For liver cancer due to hepatitis B, seroprevalence of HBsAg was used as a 
covariate as well as a covariate for alcohol and hepatitis C IgG seroprevalence, forcing a negative 
relationship between the alcohol and hepatitis C covariate and the outcome of liver cancer due to 
hepatitis B proportion. For liver cancer due to alcohol, alcohol (liters per capita) was used as a covariate 
as well as a covariate for proportion of alcohol abstainers, hepatitis B and hepatitis C seroprevalence, 
forcing a negative relationship between the proportion of alcohol abstainers, hepatitis B and hepatitis C 
covariates and the outcome of liver cancer due to alcohol proportion. All covariates used were modelled 
independently. To ensure consistency between cirrhosis and liver cancer estimates and to take 
advantage of the data for the respective other related cause (e.g. liver cancer due to hepatitis C and the 
related cause cirrhosis due to hepatitis C), we generated covariates from the liver cancer proportion 
models that we used in the cirrhosis etiology proportion models. We then created covariates from the 
cirrhosis etiology proportion models and used those in the liver cancer etiology models.  
Since the proportion models are run independently of each other, the final proportion models were 
scaled to sum to 100% within each age, sex, year, and location, by dividing each proportion by the sum 
of the four (step # 17). For the liver cancer subtype mortality estimates, we multiplied the parent cause 
“liver cancer” by the corresponding scaled proportions (step # 18). Single cause estimates were adjusted 
to fit into the separately modelled all-cause mortality in the process CoDCorrect. 
Results 
Interpretation of results 
Cancer mortality estimates for GBD 2016 can differ from the GBD 2015 results for multiple reasons. 
Updated cancer mortality data were added from vital registration system data, verbal autopsy studies, 
as well as cancer registry incidence data. Mapping of cancer ICD codes to the GBD cancer causes was 
updated slightly based on collaborator comments. Mapping for the ICD10 code D46 (myelodysplastic 
syndrome) was changed back to “other cancer” as it had been in GBD 2013 based on collaborator 
comments and the consideration of adding myelodysplastic syndrome as a separate cause for future 
GBD iterations. To improve estimation of the leukemia sub-causes, a new cause, “leukemia other” was 
added since not all leukemia subtypes can be mapped the four most common types (acute and chronic 
lymphoid and myeloid leukemia). The mortality-to-incidence ratio estimation has changed compared to 
GBD 2015. Covariate inputs for the CODEm models were changed based on recommendations from 
collaborators. Covariates used in CODEm models were updated for GBD 2016. 
The other group producing country-level cancer mortality estimates is the International Agency for 
Research on Cancer (IARC) with their GLOBOCAN database. Significantly different methods between the 
GBD study and GLOBOCAN can lead to differences in results. Whereas estimates in GLOBOCAN are 
based on the assumption that there are “In theory, […] as many methods as countries,”11 the cancer 
estimation process for the GBD study follows a coherent, well-documented method for all cancers, 
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which allows cross-validation of models as well as determination of uncertainty. Another major 
difference is the ability in the GBD study to adjust single cause estimates to the all-cause mortality, 
which is being determined independently. This also allows us to adjust individual causes of death to the 
all-cause mortality envelope which permits us to correct for the underdiagnosis of cancer in countries 
with inadequate diagnostic resources. Redistribution of a fraction of undefined causes of death to 
certain cancers is another methodical advantage the GBD study has over GLOBOCAN, and estimates for 
cancer mortality can therefore differ substantially in countries with a large proportion of undefined 
causes of deaths in their vital registration data or a large proportion of undefined cancer cases in their 
cancer registry data. 
Limitations 
There are certain limitations to consider when interpreting the GBD mortality cancer estimates. First, 
even though every effort is made to include the most recently available data for each country, data-
seeking resources are not limitless and new data cannot always be accessed as soon as they are made 
available. It is therefore possible that the GBD study does not include all available data sources for 
cancer incidence or cancer mortality. Second, different redistribution methods can potentially change 
the cancer estimates substantially if the data sources used for the estimated location contain a large 
number of undefined causes; however, neglecting to account for these undefined deaths would likely 
introduce an even greater bias in the disease estimates. Third, using mortality-to-incidence ratios to 
transform cancer registry incidence data to mortality estimates requires accurate MIR. For GBD 2016 we 
have made further changes to the MIR estimation, but the method remains sensitive to underdiagnosis 
of cancer cases or underascertainment of cancer deaths. However, given that the majority of data used 
for the cancer mortality estimation come from vital registration data and not cancer registry data this is 
not a major limitation. 
Non-melanoma skin cancer (squamous-cell carcinoma) 
Data 
Data seeking processes 
The input data were identified and processed using the same methods as all other cancers described 
above. 
Inclusion and exclusion criteria 
Inclusion and exclusion criteria followed the same methods as described for other cancers (see above). 
Bias of categories of input data 
The potential biases of the input data are the same as for other cancers (see above). 
Methods 
Overall methodological process 
The GBD produces estimates for non-melanoma skin cancer via two subgroups: non-melanoma skin 
cancer (basal cell carcinoma) and non-melanoma skin cancer (squamous cell carcinoma). While some 
cancer registries report non-melanoma skin cancer at the four- or five- digit level required to distinguish 
between the subtypes (eg, “C44.01” versus “C44.02”, “173.01” versus “173.02), most registries report 
these cancers at the three-digit level as “C44” or “173” (“Other and unspecified malignant neoplasm of 
skin”). Because of this, those incident cases that were reported at this three-digit level were split to 
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“basal cell carcinoma” and “squamous cell carcinoma” based on proportions reported by Karagas et al 
during the cause disaggregation step (step #5 in the flowchart).12 Since mortality estimates are produced 
for squamous cell carcinoma under the assumption that basal cell carcinoma causes almost no deaths, 
all mortalities reported as “C44” or “173” were mapped to the “squamous cell carcinoma” GBD cause. 
Apart from this additional step for some incident cases, the remainder of the cancer registry processing 
was the same as for other cancers as described above.  
Steps of analysis and data transformation processes 
Non-melanoma skin cancer (squamous cell carcinoma) mortality estimation followed the same steps as 
the other cancers (see flowchart and description above) except for step #5 in the flowchart as described 
above.  
Model selection 
The modelling strategy for non-melanoma skin cancer (squamous cell carcinoma) followed the general 
CODEm process. 
Model performance and sensitivity 
The modelling performance and sensitivity for non-melanoma skin cancer (squamous cell carcinoma) 
mirrored that of the general CODEm process. 
Uncertainty intervals 
Uncertainty was determined using standard CODEm methodology. 
Results 
Interpretation of results 
Non-melanoma skin cancer mortality estimates are not available from other sources. GLOBOCAN, for 
example, does not report deaths due to non-melanoma skin cancer. Even though the data availability for 
non-melanoma skin cancer is poor, the fact that it is the most common incident cancer with rates 
expected to rise makes it a necessity to include the disease in the GBD framework.  
Limitations 
Cancer registry data for non-melanoma skin cancer incidence have to be interpreted with caution due to 
a substantial amount of underreporting or rules that only the first non-melanoma skin cancer has to be 
registered. Many cancer registries therefore do not include non-melanoma skin cancers at all. For vital 
registration data we make the assumption that there are no deaths due to non-melanoma skin cancer 
(basal cell carcinoma), therefore all deaths attributed to basal cell carcinoma were included instead as 
squamous cell carcinoma. 
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Verbal Autopsy Data: We outliered VA data points in urban Indian states where high-quality vital 
registration data were also available. We also outliered data points where the VA data were implausible 
in all age groups as we determined that these data sources were unreliable. 
Vital Registration Data: We outliered all data in four urban Indian states where the source of the data 
was unreliable according to expert opinion. We also outliered ICD9BTL data points which were 
inconsistent with the rest of the data series and created unlikely time trends. 
Modeling strategy  
We used a slight variation on the standard CODEm approach to model deaths from diabetes mellitus. 
Since deaths in younger age groups are almost exclusively due to Type 1 diabetes while deaths in older 
ages are primarily due to Type 2, we used two models to estimate overall diabetes deaths. We reviewed 
the cause-fraction of deaths due to Type 1 and Type 2 diabetes at the global, super region, and regional 
level. We selected a conservative estimate of 25 years; one model is for deaths in 0-25 year olds and the 
second model is for deaths in 25+ year olds.  
The following list are the covariates included in the model. 
• Education years per-capita
• A composite score that approximates access to and quality of personal healthcare (Healthcare
Access and Quality Index)
• Lag distributed GDP per capita in base 2010 international dollars
• Estimated national availability of animal fat expressed as kilocalories per capita
• Mean diabetes fasting plasma glucose (mmol/L) by age group
• Age-standardized prevalence of diabetes
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• Age-standardized mean body mass index for adults ages 20+ (separate by sex)
• Mean serum total cholesterol (mmol/L) for individuals above age 25
• Mean systolic blood pressure (mmHg) for individuals above age 25
• Estimated energy adjusted national availability of fruits expressed in grams per person per day
• Estimated energy adjusted national availability of vegetables expressed in grams per person per
day
• Estimated energy adjusted national availability of whole grains expressed in grams per person
per day
• Estimated national availability of dietary energy expressed in kilocalories per person per day
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Sources used to estimate chronic respiratory disease mortality included vital registration, verbal 
autopsy, and surveillance data from China. Our outlier criteria excluded data points that (1) were 
implausibly high or low, (2) substantially conflicted with established age or temporal patterns, or (3) 
significantly conflicted with other data sources conducted from the same locations or locations with 
similar characteristics (ie, Socio-demographic Index). 
Modelling strategy  
The standard CODEm modelling approach was applied to estimate deaths due to chronic respiratory 
diseases. Chronic respiratory diseases served as the parent cause to chronic obstructive pulmonary 
disease, pneumoconiosis (including silicosis, asbestosis, coal worker’s pneumoconiosis, other 
pneumoconiosis), asthma, interstitial lung disease and pulmonary sarcoidosis, and other chronic 
respiratory diseases. Functionally, this means the death estimates for Chronic Respiratory Diseases serve 
as a “parent” envelope into which the “child” causes are squeezed by the CodCorrect algorithm. This 
approach allows us to use a broader range of data – specifically verbal autopsy data – which cannot be 
accurately mapped to specific respiratory diseases.  
Separate models were conducted for male and female mortality, and the age range for both models was 
0 to 95+ years. The same covariates from GBD 2015 were used, with the exception of indoor air 
pollution, which was changed from cooking-fuel-specific covariates to a generic all cooking fuel 
covariate. 
Level Covariate Direction 
1 log-transformed SEV scalar: chronic respiratory diseases + 
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cumulative cigarettes (10 years) + 
cumulative cigarettes (5 years) + 
health care quality and access index - 
2 smoking prevalence + 
indoor air pollution (all cooking fuels) + 
outdoor air pollution (PM2.5) + 
population above 1500m elevation (proportion) + 
3 log LDI (I$ per capita) - 
education (years per capita) - 
Socio-demographic Index - 
population between 500 and 1,500m elevation (proportion) + 
population density over 1,000 people/square meter (proportion) + 
Beyond changes in the underlying covariates, there were no substantial deviations from the GBD 2015 
approach.  
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Data used to estimate chronic obstructive pulmonary disease (COPD) mortality included vital 
registration and surveillance data from the cause of death (COD) database. Our outlier criteria excluded 
data points that (1) were implausibly high or low, (2) substantially conflicted with established age or 
temporal patterns, or (3) significantly conflicted with other data sources conducted from the same 
locations or locations with similar characteristics (ie, Socio-demographic Index).  
Modelling strategy  
The standard CODEm modelling approach was applied to estimate deaths due to COPD. Separate 
models were conducted for male and female mortality, and the age range for both models was 1-95+ 
years. The mortality estimates from the COPD models were ultimately fit into the chronic respiratory 
diseases envelope. 
The same covariates from GBD 2015 were used, with the exception of indoor air pollution, which was 
changed from cooking-fuel-specific covariates to a generic all cooking fuel covariate, and the health care 
access and quality index covariate, which was used in place of health systems access.  
Level Covariate Direction 
1 log-transformed SEV scalar: COPD + 
cumulative cigarettes (10 years) + 
cumulative cigarettes (5 years) + 
elevation over 1,500m (proportion) + 
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2 smoking prevalence + 
indoor air pollution (all cooking fuels) + 
outdoor air pollution (PM2.5) + 
health care access and quality index - 
3 Socio-demographic Index - 
log LDI (I$ per capita) - 
education (years per capita) - 
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Data used to estimate pneumoconiosis diseases mortality included vital registration and China mortality 
surveillance data from the cause of death (COD) database. Our outlier criteria excluded data points that 
(1) were implausibly high or low, (2) substantially conflicted with established age or temporal patterns, 
or (3) significantly conflicted with other data sources conducted from the same locations or locations 
with similar characteristics (i.e., socio-demographic index). 
Modelling strategy  
The standard CODEm modelling approach was applied to estimate deaths due to pneumoconiosis 
diseases. Separate models were conducted for male and female mortality, and the age range for both 
models was 1–95+ years. The mortality estimates from pneumoconiosis disease models were ultimately 
fit into the chronic respiratory envelope, which is the parent cause for pneumoconiosis disease. The 
pneumoconiosis model serves as an envelope for silicosis, asbestosis, coal worker’s pneumoconiosis, 
and other pneumoconiosis. In CoDCorrect, estimates are first fit within all pneumoconiosis, then within 
all chronic respiratory disease, before being fit to the all-cause mortality envelope.  
For the most part, the same covariates from GBD 2015 were used. Indoor air pollution was changed 
from cooking-fuel specific covariates to a generic all cooking fuel covariate. Adjustments were also made 
to the coal and asbestos covariates. 
The coal production covariate was improved to include subnational data for the United States and India. 
United States state-level data for 2001-2015 came from the U.S. Energy Information Administration. 
India state-level data for 2005-2014 came from the Ministry of Coal in India. We scaled these figures to 
the national estimates from the BP Statistical Review of World Energy 2016. For years with missing 
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state-level data we split the national-level data according to the proportions by state in the closest year 
for which we did have state-level data. 
We also created a covariate for asbestos consumption per capita with a 30-year lag, and used that 
instead of the GBD 2015 asbestos production covariate. This change is based on the idea that asbestos 
production may be too limited in scope, given that asbestosis may occur in locations where asbestos is 
used and handled but not necessarily mined. To create the asbestos consumption covariate we used 
data from the United States Geological Survey to run a model in DisMod 2.1. A 30-year lag was placed 
on this model to account for the delay between asbestos consumption and occurrence of disease. 
The following table indicates covariates used in the pneumoconiosis models, their level, and direction: 
Level Covariate Direction 
1 log-transformed SEV scalar: pneumoconiosis + 
asbestos consumption per capita* + 
coal production per capita* + 
gold production per capita* + 
2 smoking prevalence + 
indoor air pollution (all cooking fuels) + 
cumulative cigarettes (5 years) + 
elevation over 1,500m (proportion) + 
elevation 500 to 1,500m (proportion) + 
health care access and quality index - 
3 log LDI (I$ per capita) - 
education (years per capita) - 
Socio-demographic Index - 
* asbestos, coal, and gold covariates are each only used in a subset of the pneumoconiosis models, as
follows: all three are included in the parent all pneumoconiosis model, asbestos consumption is included 
in the asbestosis model, coal production is included in the coal worker’s pneumoconiosis model, and 

































Data used to estimate asthma mortality included vital registration and surveillance data from the cause 
of death (COD) database. Verbal autopsy data were not included and were instead mapped to the 
parent model (Chronic Respiratory Diseases). Our outlier criteria excluded data points that (1) were 
implausibly high or low relative to global or regional patterns, (2) substantially conflicted with 
established age or temporal patterns, or (3) significantly conflicted with other data sources conducted 
from the same locations or locations with similar characteristics (ie, Socio-demographic Index). 
Modelling strategy  
The standard CODEm modelling approach was applied to estimate deaths due to asthma. Separate 
models were conducted for male and female mortality, and the age range for both models was 1–95+ 
years. The mortality estimates from the asthma models were ultimately fit into the chronic respiratory 
diseases envelope.  
The same covariates from GBD 2015 were used, with the exception of indoor air pollution, which was 
changed from cooking-fuel-specific covariates to a generic all cooking fuel covariate. 
Level Covariate Direction 
1 log-transformed SEV scalar: asthma + 
cumulative cigarettes (10 years) + 
cumulative cigarettes (5 years) + 
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health care access and quality index - 
2 smoking prevalence + 
indoor air pollution (all cooking fuels) + 
outdoor air pollution (PM2.5) + 
3 log LDI (I$ per capita) - 
education (years per capita) - 
Socio-demographic Index - 
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Data used to estimate interstitial lung disease and pulmonary sarcoidosis mortality included vital 
registration and surveillance data from the cause of death (COD) database. Our outlier criteria excluded 
data points that (1) were implausibly high or low, (2) substantially conflicted with established age or 
temporal patterns, or (3) significantly conflicted with other data sources conducted from the same 
locations or locations with similar characteristics (ie, Socio-demographic Index). 
Modelling strategy  
The standard CODEm modelling approach was applied to estimate deaths due to interstitial lung disease 
and pulmonary sarcoidosis. Separate models were conducted for male and female mortality, and the 
age range for both models was 1–95+ years. The mortality estimates from the interstitial lung disease 
and pulmonary sarcoidosis models were ultimately fit into the chronic respiratory envelope. 
The same covariates from GBD 2015 were used, with the exception of indoor air pollution, which was 
changed from cooking-fuel-specific covariates to a generic all cooking fuel covariate. 
Level Covariate Direction 
1 log-transformed SEV scalar: interstitial lung disease + 
smoking prevalence + 
cumulative cigarettes (5 years) + 
2 elevation over 1,500m (proportion) + 
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elevation between 500 and 1,500m (proportion) + 
population density over 1,000 ppl/sqkm (proportion) + 
indoor air pollution (all cooking fuels) + 
outdoor air pollution (PM2.5) + 
health care access and quality index - 
3 log LDI (I$ per capita) - 
education (years per capita) - 
Socio-demographic Index - 
190

































Data used to estimate other chronic respiratory diseases included vital registration and surveillance data 
from the cause of death (COD) database. Our outlier criteria excluded data points that (1) were 
implausibly high or low, (2) substantially conflicted with established age or temporal patterns, or (3) 
significantly conflicted with other data sources conducted from the same locations or locations with 
similar characteristics (ie, Socio-demographic Index).  
Modelling strategy  
The standard CODEm modelling approach was applied to estimate deaths due to other chronic 
respiratory diseases. Separate models were conducted for male and female mortality, and the age range 
for both models was 0 days to 95+ years. Like other respiratory causes, the mortality estimates from 
other chronic respiratory diseases were ultimately fit into the chronic respiratory envelope. 
The same covariates from GBD 2015 were used, with the exception of indoor air pollution, which was 
changed from cooking-fuel-specific covariates to a generic all cooking fuel covariate. 
Level Covariate Direction 
1 log-transformed SEV scalar: other chronic respiratory diseases + 
smoking prevalence + 
cumulative cigarettes (5 years) + 
indoor air pollution (all cooking fuels) + 
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outdoor air pollution (PM2.5) + 
2 elevation over 1,500m (proportion) + 
elevation between 500 and 1,500m (proportion) + 
population density over 1,000 ppl/sqkm (proportion) + 
health care access and quality index - 
3 log LDI (I$ per capita) - 
education (years per capita) - 














































































































































1.1.d  Motor vehicle road injuries  CODEm and fatal discontinuity estimation
1.1.e  Other road injuries  CODEm























































ID  Cause  Modelling Strategy Covariate changes from GBD 2015
4.1  Exposure to forces of nature  Fatal discontinuity estimation for disaster 
(appended post‐CoDCorrect) 
N/A 







































































































































































We  defined  exposure  as  the  grams  per  day  of  pure  alcohol  consumed  amongst  drinkers.  We 
constructed this exposure using the indicators outlined below: 




















  A systematic  review of  the  literature was performed to extract data on our primary  indicators. The 
Global  Health  Exchange  (GHDx),  IHME’s  online  database  of  health‐related  data,  was  searched  for 
population  survey  data  containing  participant‐level  information  from  which  we  could  formulate  the 
required alcohol use indicators on current drinkers,  lifetime abstainers, alcohol consumption, and binge 
drinkers. Data‐sources were included if they captured a sample representative of the geographic location 
under  study.  We  documented  relevant  survey  variables  from  each  data‐source  in  a  spreadsheet  and 
extracted using STATA 13.1 and R 3.3 . A total of 2,821 potential data‐sources were available in the GHDx 
across  countries  with  subnational  locations,  out  of  which  191  data‐sources  (corresponding  88,734 
tabulated data‐points by location/year/sex/age) were included across the four indicators mentioned above.  
To generate estimates of alcohol consumption in  liters per capita (LPC), we obtained data from 
FAOSTAT,  and  WHO  GISAH  database  [1‐2].  To  provide  more  stable  time  trends  in  the  model,  we 
transformed FAO sales data (which calculates stock based on primary inputs) to a lagged five‐year average. 






ܮ݋݃	ܣݒ݁ݎܽ݃݁	ܦܽݐܽ ൌ ܦ ൅ ሺܵݑ݌݁ݎ	ܴ݁݃݅݋݊	|ܦ, ܴ݁݃݅݋݊	|	ܦ, ܥ݋ݑ݊ݐݎݕ	|ܦ, ܻ݁ܽݎ|	ܦሻ 



























we  outline  how  we  estimated  each  primary  input  in  the  alcohol  exposure model,  as  well  as  how  we 
combined these inputs to arrive at our final estimate of grams per day of pure alcohol. We estimated all 
models below using 1000 draws. 
  For  data  obtained  through  surveys,  we  used  DisMod‐MR  2.1  to  construct  estimates  for  each 







variation  across  countries  and  time‐periods, we  took  1000 draws  from  the uniform distribution  of  the 























After  adjusting  alcohol  LPC  by  tourist  consumption  and  unrecorded  consumption  for  all 
location/years reported, sex‐specific and age‐specific estimates were generated by incorporating estimates 
modeled  in  DisMod  for  percentage  of  current  drinkers  within  a  location/year/sex/age,  as  well  as 













ൌ 	 ܣ݈ܿ݋݄݋݈		݃/݀ܽݕ		௟,௬,௦,௔	 ∗ 	ܲ݋݌ݑ݈ܽݐ݅݋݊	௟,௬,௦,௔	 ∗ 	%	ܥݑݎݎ݁݊ݐ	݀ݎ݅݊݇݁ݎݏ	௟,௬,௦,௔∑ ܣ݈ܿ݋݄݋݈		݃/݀ܽݕ	௟,௬,௦,௔ 	∗ 	ܲ݋݌ݑ݈ܽݐ݅݋݊	௟,௬,௦,௔	 ∗ 	%	ܥݑݎݎ݁݊ݐ	݀ݎ݅݊݇݁ݎݏ	௟,௬,௦,௔	௦,௔  
 
 
ܣ݈ܿ݋݄݋݈	ܮܲܥ	௟,௬,௦,௔ ൌ 	ܣ݈ܿ݋݄݋݈	ܮܲܥ	௟,௬ 	∗ 	ܲ݋݌ݑ݈ܽݐ݅݋݊	௟,௬ 	∗ 	ܲݎ݋݌݋ݎݐ݅݋݊	݋݂	ݐ݋ݐ݈ܽ	ܿ݋݊ݏݑ݉݌ݐ݅݋݊	௟,௬,௦,௔	%	ܥݑݎݎ݁݊ݐ	݀ݎ݅݊݇݁ݎݏ	௟,௬,௦,௔ ∗ ܲ݋݌ݑ݈ܽݐ݅݋݊	௟,௬,௦,௔  
 








































  For  GBD2016,  we  performed  a  systematic  literature  review  of  all  cohort  and  case‐control  studies 
reporting a relative risk, hazard ratio, or odds ratio for any risk‐outcome pairs studied in GBD 2016. Studies 
were  included  if  they  reported  a  categorical  or  continuous  dose  for  alcohol  consumption,  as  well  as 
uncertainty measures for their outcomes, and the population under study was representative.  
  We  then  used  these  studies  to  calculate  a  dose‐response, modeled  using DisMod ODE. We  chose 
DisMod ODE rather than a conventional mixed effect meta‐regression because of  its ability  to estimate 
nonparametric  splines  over  doses  (i.e.  for most  alcohol  causes,  there  is  a  non‐linear  relationship with 
different doses) and incorporate heterogeneous doses through dose‐integration (i.e. most studies report 
doses categorically in wide ranges. DisMod ODE estimates specific doses when categories overlap across 






















ܣ݆݀ݑݏݐ݁݀	ܲܣܨ௜ ൌ ∑ ܲܣܨௗ ∗ ܦܣܮ ௗܻ ∗ ܣݒ݃	ܨܽݐ݈ܽ݅ݐ݅݁ݏௗௗ ∗ 	ܲሺ݅	݅ݏ	ܽ	ݒ݅ܿݐ݅݉ሻௗܦܣܮ ௜ܻ  
 
where: 




































3. UN  World  Tourism  Organization  (UNWTO).  UN  World  Tourism  Organization  Compendium  of 
Tourism  Statistics  2015  [Electronic]. Madrid,  Spain:  UN World  Tourism Organization  (UNWTO), 
2016. 

















and  the  impact  of  improved measurement  on  coverage  of  alcohol  sales  in  the  2000  National 
Alcohol Survey." Alcoholism: Clinical and Experimental Research 31.10 (2007): 1714‐1722. 


















































































































































































































































݉௖ሺݐሻ ൌ ܺߚ ൅ ݄ሺݎ௖,௧ሻ 
where ܺߚ is a linear model and ݄ሺݎ௖,௧ሻ is a smoothing function for the residuals; and ݎ௖,௧ is derived from 
the linear model. The following linear model was used for the estimation of TFR:  



































































































































































































ܫ௟,௬ ൌ log	ሺܴܵܣܵܦ௟,௬ሻ െ min
ሺlog	ሺܴܵܣܵܦ஼௒ᇱ ሻሻ

























































































































































































































݉௖ሺݐሻ ൌ ܺߚ ൅ ݄ሺݎ௖,௧ሻ 
where ܺߚ is a linear model and ݄ሺݎ௖,௧ሻ is a smoothing function for the residuals; and ݎ௖,௧ is derived from 
the linear model. The following linear model was used to model DPT3, measles, and polio coverage:  

























































































































































































































݉௖ሺݐሻ ൌ ܺߚ ൅ ݄ሺݎ௖,௧ሻ 
where ܺߚ is a linear model and ݄ሺݎ௖,௧ሻ is a smoothing function for the residuals; and ݎ௖,௧ is derived from 
the linear model. The following linear model was used for the estimation of ANC indicators:  




















































































































































































݉௖ሺݐሻ ൌ ܺߚ ൅ ݄ሺݎ௖,௧ሻ 
where ܺߚ is a linear model and ݄ሺݎ௖,௧ሻ is a smoothing function for the residuals; and ݎ௖,௧ is derived from 
the linear model. The following linear model was used for the estimation of ANC indicators:  


















































































































TB prevalence and latent TB infection 
prevalence estimates from DisMod
Input data 
Input data for modeling tuberculosis mortality among HIV-negative individuals include vital registration, 
verbal autopsy, and surveillance data. Vital registration data were adjusted for garbage coding (including 
ill-defined codes, and the use of intermediate causes) following GBD algorithms and misclassified HIV 
deaths (i.e., HIV deaths being assigned to other underlying causes of death such as tuberculosis or 
diarrhea because of stigma or misdiagnosis). This correction was done based on examining changes in 
the age pattern of diseases over time.  
Verbal autopsy data in countries with age-standardized HIV prevalence greater than 5% were removed 
because of a high probability of misclassification, as verbal autopsy studies have poor validity in 
distinguishing HIV deaths from HIV-TB deaths.  
Modeling strategy  
We changed the modeling strategy of tuberculosis in GBD2016 by first modeling prevalence of disease 
and prevalence of latent infection which were then used as covariates in the CODEm model. We 
dropped the health system access covariate and replaced it by the newly developed Healthcare Access 
and Quality Index covariate. We also added the adult underweight proportion covariate. Other location-
level covariates included in the CODEm model were the same as in GBD 2015: alcohol (liters per capita), 
diabetes (fasting plasma glucose mmol/L), education (years per capita), lag-distributed income, indoor 
air pollution, outdoor air pollution, population density, smoking prevalence, sociodemographic status, 
and a summary exposure variable reflecting the average exposure to all of the risk factors.  
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MDR-TB in all 
TB cases by 
location/year
Studies reporting on relative risk of 
mortality in MDR-TB cases compared 
with drug-sensitive TB cases from 
systematic review 
Meta-analysis
Pooled RR of  
MDR-TB 
mortality






MDR-TB cases and TB cases with DST 
results from WHO anti-TB drug resistance 
surveillance and TB drug susceptibility 
testing surveys 
Apply fractions of 
MDR-TB deaths to  
TB deaths
Subtract MDR-
TB deaths from 
all TB deaths
Drug-sensitive 










TB deaths from 
MDR-TB deaths
MDR-TB deaths 
(without XDR)  
by location, 
year, age, sex
TB prevalence and latent TB 
infection prevalence estimates 
from DisMod 




TB in TB no-HIV 
cases
Proportions 
of MDR-TB in 
TB no-HIV 
cases 
HIV-TB and TB no-HIV incidence 
estimates from DisMod
XDR-TB and MDR-TB cases with DST to 
second-line drugs from WHO surveillance 
and TB drug susceptibility testing surveys 
Calculate super-region 
level proportions of 
XDR- TB among MDR-TB 
cases
Calculate fractions of 
XDR-TB deaths in  
MDR-TB deaths
Studies reporting on relative risk of 
mortalilty in XDR-TB cases compared 
with MDR-TB cases
Apply fractions of 
XDR-TB deaths 
Fraction of XDR-












Input data include: (i) the number of drug-resistant cases by type (multidrug-resistant tuberculosis 
[MDR-TB], extensively drug-resistant tuberculosis [XDR-TB], all TB cases with a drug sensitivity testing 
[DST] result for isoniazid and rifampicin, and MDR-TB cases with DST for second-line drugs) from routine 
surveillance and surveys reported to the World Health Organization, (ii) data from studies (identified 
through our systematic review) reporting on the relative risk of death in MDR-TB cases compared with 
non-MDR TB (drug-sensitive TB) cases, and the relative risk of death in XDR-TB cases compared with 
MDR-TB cases, and (iii) the risk of MDR-TB associated with HIV infection from the literature.1   
Modelling strategy  
We conducted a systematic review and meta-analysis of studies reporting the relative risk of death in 
MDR-TB cases compared with drug-sensitive TB cases. We also ran a spatiotemporal Gaussian process 
regression to predict the proportions of MDR-TB cases among all TB cases for all locations and years. We 
computed the weighted average of the proportions of new and previously treated cases with MDR-TB, 
and used these as the input data for this regression. We then used the predicted proportions of MDR-
TB, along with the HIV-TB and TB no-HIV incidence estimates (from our modeling of non-fatal TB), and 
the relative risk of MDR-TB associated with HIV infection from the literature1 to compute the 
proportions of MDR-TB cases among HIV negative TB cases �𝑃𝑃𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠� by location, year, age, and 
sex using the following formula: 
𝑃𝑃𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠 = 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦
�1 + �𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠𝐻𝐻𝐻𝐻𝑇𝑇𝑇𝑇𝐻𝐻𝐻𝐻𝐻𝐻𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠��  𝐻𝐻𝐻𝐻𝑇𝑇𝑇𝑇𝐻𝐻𝐻𝐻𝐻𝐻𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠
where 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦 is the number of all MDR-TB cases among HIV-positive and HIV-negative individuals by 
location and year, 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀  is the relative risk of MDR-TB associated with HIV infection, 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠 is the 
number of HIV-TB incident cases by location, year, age, and sex, and 𝐻𝐻𝐻𝐻𝑇𝑇𝑇𝑇𝐻𝐻𝐻𝐻𝐻𝐻𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠 is the number of TB 
no-HIV incident cases by location, year, age, and sex. 
We then computed the fraction of MDR-TB deaths among all HIV-negative TB deaths (𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠) 
using the following formula: 
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠 = 𝑃𝑃𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑃𝑃𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 + 1 − 𝑃𝑃𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀,𝑦𝑦,𝑎𝑎,𝑠𝑠
where 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀  is the relative risk of death in MDR-TB cases compared with drug-sensitive TB cases. We 
then applied the predicted fractions of MDR-TB deaths among HIV-negative TB deaths to our CODEm TB 
death estimates to generate MDR-TB deaths by location, year, age, and sex. Next, we subtracted MDR-
TB deaths from all TB deaths to generate drug-sensitive TB deaths by location, year, age, and sex.  
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To separate out XDR-TB from MDR-TB, we aggregated the XDR-TB cases and MDR-TB cases (with DST for 
second-line drugs) up to the super-region level and calculated the super-region level proportions of XDR-
TB among MDR-TB cases. Next, we computed the super-region-specific fractions of XDR-TB deaths 
among all MDR-TB deaths (𝑀𝑀𝑋𝑋𝑀𝑀𝑀𝑀𝑠𝑠𝑋𝑋) using the following formula: 
𝑀𝑀𝑋𝑋𝑀𝑀𝑀𝑀𝑠𝑠𝑋𝑋 = 𝑃𝑃𝑋𝑋𝑀𝑀𝑀𝑀𝑠𝑠𝑋𝑋𝑀𝑀𝑀𝑀𝑋𝑋𝑀𝑀𝑀𝑀𝑃𝑃𝑋𝑋𝑀𝑀𝑀𝑀𝑠𝑠𝑋𝑋𝑀𝑀𝑀𝑀𝑋𝑋𝑀𝑀𝑀𝑀 + 1 − 𝑃𝑃𝑋𝑋𝑀𝑀𝑀𝑀𝑠𝑠𝑋𝑋
where 𝑃𝑃𝑋𝑋𝑀𝑀𝑀𝑀𝑠𝑠𝑋𝑋 is the proportion of XDR-TB among MDR-TB cases for each super-region, and 𝑀𝑀𝑀𝑀𝑋𝑋𝑀𝑀𝑀𝑀 is 
the pooled relative risk of mortality in XDR-TB cases compared with MDR-TB cases. These fractions were 
then applied to MDR-TB deaths in corresponding countries within the super-regions to produce XDR-TB 
deaths by location, age, and sex for the most recent year of estimation. We linearly extrapolated XDR-TB 
mortality rates back assuming the mortality rates were zero in 1992, one year before 1993 when XDR-TB 
was first recorded in USA surveillance data.2 Finally, we subtracted XDR-TB deaths from MDR-TB deaths 
to generate MDR-TB (without extensive drug resistance) deaths by location, year, age, and sex.   
Reference 
1. Mesfin YM, Hailemariam D, Biadglign S, Kibret KT. Association between HIV/AIDS and multi-drug
resistance tuberculosis: a systematic review and meta-analysis. PLoS One. 2014;9(1):e82235.
2. Centers for Disease Control and Prevention (CDC). Extensively Drug-Resistant Tuberculosis ---




Cause of death. Diarrheal disease mortality was estimated in CODEm. We estimated diarrhea 
mortality separately for males and females and for children under 5 years and older than 5 
years. We used all available data from vital registration systems, surveillance systems and 
verbal autopsy (Table 1). We checked for and excluded outliers from our data by country or 
region. We also excluded early neonatal mortality data in the Philippines (1994–1998) and India 
Civil Registration System data in all states (1986–1995).  
Etiologies. We conducted a systematic literature review for the proportion of diarrhea cases 
that tested positive for each etiology. We updated our review of literature to include studies 
published between May 2015 and May 2016. Inclusion criteria included diarrhea as the case 
definition, studies with a sample size of at least 100, and studies with at least one year of 
follow-up. We excluded studies that reported on diarrheal outbreaks exclusively and those that 
used acute gastroenteritis with or without diarrhea. We identified 442 studies, of which 36 met 
our criteria of inclusion and were included. We extracted data points for location, sex, year, and 
age. We assigned an age range based on the prevalence-weighted mean age of diarrhea in the 
appropriate year/sex/location if the age of the study participants was not reported.  
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We used the Global Enteric Multicenter Study (GEMS), a seven-site, case-control study of 
moderate-to-severe diarrhea in children under 5 years,1 to calculate odds ratios for the 
diarrheal pathogens. We analyzed raw data for a systematic reanalysis, representative of the 
distribution of cases and controls by age and site, of roughly half of the 22,000 original GEMS 
samples that were tested for the presence of pathogen using quantitative polymerase chain 
reaction (qPCR).2  
Modeling strategy 
Cause of death. We used country-level covariates to inform our CODEm models. We included 
covariates for years of education per capita, income per capita, prevalence of undernutrition 
(weight-for-age, weight-for-height, and height-for-age), population density above 1,000 or 
below 150 people per square kilometer, sanitation access, safe water access, Socio-
Demographic Index, and rotavirus vaccine coverage. We evaluated our diarrheal disease cause 
of death models using in and out of sample predictive performance.  
Etiologies. We estimated diarrheal disease etiologies separately from overall diarrhea mortality 
using a counterfactual strategy for enteric adenovirus, Aeromonas, Entamoeba histolytica 
(amoebiasis), Campylobacter enteritis, Cryptosporidium, typical enteropathogenic Escherichia 
coli (t-EPEC), enterotoxigenic Escherichia coli (ETEC), norovirus, non-typhoidal salmonella 
infections, rotavirus, and Shigella. Vibrio cholerae and Clostridium difficile were modeled 
separately.  
Diarrheal etiologies are attributed to diarrheal deaths using a counter-factual approach. We 
calculated a population attributable fraction (PAF) from the proportion of severe diarrhea cases 
that are positive for each etiology. The PAF represents the relative reduction in diarrhea 
mortality if there was no exposure to a given etiology. As diarrhea can be caused by multiple 
pathogens and the pathogens may co-infect, PAFs can overlap and add up to more than 100%. 
We calculated the PAF from the proportion of severe diarrhea cases that are positive for each 
etiology. We assumed that hospitalized diarrhea cases are a proxy of severe and fatal cases. We 
used the following formula to estimate PAF:4 
𝑃𝑃𝑃𝑃𝑃𝑃 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 ∗ (1 − 1
𝑂𝑂𝑂𝑂
) 
Where Proportion is the proportion of diarrhea cases positive for an etiology and OR is the odds 
ratio of diarrhea given the presence of the pathogen. 
We dichotomized the continuous qPCR test result using the value of the cycle threshold (Ct) 
that most accurately discriminated between cases and controls. The Ct values range from 0 to 
35 cycles representing the relative concentration of the target gene in the stool sample. A low 
value indicates a higher concentration of the pathogen while a value of 35 indicates the 
absence of the target in the sample. We used the lower Ct value when we had multiple Ct 
values for the cutpoint. The case definition for each pathogen is a Ct value that is below the 
established cutoff point.  
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We used a mixed effects conditional logistic regression model to calculate the odds ratio for 
under 1 year and 1-4 years old for each of our pathogens. The odds ratio for 1-4 years was 
applied to all GBD age groups over 5 years. There were three pathogen-age odds ratios that 
were not statistically significant: Aeromonas and Amoebiasis in under 1 year and 
Campylobacter in 1-4 years. The mean value of the odds ratio was above 1 in all three cases so 
we transformed the odds ratios for these three exceptions only in log-space such that 
exponentiated values could not be below 1. The transformation was: 
Odds ratio = exp(log(or) – 1)) + 1 
We modeled the proportion data using the meta-regression tool DisMod-MR to estimate the 
proportion of positive diarrhea cases for each separate etiology by location/year/age/sex and 
to adjust for the covariates.  
We used the estimated sensitivity and specificity of the laboratory diagnostic technique used in 
the GEMS study compared to the qPCR case definition to adjust our proportion before we 
computed the PAF:5 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 = (𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂𝑂𝑂𝑂𝑂𝑇𝑇𝑇𝑇𝑂𝑂𝑇𝑇𝑂𝑂 + 𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆𝑃𝑃𝑆𝑆𝑃𝑃𝑆𝑆𝑃𝑃𝑃𝑃𝑆𝑆 − 1)(𝑆𝑆𝑆𝑆𝑃𝑃𝑆𝑆𝑃𝑃𝑃𝑃𝑃𝑃𝑆𝑆𝑃𝑃𝑃𝑃𝑆𝑆 + 𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆𝑃𝑃𝑆𝑆𝑃𝑃𝑆𝑆𝑃𝑃𝑃𝑃𝑆𝑆 − 1)
We used this correction to account for the fact that the proportions we used are based on a 
new test that is not consistent with the laboratory-based case definition (qPCR versus GEMS 
conventional laboratory testing for pathogens).15 
Our literature review extracted the proportion of any enteropathogenic Escherichia coli (EPEC) 
without differentiating between typical (tEPEC) and atypical (aEPEC). In order to be consistent 
with the odds ratios that we obtained, we adjusted our proportion estimates of any EPEC to 
typical EPEC only. This adjustment was informed by a subset of our literature review that 
reported both atypical and typical EPEC. We estimated a ratio by super-region of tEPEC to any 
EPEC and adjusted our proportion estimates accordingly. We found that the majority of EPEC 
diarrhea cases were positive for atypical EPEC, consistent with other published work.3  
For Vibrio cholerae (cholera), we used the literature review to estimate expected number of 
cholera cases for each country-year using the incidence of diarrhoea, estimated using DisMod-
MR, and the proportion of diarrhoea cases that are positive for cholera. We assigned cholera 
PAF using odds ratios from the qPCR results to estimate a number of cholera-attributable cases. 
We compared this expected number of cholera cases to the number reported to the World 
Health Organization at the country-year level.6 We modeled the underreporting fraction to 
correct the cholera case notification data for all countries using health system access and the 
diarrhoea SEV scalar to predict total cholera cases. We used the age-specific proportion of 
positive cholera samples in DisMod and our incidence estimates to predict the number of 
cholera cases for each age/sex/year/location. Finally, we modeled the case fatality ratio of 
cholera using DisMod-MR and to estimate the number of cholera deaths.  
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For C. difficile, we modeled incidence and mortality in DisMod-MR for each age, sex, year, 
location. DisMod-MR is a Bayesian meta-regression tool that uses spatio-temporal information 
as priors to estimate prevalence, incidence, remission, and mortality for C. difficile infection. 
DisMod-MR uses a compartmental model to relate prevalence, incidence, remission, and 
mortality. We set remission in our model to 1 month.  
Table 1. Cause-specific mortality input data. 
Type of data Input data 
Total data sources 16,980 site-years 
Vital registration data 15,087 site-years 
Surveillance data 877 site-years 
Verbal autopsy data 1,016 site-years 
References 
1 Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in 
infants and young children in developing countries (the Global Enteric Multicenter Study, 
GEMS): a prospective, case-control study. Lancet Lond Engl 2013; 382: 209–22. 
2 Liu J, Gratz J, Amour C, et al. A laboratory-developed TaqMan Array Card for simultaneous 
detection of 19 enteropathogens. J Clin Microbiol 2013; 51: 472–80. 
3 Ochoa TJ, Barletta F, Contreras C, Mercado E. New insights into the epidemiology of 
enteropathogenic Escherichia coli infection. Trans R Soc Trop Med Hyg 2008; 102: 852–6. 
4 Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or 
intervention. Am J Epidemiol 1974; 99: 325–32. 
5 Reiczigel J, Földi J, Ozsvári L. Exact confidence limits for prevalence of a disease with an 
imperfect diagnostic test. Epidemiol Infect 2010; 138: 1674–8. 
6 World Health Organization. Global Health Observatory data repository: Cholera. 2016. 
http://apps.who.int/gho/data/node.main.174?lang=en (accessed Aug 25, 2016). 
244
Lower Respiratory Infections 
Input data 
Cause of deaths. Lower respiratory infection (LRI) mortality was estimated in CODEm. We estimated LRI 
mortality separately for males and females and for children under 5 years and older than 5 years. We 
used all available data from vital registration systems, surveillance systems, and verbal autopsy (Table 
1). We checked for and excluded outliers from our data by country or region. We also excluded ICD9-
coded mortality data in Sri Lanka (1982, 1987–1992), ICD9-coded neonatal mortality data in Guatemala 
(1980, 1981, 1984, 2000–2004), and Civil Registration System data in many Indian states (1986–1995).  
Etiologies. We updated our systematic review of scientific literature for the proportion of LRI that tested 
positive for influenza and respiratory syncytial virus (RSV) to include all data from GBD 2015 and from 
studies published between May 2015 and May 2016. Inclusion criteria were studies that had a sample 
size of at least 100, studies that were at least one year in duration, and studies describing lower 
respiratory infections, pneumonia, or bronchiolitis as the case definition. During our literature review 
we identified 209 studies, of which 7 met our inclusion criteria and were extracted. We excluded studies 
that described pandemic H1N1 influenza solely and studies that used influenza-like illness as the case 
definition. We assigned an age range based on the prevalence-weighted mean age of LRI in the 
appropriate year/sex/location if the ages of the study participants were not reported.  
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We also conducted a systematic literature review of studies on the Hib vaccine and PCV effectiveness 
studies against X-ray-confirmed pneumonia and against pneumococcal and Hib disease until May 2016. 
For PCV studies, we extracted, if available, the distribution of pneumococcal pneumonia serotypes and 
the serotypes included in the PCV used in the study. No new studies were identified for GBD 2016. We 
excluded observational and case-control studies due to implausibly high vaccine efficacy estimates. Hib 
trial data were exclusively from children <5 years so we did not include the effect of Hib on ages over 5 
years of age. PCV trial data are also frequently limited to younger age populations. To understand the 
contribution of pneumococcal pneumonia in older populations, we also included PCV efficacy studies 
that used before-after approaches. 
Modeling strategy 
Cause of death. We used country-level covariates to inform our CODEm models. We included the 
following covariates in our LRI models: diphtheria-tetanus-pertussis vaccine coverage, years of 
education per capita, health system access, income per capita, prevalence of children malnutrition (<2 
standard deviations below global mean of weight for age), prevalence of exposure to indoor air 
pollution (solid fuel use), outdoor air pollution level of PM2.5, smoking prevalence, pneumococcal 
conjugate vaccine (PCV) coverage, Haemophilus influenzae type B (Hib) vaccine coverage, access to 
improved water, access to improved sanitation, and Socio-Demographic Index. We evaluated our LRI 
cause of death models using in and out of sample predictive performance.  
Like all models of mortality in GBD, LRI mortality models are single-cause, requiring in effect that the  
sum of all mortality models must be equal to the all-cause mortality envelope. We correct LRI mortality 
estimates, and other causes of mortality, by re-scaling them according to the uncertainty around the 
cause-specific mortality rate. This process is called CoDCorrect and is essential to ensure internal 
consistency among causes of death. Before CoDCorrect, we also adjust LRI mortality for unreliable 
estimates due to improper death certification and ICD coding among elderly adults where the 
underlying cause of death should be Alzheimer’s or Parkinson’s diseases. This process scales LRI 
mortality among adult age groups 70+ years into a new envelope without Alzheimer’s and Parkinson’s. 
Further details can be found in section 4 of the appendix.   
Etiologies. We estimated LRI etiologies separately from overall LRI mortality using two distinct 
counterfactual modeling strategies to estimate population attributable fractions (PAFs), described in 
detail below. The PAF represents the relative reduction in LRI mortality if there was no exposure to a 
given etiology. As LRIs can be caused by multiple pathogens and the pathogens may co-infect, PAFs can 
overlap and add up to more than 100%. Separate strategies were used for viral- influenza and 
respiratory syncytial virus (RSV)- and bacterial- Streptococcus pneumoniae and Haemophilus influenzae 
type B- etiologies. We did not attribute etiologies to neonatal pneumonia deaths due to a dearth of 
reliable data in this age group. We calculated uncertainty of our PAF estimates from 1,000 draws of each 
parameter using normal distributions in log space.  
Influenza and RSV. We calculated the population attributable fraction (PAF) from the proportion of 
severe LRI cases positive for influenza and RSV. We assumed that hospitalized LRI cases are a proxy of 
severe cases. We used the following formula to estimate PAF:1 
PAF = Proportion * (1-1/OR) 
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Where Proportion is the proportion of LRI cases that test positive for influenza or RSV and OR is the odds 
ratio of LRI given the presence of the pathogen. We used an odds ratio of 5.1 (3.19 – 8.14) for influenza 
and 9.79 (4.98 – 19.27) for RSV from a recently published meta-analysis.2 These odds ratios are 
marginally different from those used in GBD 2013. 
We modeled the proportion data using the meta-regression tool DisMod-MR to estimate the proportion 
of LRI cases that are positive for influenza and RSV, separately, by location/year/age/sex. We accounted 
for study-level covariates in our models such as PCR as the diagnostic technique, studies that 
investigated RSV or influenza exclusively, and studies from inpatient populations. 
As the case-fatality of viral causes of pneumonia is lower than for bacterial causes, we adjusted for 
differential case-fatality by determining the etiological fractions for mortality attributable to RSV and 
influenza (Table 2). We measured the etiologic fractions by applying a relative case-fatality adjustment 
based on in-hospital case-fatality, which we coded to specific pneumonia etiologies. Hospital admissions 
data of this type were limited to data from the USA, Austria, Brazil, and Mexico. We generated the 
pooled estimate of the case-fatality differential between bacterial (pneumococcus, Hib) and viral 
etiologies (RSV, influenza) using DisMod-MR. 
Pneumococcal pneumonia and Hib. For Streptococcus pneumoniae (pneumococcal pneumonia) and 
Haemophilus influenzae type B (Hib), we calculated the population attributable fraction using a vaccine 
probe design.3,4 The ratio of vaccine effectiveness against nonspecific pneumonia to pathogen-specific 
disease represents the fraction of pneumonia cases attributable to each pathogen.  
To estimate the PAF for Hib and pneumococcal pneumonia, we calculated the ratio of vaccine 
effectiveness against nonspecific pneumonia to pathogen-specific pneumonia (Equations 1 and 3). We 
estimated a study-level estimate of PAF from a meta-analysis of these ratios. To estimate the PAF for 
Hib, we only used randomized controlled trials because of implausibly high values of vaccine efficacy in 
case-control studies. To estimate the PAF for pneumococcal pneumonia, we included RCTs and before 
and after vaccine introduction longitudinal studies. 
We adjusted the study-level PAF estimate by vaccine coverage and expected vaccine performance to 
estimate country- and year-specific PAF values. For pneumococcal pneumonia, we adjusted the PAF by 
the final Hib PAF estimate and by vaccine serotype coverage. Finally, we used an age distribution of PAF 
modeled in DisMod to determine the PAF by age. Because of an absence of data describing vaccine 
efficacy against Hib in children older than two years, we did not attribute Hib to episodes of LRI in ages 
five years and older. 
We used a vaccine probe design to estimate the PAF for pneumococcal pneumonia and (Hib) by first 
calculating the ratio of vaccine effectiveness against nonspecific pneumonia to pathogen-specific 
pneumonia at the study level (Equations 1 and 2).3–5 We then adjusted this estimate by vaccine coverage 
and expected vaccine performance to estimate country- and year-specific PAF values (Equations 3 and 
4). 
1) 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 = 1 − 𝑉𝑉𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑉𝑉𝑉𝑉𝐻𝐻𝑃𝑃𝐻𝐻 
2) 𝐻𝐻𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝐻𝐻𝐻𝐻𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 = 1 −  𝑉𝑉𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 ∗(1−𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝑃𝑃𝐻𝐻∗𝑉𝑉𝑉𝑉𝐻𝐻𝑃𝑃𝐻𝐻 𝑂𝑂𝑂𝑂𝑂𝑂𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂)𝑉𝑉𝑉𝑉𝑆𝑆𝑂𝑂𝑆𝑆𝑃𝑃𝑂𝑂𝑂𝑂𝑃𝑃𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆𝑃𝑃𝑆𝑆∗𝐶𝐶𝐶𝐶𝐶𝐶𝑆𝑆𝑃𝑃𝑆𝑆𝑃𝑃𝑂𝑂𝑆𝑆𝑂𝑂𝑃𝑃
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3) 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 =  𝐻𝐻𝐻𝐻𝐻𝐻𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 ∗ �1−𝐶𝐶𝐶𝐶𝐶𝐶𝐻𝐻𝑃𝑃𝐻𝐻∗𝑉𝑉𝑉𝑉𝐻𝐻𝑃𝑃𝐻𝐻 𝑂𝑂𝑂𝑂𝑂𝑂𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂�(1−𝑃𝑃𝑃𝑃𝑃𝑃𝐵𝐵𝑃𝑃𝑆𝑆𝑃𝑃∗𝐶𝐶𝐶𝐶𝐶𝐶𝐻𝐻𝑃𝑃𝐻𝐻∗𝑉𝑉𝑉𝑉𝐻𝐻𝑃𝑃𝐻𝐻 𝑂𝑂𝑂𝑂𝑂𝑂𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂)
4) 𝐻𝐻𝐻𝐻𝐻𝐻𝑃𝑃𝑃𝑃𝐵𝐵𝑃𝑃𝑃𝑃𝐶𝐶 = 𝑃𝑃𝑃𝑃𝑃𝑃𝐵𝐵𝑃𝑃𝑆𝑆𝑃𝑃∗�1−𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝑃𝑃𝑃𝑃∗𝑉𝑉𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃 𝑂𝑂𝑂𝑂𝑂𝑂𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂�
�1−𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝑃𝑃𝐻𝐻∗𝐶𝐶𝐶𝐶𝐶𝐶𝐻𝐻𝑃𝑃𝐻𝐻∗𝑉𝑉𝑉𝑉𝐻𝐻𝑃𝑃𝐻𝐻 𝑂𝑂𝑂𝑂𝑂𝑂𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂�∗�1− 𝑃𝑃𝑃𝑃𝑃𝑃𝐵𝐵𝑃𝑃𝑆𝑆𝑃𝑃𝑃𝑃𝑃𝑃𝐶𝐶𝑃𝑃𝑃𝑃𝑃𝑃∗𝑃𝑃𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃 𝑂𝑂𝑂𝑂𝑂𝑂𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂
�1−𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝑃𝑃𝐻𝐻∗𝑃𝑃𝑃𝑃𝐶𝐶𝐻𝐻𝑃𝑃𝐻𝐻∗𝑃𝑃𝑉𝑉𝐻𝐻𝑃𝑃𝐻𝐻 𝑂𝑂𝑂𝑂𝑂𝑂𝑃𝑃𝑃𝑃𝑃𝑃𝑂𝑂��
Where 𝑉𝑉𝑉𝑉𝑃𝑃𝑃𝑃𝐵𝐵𝑃𝑃𝑃𝑃𝐶𝐶𝑃𝑃𝐻𝐻𝐵𝐵 is the vaccine efficacy against nonspecific pneumonia, 𝑉𝑉𝑉𝑉𝐻𝐻𝐻𝐻𝐻𝐻 is the vaccine efficacy 
against invasive Hib disease, 𝑉𝑉𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵𝑆𝑆𝑆𝑆𝐶𝐶𝑆𝑆𝐶𝐶𝑆𝑆𝑆𝑆𝑃𝑃𝐵𝐵 is the vaccine efficacy against serotype-specific 
pneumococcal pneumonia, 𝐶𝐶𝑃𝑃𝐶𝐶𝐵𝐵𝐵𝐵𝑆𝑆𝐶𝐶𝑆𝑆𝑠𝑠𝑆𝑆𝐵𝐵 is the serotype-specific vaccine coverage for PCV,6  
𝑉𝑉𝑉𝑉𝐻𝐻𝐻𝐻𝐻𝐻 𝑂𝑂𝑆𝑆𝑆𝑆𝐻𝐻𝑃𝑃𝐵𝐵𝑂𝑂 is the Hib effectiveness in the community (0.8)7,  𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 is the final PAF for Hib, 𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃𝐶𝐶𝑉𝑉 is 
the PCV coverage, 𝐶𝐶𝑃𝑃𝐶𝐶𝐻𝐻𝐻𝐻𝐻𝐻 is the Hib coverage by country, and 𝑉𝑉𝑉𝑉𝑃𝑃𝐶𝐶𝑉𝑉 𝑂𝑂𝑆𝑆𝑆𝑆𝐻𝐻𝑃𝑃𝐵𝐵𝑂𝑂 is the vaccine effectiveness 
in the community (0.8).8  
For Hib, we assumed that the vaccine efficacy against invasive Hib disease is the same against Hib 
pneumonia. For pneumococcal pneumonia, a recent study in adults 9 found that the vaccine efficacy 
against invasive pneumococcal disease may be significantly higher than against pneumococcal 
pneumonia. We used this ratio to adjust estimates of vaccine efficacy against invasive pneumococcal 
disease from other studies. However, recognizing that the study is unique in that it uses a urine antigen 
test among adults, we added uncertainty around our adjustment using a wide uniform distribution 
(median 0.65, 0.3-1.0). This has increased the estimates of pneumococcal pneumonia mortality in a 
meaningful way. 
There are no major changes to the cause of death estimation strategy for LRI or its etiologies from GBD 
2015 to GBD 2016.  
Table 1. Summary of cause-specific mortality modeling input data. 
Type of data Input data 
Total data sources 12,155 site-years 
Vital registration data 10,312 site-years 
Surveillance data 928 site-years 
Verbal autopsy data 915 site-years 
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Table 2: The median values for the ratio of viral to bacterial pneumonia case fatality ratio by 
age is shown. These estimates are modeled using hospital-based, ICD-coded admissions and 
mortality for etiology-specified pneumonia. Values in parentheses represent 95% Uncertainty 
Interval. 
Age Group Ratio 
Early Neonatal 0.34 (0.19-0.58) 
Late Neonatal 0.34 (0.19-0.58) 
Post Neonatal 0.34 (0.19-0.58) 
1 to 4 0.28 (0.16-0.44) 
5 to 9 0.31 (0.15-0.56) 
10 to 14 0.33 (0.19-0.53) 
15 to 19 0.37 (0.2-0.64) 
20 to 24 0.46 (0.12-1.16) 
25 to 29 0.44 (0.17-0.93) 
30 to 34 0.46 (0.22-0.83) 
35 to 39 0.5 (0.22-1) 
40 to 44 0.61 (0.13-1.75) 
45 to 49 0.5 (0.21-0.99) 
50 to 54 0.44 (0.23-0.74) 
55 to 59 0.42 (0.21-0.75) 
60 to 64 0.42 (0.15-0.95) 
65 to 69 0.39 (0.19-0.7) 
70 to 74 0.38 (0.21-0.61) 
75 to 79 0.37 (0.2-0.62) 
80 to 84 0.37 (0.17-0.71) 
85 to 89 0.34 (0.19-0.59) 
90 to 94 0.33 (0.16-0.61) 
95 to 99 0.34 (0.13-0.8) 
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Cause of death 
database
Input data 
Vital registration and surveillance data from the cause of death database were used. Data with very high 
cause fractions (those greater than the 99th percentile values) were excluded in the regression. 
Modeling strategy  
Due to a small number of deaths, mortality from upper respiratory infections was modeled using a 
negative binomial regression, which is more appropriate than a Poisson count model as it accounts for 
greater variance (over-dispersion) in the data. By utilizing the exposure option in Stata, we model cause 
fractions with a negative binomial model. We tested both rate- and cause fraction-based models but 
selected a cause fraction model due to better model performance. Using the input data mentioned 
above, we modeled mortality from upper respiratory infections using the lag distributed income 
covariate and age dummy variables and the exposure set to the total number of deaths in the study. 
Uncertainty was estimated by taking 1,000 iterations of the predictions based on the variance 
covariance matrix and a random sample from a gamma distribution. The fit of the model was evaluated 


































Vital registration and surveillance data from the cause of death database were used. Data with very high 
cause fractions (those greater than the 99th percentile values) were excluded in the regression. 
Modeling strategy  
Due to the small number of deaths, diphtheria mortality was modeled using a negative binomial 
regression, which is more appropriate than a Poisson count model as it accounts for greater variance 
(over-dispersion) in the data. Using the input data mentioned above, we modeled mortality due to 
diphtheria with the diphtheria-pertussis-tetanus third-dose (DPT3) vaccine coverage covariate and age 
dummy variables, with the offset as the total number of deaths in the study. Uncertainty was estimated 
by taking 1,000 iterations of the predictions based on the variance-covariance matrix and a random 
sample of the dispersion parameter from a gamma distribution. 
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Vital registration data from the cause of death database were used for data-rich countries. To inform 
the natural history model, we used data from the following sources: World Health Organization (WHO) 
case notifications; historical case notifications for the United Kingdom back to 1940; case fatality data 
identified by collaborators; and case fatality data identified through systematic literature reviews for 
GBD 2010, GBD 2013, and GBD 2016. The PubMed search query for GBD 2016 was: (whooping cough 
[Title/Abstract]) OR (pertussis [Title/Abstract]) AND (case fatality [Title/Abstract]) AND ("2013"[Date - 
Publication]: "2016"[Date - Publication]). Studies were included if they reported case fatality rate, 
number of deaths, and number of cases. Studies were excluded if they included non-representative 
samples only.  
Modeling strategy – data-rich countries 
Mortality was modeled separately for data-rich and other countries. For data-rich countries (i.e., 
countries with vital registration more than 95% complete for more than 25 years), we used a general 
CODEm strategy with DPT3 vaccination coverage, lagged distributed income, and education as country-
level covariates. We made estimations for the age range post-neonatal to 59 years.  
Modeling strategy – other countries 
For the remaining countries, we used a natural history-based model because CODEm does not predict 
well for those countries. First, we modeled log-transformed incidence with a mixed-effects linear 
regression of case notifications from the WHO (1985-2015) on diphtheria-tetanus-pertussis dose 3 
(DTP3) vaccination coverage. Historical data of United Kingdom (UK) pertussis cases and UK DTP3 
coverage rates (both back to 1940) were also used to inform the incidence model. The random effect by 
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country allowed for registration completeness to vary by country. The results of this model were then 
used to predict incidence as a function of vaccine coverage.  To correct for underreporting in case 
notifications, we used a value of the random effect that matched the highest random effect in a high 
income region—Switzerland (which has a pertussis monitoring system which captures a high percentage 
of cases)—to get an implied attack rate assumed to be the same for all unvaccinated populations. 
Uncertainty was estimated by taking 1,000 iterations of the predictions based on the variance-
covariance matrix.  
Second, we modeled the pertussis case fatality rate using a negative binomial model with the health 
system access and lagged-distributed income covariates. Uncertainty was estimated by taking 1,000 
iterations of the predictions based on the variance-covariance matrix and a random sample from a 
gamma distribution of the dispersion parameter. Finally, whooping cough deaths were calculated at the 
1,000-draw level as 
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑ℎ𝑠𝑠 = 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑 ∗ 𝐶𝐶𝐶𝐶𝐶𝐶 . 
We estimated overall number of deaths and then assigned an age-sex distribution based on the age- and 
sex-specific patterns found in the cause of death data. We made estimations for the age range post-
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Mortality data from vital registration, verbal autopsy, and surveillance sources were used. Data were 
outliered if they largely conflicted with the majority of data from other studies conducted either in the 
same or different countries with similar sociodemographic characteristics in the same region. 
Modeling strategy  
A general CODEm modeling strategy was used. We ran separate models for under 1 year and 1 to 95+ 
years. There were no substantive changes in modeling strategy from GBD 2015. 
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Vital registration data from the cause of death database were used for data-rich countries. To inform 
the natural history model, we used data from the following sources: World Health Organization (WHO) 
case notifications from 1995 to 2015; case notifications identified by collaborators; vital registration (VR) 
data in countries in the following three super-regions: high-income, Central Europe/Eastern 
Europe/Central Asia, and Latin America and Caribbean; and case fatality data identified through 
systematic literature reviews for GBD 2010, GBD 2013, and GBD 2016. The PubMed search query for 
GBD 2016 was: (measles [Title/Abstract]) AND (case fatality [Title/Abstract]) AND ("2013"[Date - 
Publication]: "2016"[Date - Publication]). Studies were included if they reported case fatality rate, 
number of deaths, and number of cases. Studies were excluded if they included non-representative 
samples only.  
Modeling strategy – data-rich countries 
Mortality was modeled separately for data-rich and other countries. For data-rich countries (i.e., 
countries with vital registration more than 95% complete for more than 25 years), we used a general 
CODEm strategy to model VR data with measles-containing vaccination dose one (MCV1) coverage, 
childhood malnutrition, lagged distributed income the healthcare access and quality index, and 
education as country-level covariates. We made estimations for the age range post-neonatal to 59 
years. 
Modeling strategy – other countries 
Measles mortality in the remaining countries was modeled using a natural-history-based model. First, 
we modeled measles incidence with a mixed-effects linear regression of case notifications from the 
WHO (1995-2015) on routine measles vaccination rates and supplementary immunization activities 
(SIAs). More precisely, log-transformed incidence rates were regressed on the log of the proportion 
unvaccinated with first- and second-dose measles-containing vaccine, and additional SIA coverage 
lagged by one, two, three, four, and five years, with super-region, region, and country-level random 
effects. The results of this mixed effects regression model were then used to predict location-year-
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specific incidence as a function of routine vaccine coverage and SIAs. To correct for underreporting in 
case notifications, we added the effect of a 95% attack rate, assumed to be the same across all 
unvaccinated populations. Uncertainty was estimated by taking 1,000 iterations of the predictions based 
on the variance-covariance matrix. For locations in three super-regions—high-income, Central 
Europe/Eastern Europe/Central Asia and Latin America and Caribbean—we used reported measles cases 
as incident cases.  
Second, the case fatality rate was modeled using a mixed effects negative binomial regression with the 
child malnutrition covariate and study-level indicators (hospital-based or not; outbreak or not; and rural 
or urban/mixed), with country random effects. Uncertainty was estimated by taking 1,000 iterations of 
the predictions based on the variance-covariance matrix and uncertainty in country random effects. The 
fit of the model was evaluated using diagnostic plots of predicted versus observed values. Finally, 
estimated deaths were calculated at the 1,000-draw level as 
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑ℎ𝑠𝑠 = 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑 ∗ 𝐶𝐶𝐶𝐶𝐶𝐶 . 
We estimated overall number of deaths and then assigned an age-sex distribution based on the age- and 
sex-specific patterns found in the cause of death data. We made estimations for the age range post-






































For the neonatal disorders envelope, preterm birth complications, and neonatal encephalopathy, vital 
registration, verbal autopsy, surveillance, and sibling history data were used for GBD 2016 to estimate 
number of deaths from each condition. For sepsis and other neonatal infections, vital registration, 
surveillance, and sibling history data were used. And for neonatal hemolytic disease and other neonatal 
conditions, vital registration and surveillance data were used. For all neonatal causes of death, vital 
registration was by far the most common data type. We only modelled deaths among males and 
females under age 5. Data points were selected as outliers if they were implausibly high, low, or 
significantly conflicted with established age or temporal patterns. Addition of significant new data from 
the Sample Registration System (SRS) in India had a significant effect on the estimates of mortality due 
to neonatal conditions at the global level. 
Modelling strategy  
For GBD 2016, an ensemble modelling approach was used via CODEm to model each of the different 
neonatal conditions. The same was done for GBD 2013 and 2015.  
Varying levels of data quality and coding issues may still have affected our results. Validation studies 
suggest that verbal autopsy methods tend to be less accurate for cause of death ascertainment in the 
neonatal age groups.1–4 This implies that in regions such as sub-Saharan Africa or South Asia, where the 
data primarily come from verbal autopsy studies, the distribution of sub-causes within all neonatal 
conditions may be less accurate. Furthermore, validation studies suggest that verbal autopsy methods 
tend to be particularly poor at ascertaining deaths from neonatal sepsis. Thus, for GBD 2016, all verbal 
autopsy data were excluded for neonatal sepsis and neonatal hemolytic disease.  
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Selected Covariates 
Covariate Transformation Level Direction 
Education (years per 
capita) 
None 3 -1 
Health System Access None 2 -1 
In-Facility Delivery None 2 -1 
LDI (I$ per capita) Log 3 -1 
Underweight 
(proportion <2SD 
weight for age, <5 
years) 
None 2 1 
Live Births 35+ None 2 1 
Indoor Air Pollution (All 
cooking fuels) 




None 1 1 
Total Fertility Rate Log 3 1 
SDI None 3 -1 
HAQI None 2 -1 
Skilled Birth 
Attendance 
None 2 -1 
Antenatal Care (4 visit) None 2 -1 
References 
1 Anker M, Black RE, Coldham C, et al. A Standard Verbal Autopsy Method for Investigating Causes of 
Death in Infants and Children. Geneva, Switzerland: World Health Organization Department of 
Communicable Disease Surveillance and Response; The Johns Hopkins School of Hygiene and Public 
Health; The London School of Hygiene and Tropical Medicine, 1999. 
2 Kalter HD, Gray RH, Black RE, Gultiano SA. Validation of postmortem interviews to ascertain selected 
causes of death in children. Int J Epidemiol 1990; 19: 380–6. 
3 Quigley MA, Armstrong Schellenberg JR, Snow RW. Algorithms for verbal autopsies: a validation study 
in Kenyan children. Bull World Health Organ 1996; 74: 147–54. 
4 Snow RW, Armstrong JR, Forster D, et al. Childhood deaths in Africa: uses and limitations of verbal 
autopsies. The Lancet 1992; 340: 351–5. 
259





























Cause of death 
database
Input data 
Data used to estimate mortality of peptic ulcer disease consisted of vital registration data from the 
cause of death (COD) database. We outliered data in instances where garbage code redistribution and 
noise reduction, in combination with small sample sizes, resulted in unreasonable cause fractions, and 
data that violated well-established time or age trends.  
Modelling strategy  
We modelled deaths due to peptic ulcer disease with a standard CODEm model using the cause of death 
database and location-level covariates as inputs. The model followed standard parameters, with the 
exception that the start age of the model was 1 year old instead of 0. We hybridized separate global and 
data-rich models to acquire unadjusted results, which we finalized and adjusted using CodCorrect to 
reach final years of life lost (YLLs) due to peptic ulcer disease. The covariate changes from GBD 2015 to 
GBD 2016 include changing the directionality of vegetables adjusted (grams per person availability) from 
-1 to 0, the addition of the summary exposure variable unsafe water, and the addition of the healthcare 
access and quality index (HAQI) covariate.  
Covariate Level Direction 
Alcohol (liters per capita) 1 1 
Cumulative cigarettes (10 years) 1 1 
Cumulative cigarettes (5 years) 1 1 
Lag distributed income (per capita) 3 -1 
Sanitation (proportion with access) 2 -1 
Smoking (prevalence) 
Maternal education (years per capita) 
Improved water source (proportion with access) 
Sociodemographic index 
Vegetables (grams adjusted) 













































Data used to estimate appendicitis mortality consisted of vital registration and verbal autopsy data from 
the cause of death (COD) database. We outliered data in instances where garbage code redistribution 
and noise reduction, in combination with small sample sizes, resulted in unreasonable cause fractions; 
and data that violated well-established time or age trends.  
Modelling strategy  
We modelled deaths due to appendicitis with a standard CODEm model using the cause of death 
database and location-level covariates as inputs. The model followed standard parameters, with the 
exception that the start age of the model was 1 year old instead of 0 and the linear floor rate was 
lowered to 0.0001 in order to better capture low data. We hybridized separate global and data-rich 
models to acquire unadjusted results, which we finalized and adjusted using CodCorrect to reach final 
YLLs due to appendicitis.  
There were no significant changes in the modelling process between GBD 2015 and GBD 2016. 
Covariate Level Direction 
Education (years per capita) 3 -1 
Log LDI (I$ per capita) 3 -1 
Health system access (capped) 3 -1 
Socio-demographic Index 3 -1 
Fruits adjusted (g) 2 -1 
Vegetables adjusted (g) 2 -1 
Healthcare access and quality index 2 -1 
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Cause of death 
database
Input data 
Vital registration and verbal autopsy data were used to model this cause. We outliered data in instances 
where garbage code redistribution and noise reduction, in combination with small sample sizes, resulted 
in unreasonable cause fractions; and data that violated well-established time or age trends. Outliering 
methods were consistent across both vital registration and verbal autopsy data.  
Modelling strategy  
We modelled deaths due to inguinal, femoral, and abdominal hernias with a standard CODEm model 
using the cause of death database and location-level covariates as inputs. The model followed standard 
parameters, with the exception that the start age of the model was 1 year old instead of 0 and the linear 
floor rate was lowered to 0.0001 in order to better capture low data. We hybridized separate global and 
data-rich models to acquire unadjusted results, which we finalized and adjusted using CodCorrect to 
reach final years of life lost (YLLs) due to inguinal, femoral, and abdominal hernias. In GBD 2016 we 
added the healthcare access and quality index (HAQI) covariate to the model. 
Covariate Level Direction 
Education (years per capita) 3 -1 
Lag distributed income (per capita) 
Sociodemographic index 
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Cause of death 
database
Input data 
Data used to estimate mortality of gallbladder and biliary diseases consisted of vital registration data 
from the cause of death (COD) database. We outliered data in instances where garbage code 
redistribution and noise reduction, in combination with small sample sizes, resulted in unreasonable 
cause fractions; and data that violated well-established time or age trends.  
Modelling strategy  
We modelled deaths due to gallbladder and biliary diseases with a standard CODEm model using the 
cause of death database and location-level covariates as inputs. The model followed standard 
parameters, with the exception that the start age of the model was 1 year old instead of 0 and the linear 
floor rate was lowered to 0.0001 in order to better capture low data. We hybridized separate global and 
data-rich models to acquire unadjusted results, which we finalized and adjusted using CodCorrect to 
reach final years of life lost (YLLs) due to gallbladder and biliary diseases. In GBD 2016 we added the 
healthcare access and quality index (HAQI) covariate and replaced the animal fats (kcal per capita) 
covariate with an updated saturated fats (adjusted percent).  
Covariate Level Direction 
Alcohol (liters per capita) 2 1 
Education (years per capita) 3 0 
Lag distributed income (per capita) 
Body mass index (mean) 
Population over 65 (proportion) 
Sociodemographic index 
Red meats (grams adjusted) 
Saturated fats (adjusted percent) 


















































Data used to estimate epilepsy mortality included vital registration (VR), verbal autopsy, and China 
mortality surveillance data from the cause of death (COD) database. Our outlier criteria were to exclude 
data points that were (1) implausibly high or low relative to global or regional patterns, (2) substantially 
conflicted with established age or temporal patterns, or (3) significantly conflicted with other data 
sources based from the same locations or locations with similar characteristics (i.e., socio-demographic 
index). 
Based on these criteria, we excluded ICD-9 BTL data for Sri Lanka, Fiji, and Kiribati as the estimates 
varied from year to year between zero and high values. We also excluded the Survey of Causes of Death 
Data and Medical Certification of Cause of Death Data for India, as these data types were not consistent 
with the Sample Registration System Data and would have led to discontinuities in our estimates over 
time.   
Modelling strategy  
The standard CODEm modelling approach was applied to estimate deaths due to epilepsy. Separate 
models were conducted for male and female mortality, and the age range for both models was 28 days–
95+ years. For GBD 2016, the health systems access covariate was replaced with the health access and 
quality index covariate. There were no other substantial changes for GBD 2016.  The covariates used are 
displayed below.   
Level Covariate Direction 
1 pig meat consumption (kcal per capita) + 
pigs (per capita) + 
SEV scalar: epilepsy + 
mean systolic blood pressure (mmHg) + 
2 health access and quality index - 
mean body mass index + 
mean serum total cholesterol (mmol/L) + 
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3 cumulative cigarettes (10 years) + 
cumulative cigarettes (5 years) + 
education (years per capita) - 
log LDI (per capita) - 
Socio-demographic Index - 
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Vital registration and verbal autopsy data were used to model mortality due to urolithiasis. Outliers 
were identified by systematic examination of data points for all location-years. Data were standardised 
and mapped according to the GBD causes of death ICD mapping method. These data were then age-sex 
split, and appropriate redistribution of garbage code data was performed. Data points that violated well-
established age or time trends or that resulted in extremely high or low cause fractions were 
determined to be outliers. For GBD 2016, deaths due to congenital kidney anomalies (cystic kidney 
disease and reflux hydronephrosis) were attributed to chronic kidney disease, marking a change from 
GBD 2015 when these deaths were assigned to congenital anomalies.  
Modelling strategy  
The estimation strategy used for fatal chronic kidney disease is largely similar to methods used in GBD 
2015. A standard CODEm model with location-level was used to model deaths due to chronic kidney 
disease. Iterations of models were assessed at the location/year/age-group/sex level to determine 
whether data points merited exclusion via outliering. Unadjusted death estimates were adjusted using 
CoDCorrect to produce final estimates of YLLs. The covariates used are displayed below.   
Level Covariate Direction 
1 
Diabetes fasting plasma glucose (mmol/L) + 
Diabetes age-standardized prevalence (proportion) + 
Mean systolic blood pressure (mmHg) + 
Mean BMI + 
Health care access and quality index − 
2 
Mean cholesterol + 
Total calories (kcal per capita) − 
Red meat (kcal per capita) 0 
Whole grains (kcal per capita) 0 
Animal fat (kcal per capita) 0 
3 
Socio-demographic Index  0 
Education (years per capita) − 
Log LDI ($I per capita) − 
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Chronic Kidney Disease subtypes 
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diabetes mellitus 
Unadjusted deaths by 
location/year/age/sex 
due to CKD due to 
hypertension 
Unadjusted deaths by 
location/year/age/sex 
due to CKD due to 
glomerulonephritis 
Input data  
The estimation strategy for CKD subtypes of 1) diabetes mellitus, 2) hypertension, 3) glomerulonephritis, 
and 4) “other” has changed significantly from the GBD 2015 analysis to achieve consistency of method 
among the four subtypes. This improved method is detailed below.  
Data from end-stage renal disease registries were used to inform estimates of proportion of CKD 
mortality attributable to each CKD subtype. These data were age-split using the age pattern obtained 
from the Australia & New Zealand Dialysis and Transplant Registry (ANZDATA) which provides age and 
subtype-specific data. The age-pattern was determined by calculating the number of cases of CKD by 
etiology over the total number of cases for all etiologies for each 5-year age group. Then, aggregate-age 
proportions were split using the age-specific prevalence proportions and rescaled to sum to 1 within 
each 5-year age group.  
Vital registration (VR) data were excluded from estimates as etiology coding in VR sources was 
considered highly variable and inconsistent between countries.  
Modelling strategy  
We ran DisMod-MR 2.1 models including diabetes prevalence and mean systolic blood pressure as 
country-level covariates to obtain estimates of proportions for each subtype by location, year, age, and 
sex. The results from these models were adjusted so that estimates across the subtypes equaled 1 at 
each of 1,000 draws. These adjusted proportions were applied to the parent CKD CODEm model. 
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Model Covariate Value Exponentiated 
CKD proportion due 





(0.29 – 0.42) 
1.43 
(1.34 – 1.53) 





(0.00036 – 0.043) 
1.01 
(1.00 – 1.04) 
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Congenital Birth Defects: Neural tube defects, Congenital heart anomalies, Orofacial 
clefts, Down Syndrome, Turner syndrome, Klinefelter syndrome, Other chromosomal 
disorders, Congenital musculoskeletal anomalies, Urogenital congenital anomalies, 


































For GBD 2016, input data for estimating mortality due to congenital anomalies was centrally extracted, 
processed, and stored in causes of death (CoD) database. Vital registration (VR) was the dominant data 
type, followed by verbal autopsy (VA) and surveillance. Those CoD data sources that specified the sub-
cause of birth defect were included in estimation of both the parent congenital anomalies model as well 
as in sub-type-specific models.  
For GBD 2016, data exclusions were limited. We outliered all VA data in those over 5 years old as the 
age patterns were unreliable and led to poor model performance in the under-5 age groups. We also 
excluded some data sources from the parent model where only a subset of sub-causes were specified 
(eg, congenital heart disease, neural tube defects, and other congenital anomalies) and the sum of the 
sub-causes clearly represented systematic underreporting of one of the sub-causes. Systematic 
underreporting was suspected when sex- and age-specific rates were more than an order of magnitude 
lower than neighboring or comparable locations. Data sources for those locations were still included by 
default for sub-cause specific models because under-reporting of the total was not assumed to 
necessarily be associated with under-reporting of all of the component conditions.  
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Modeling strategy  
All types of congenital anomalies were estimated using cause of death ensemble modeling (CODEm) for 
GBD 2016, as was done for previous iterations of the GBD study. Specific causes included neural tube 
defects, congenital heart anomalies, orofacial clefts, Down Syndrome, other chromosomal anomalies, 
congenital musculoskeletal anomalies, urogenital congenital anomalies, digestive congenital anomalies, 
and other congenital birth defects. We assumed no mortality from either Klinefelter syndrome or Turner 
syndrome, for which we model nonfatal outcomes only. For GBD 2016, we modeled congenital 
anomalies as a cause of death for ages 0-69 years only, assuming that all mortality from congenital 
conditions occurs before age 70 years of age.  
For GBD 2016, we added three new causes to the congenital anomalies: congenital musculoskeletal and 
limb anomalies; urogenital congenital anomalies; and digestive congenital anomalies. 
Covariates selected for CODEm model of overall congenital birth defects 
Covariate Transformation Level Direction 
Maternal alcohol consumption during 
pregnancy (proportion) 
None 1 Positive 
In-Facility Delivery (proportion) None 1 Negative 
Live Births 35+ (proportion) None 1 Positive 
Folic acid unadjusted (ug) None 1 Negative 
Legality of Abortion None 2 Negative 
Antenatal Care (1 visit) Coverage 
(proportion) 
None 2 Not specified 
Smoking Prevalence (Reproductive Age 
Standardized) 
None 2 Positive 
Antenatal Care (4 visits) Coverage 
(proportion) 
None 2 Negative 
Healthcare access and quality index None 2 Negative 
Education (years per capita) None 2 Negative 
Alcohol (liters per capita) None 3 Positive 
fruits unadjusted(g) None 3 Positive 
Outdoor Air Pollution (PM2.5) None 3 Positive 
Indoor Air Pollution (All Cooking Fuels) None 3 Positive 
Socio-demographic Index None 3 Negative 
vegetables unadjusted(g) None 3 Positive 
Covariates selected for CODEm model of neural tube defects 
Covariate Transformation Level Direction 
Health System Access (capped) None 1 Negative 
fruits adjusted(g) None 2 Negative 
vegetables adjusted(g) None 2 Negative 
Healthcare access and quality index None 2 Negative 
Education (years per capita) None 3 Negative 
LDI (I$ per capita) Log 3 Negative 
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Socio-demographic Index None 3 Negative 
Covariates selected for CODEm model of congenital heart anomalies 
Covariate Transformation Level Direction 
Maternal alcohol consumption during 
pregnancy (proportion) 
None 1 Positive 
Socio-demographic Index Log 2 Negative 
Smoking Prevalence (Reproductive Age 
Standardized) 
None 2 Positive 
Diabetes Age-Standardized Prevalence 
(proportion) 
None 2 Positive 
Healthcare access and quality index None 2 Negative 
Legality of Abortion None 2 Negative 
Antenatal Care (1 visit) Coverage (proportion) None 2 Negative 
In-Facility Delivery (proportion) None 2 Negative 
Education (years per capita) None 2 Negative 
Alcohol (liters per capita) None 3 Positive 
Antenatal Care (4 visits) Coverage (proportion) None 3 Negative 
Skilled Birth Attendance (proportion) None 3 Negative 
Live Births 35+ (proportion) None 3 Positive 
Covariates selected for CODEm model of cleft lip and cleft palate 
Covariate Transformation Level Direction 
Indoor Air Pollution (All Cooking Fuels) None 1 Positive 
Diabetes Age-Standardized Prevalence 
(proportion) 
None 2 Positive 
Maternal alcohol consumption during 
pregnancy (proportion) 
None 2 Positive 
Healthcare access and quality index None 2 Negative 
Outdoor Air Pollution (PM2.5) None 2 Positive 
Legality of Abortion None 2 Negative 
Skilled Birth Attendance (proportion) None 2 Negative 
Smoking Prevalence (Reproductive Age 
Standardized) 
None 2 Positive 
vegetables unadjusted(g) None 3 Not specified 
Alcohol (liters per capita) None 3 Positive 
Antenatal Care (4 visits) Coverage (proportion) None 3 Negative 
Education (years per capita) None 3 Negative 
fruits unadjusted(g) None 3 Not specified 
Antenatal Care (1 visit) Coverage (proportion) None 3 Negative 
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Covariates selected for CODEm model of Down Syndrome 
Covariate Transformation Level Direction 
Live Births 35+ (proportion) None 1 Positive 
Legality of Abortion None 1 Negative 
Live Births 40+ (proportion) None 1 Positive 
Socio-demographic Index None 2 Negative 
LDI (I$ per capita) Log 2 Negative 
In-Facility Delivery (proportion) None 2 Negative 
Healthcare access and quality index None 2 Negative 
Maternal alcohol consumption during 
pregnancy (proportion) None 3 Positive 
Antenatal Care (1 visit) Coverage (proportion) None 3 Negative 
Education (years per capita) None 3 Negative 
Indoor Air Pollution (All Cooking Fuels) None 3 Positive 
Antenatal Care (4 visits) Coverage (proportion) None 3 Negative 
vegetables unadjusted(g) None 3 Negative 
Smoking Prevalence (Reproductive Age 
Standardized) None 3 Positive 
Covariates selected for CODEm model of other chromosomal abnormalities 
Covariate Transformation Level Direction 
Live Births 35+ (proportion) None 1 Positive 
Live Births 40+ (proportion) None 1 Positive 
Legality of Abortion None 1 Negative 
LDI (I$ per capita) Log 2 Negative 
Healthcare access and quality index None 2 Negative 
Antenatal Care (4 visits) Coverage (proportion) None 2 Negative 
Antenatal Care (1 visit) Coverage (proportion) None 2 Negative 
In-Facility Delivery (proportion) None 2 Negative 
Maternal alcohol consumption during 
pregnancy (proportion) None 2 Positive 
Socio-demographic Index None 3 Not specified 
Alcohol (liters per capita) None 3 Positive 
Smoking Prevalence (Reproductive Age 
Standardized) None 3 Positive 
Education (years per capita) None 3 Negative 
Skilled Birth Attendance (proportion) None 3 Negative 
Covariates selected for CODEm model of congenital musculoskeletal and limb anomalies 
Covariate Transformation Level Direction 
Maternal alcohol consumption during pregnancy 
(proportion) None 1 Positive 
Legality of Abortion None 1 Negative 
In-Facility Delivery (proportion) None 2 Negative 
Diabetes Age-Standardized Prevalence (proportion) None 2 Positive 
Socio-demographic Index None 2 Negative 
Healthcare access and quality index None 2 Negative 
Indoor Air Pollution (All Cooking Fuels) None 2 Positive 
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Smoking Prevalence (Reproductive Age 
Standardized) None 2 Positive 
Antenatal Care (4 visits) Coverage (proportion) None 3 Negative 
Alcohol (liters per capita) None 3 Positive 
vegetables unadjusted(g) None 3 Not specified 
fruits unadjusted(g) None 3 Not specified 
Education (years per capita) None 3 Negative 
Antenatal Care (1 visit) Coverage (proportion) None 3 Negative 
Covariates selected for CODEm model of urogenital congenital anomalies 
Covariate Transformation Level Direction 
Smoking Prevalence (Reproductive Age 
Standardized) None 1 Positive 
Maternal alcohol consumption during 
pregnancy (proportion) None 1 Positive 
Healthcare access and quality index None 2 Negative 
Diabetes Age-Standardized Prevalence 
(proportion) None 2 Positive 
Socio-demographic Index None 2 Negative 
Outdoor Air Pollution (PM2.5) None 2 Positive 
In-Facility Delivery (proportion) None 2 Negative 
Indoor Air Pollution (All Cooking Fuels) None 2 Positive 
Antenatal Care (1 visit) Coverage (proportion) None 3 Negative 
Alcohol (liters per capita) None 3 Positive 
Education (years per capita) None 3 Negative 
LDI (I$ per capita) Log 3 Negative 
Antenatal Care (4 visits) Coverage (proportion) None 3 Negative 
Covariates selected for CODEm model of digestive congenital anomalies 
Covariate Transformation Level Direction 
Maternal alcohol consumption during 
pregnancy (proportion) None 1 Positive 
Smoking Prevalence (Reproductive Age 
Standardized) None 1 Positive 
Indoor Air Pollution (All Cooking Fuels) None 2 Positive 
Diabetes Age-Standardized Prevalence 
(proportion) None 2 Positive 
Socio-demographic Index None 2 Negative 
Prevalence of obesity (age-standardized) None 2 Positive 
In-Facility Delivery (proportion) None 2 Negative 
Healthcare access and quality index None 2 Negative 
Alcohol (liters per capita) None 3 Positive 
Health System Access (capped) None 3 Negative 
Education (years per capita) None 3 Negative 
vegetables unadjusted(g) None 3 Not specified 
Antenatal Care (1 visit) Coverage (proportion) None 3 Negative 
Antenatal Care (4 visits) Coverage (proportion) None 3 Negative 
fruits unadjusted(g) None 3 Not specified 
LDI (I$ per capita) Log 3 Negative 
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Covariates selected for CODEm model of other congenital birth defects 
Covariate Transformation Level Direction 
Maternal alcohol consumption during 
pregnancy (proportion) None 1 Positive 
Live Births 35+ (proportion) None 1 Positive 
Education (years per capita) None 2 Negative 
Smoking Prevalence (Reproductive Age 
Standardized) None 2 Positive 
Legality of Abortion None 2 Negative 
In-Facility Delivery (proportion) None 2 Negative 
Indoor Air Pollution (All Cooking Fuels) None 2 Positive 
Healthcare access and quality index None 2 Negative 
Antenatal Care (1 visit) Coverage (proportion) None 3 Negative 
Diabetes Age-Standardized Prevalence 
(proportion) None 3 Positive 
LDI (I$ per capita) Log 3 Negative 
Socio-demographic Index None 3 Negative 
Antenatal Care (4 visits) Coverage (proportion) None 3 Negative 
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where ܥ௅஼  is the lung cancer mortality rate specific to the age‐sex‐geography‐year of interest,  ௅ܰ஼  is the 
age‐sex‐geography‐year‐specific lung cancer mortality rate of never‐smokers in the population of 






































































































































































































݉௖ሺݐሻ ൌ ܺߚ ൅ ݄ሺݎ௖,௧ሻ 
where ܺߚ is a linear model and ݄ሺݎ௖,௧ሻ is a smoothing function for the residuals; and ݎ௖,௧ is derived from 
the linear model. The following linear model was used to model DPT3, measles, BCG, polio coverage:  
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Part 2. SDG index construction and sensitivity analyses 
In this analysis we have constructed indices that represent overall performance on: the health-related 
SDG indicators (referred to as the SDG index); the indicators that were previous MDG indicators (MDG 
index); and indicators that are newly added compared to the MDGs (non-MDG index).  
For rate-space indicators, we first transformed the values to natural log space; proportion indicators were 
not transformed. The resultant indicator distributions were then rescaled to a 0 to 100 scale with 0 being 
the 2.5th quantile and 100 being the 97.5th quantile of the distribution of indicator values over the time 
period 1990 to 2030. The health-related SDG index was then computed by first determining the 
geometric mean of each rescaled health-related SDG indicator for a given target and then taking the 
geometric mean of the resulting values across the targets. This approach weights each of the health-
related SDG targets equally and assumes partial substitutability with high values on one target partly 
compensating for low values on another target. 
As a sensitivity analysis, for a second approach, we first take the arithmetic mean of indicator values for a 
given target and then the arithmetic mean of the resulting values across the targets. In contrast to the 
approach using the geometric mean, this approach assumes complete substitutability whereby poor 
performance on a target is linearly compensated for by better performance on another target. The 
resulting index using this approach was highly correlated with the approach using the geometric mean 
both in terms of 2016 values of the health-related SDG index (Methods Appendix Figure 1; Pearson 
correlation coefficient = 0.99, p<0.0001) as well as the corresponding country ranks (Methods Appendix 
Figure 2; Spearman’s rank correlation coefficient=0.97, p<0.0001).  
For the third approach, we first take the geometric mean of indicator values for a given target then 
determine the minimum of the resulting values across the health-related targets. This approach adopts 
what is called zero substitutability, such that better performance on one target in no way compensates 
for poor performance on another target. The resulting index using this approach was also well correlated 
with the approach using the geometric mean both in terms of 2016 values of the health-related SDG 
index (Methods Appendix Figure 3; Pearson correlation coefficient = 0.78, p<0.0001) and country rank 
(Methods Appendix Figure 4; Spearman’s rank correlation coefficient=0.79 p<0.0001), although not as 
highly as the approach taking the arithmetic mean.  
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Part 3. Projections for the health-related SDGs 
Section 1. Overall projection modeling strategy 
We projected the health-related Sustainable Development Goal (SDG) indicators based on past trends. 
We first calculated for each country the change in each year from 1990 to 2016 in natural-log space or, 
for indicators bounded between 0 and 1 (eg, intervention coverage, percentage of population) in logit-
space.  
We then calculated the median annualised rate of change for each country, with monotonically increasing 
temporal weights to favor more recent trends (with 𝑡𝑡 being the years between the start and end of the 
time-series [1990 to 2007 for predictive validity, 1990 to 2016 when calculating final projections]):  
𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤ℎ𝑡𝑡𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 =  (𝑦𝑦𝑤𝑤𝑦𝑦𝑦𝑦 − 1990)𝜔𝜔∑ (𝑦𝑦𝑤𝑤𝑦𝑦𝑦𝑦 − 1990)𝜔𝜔𝑇𝑇𝑡𝑡=1990
To determine the indicator specific value of 𝜔𝜔, we undertook an out-of-sample validity test by holding out 
data from 2008-2016 and using data from 1990-2007 to predict values for the 2008-2016 period. We 
tested 𝜔𝜔 values ranging from 0 to 2, in increments of 0.2. We chose the value of 𝜔𝜔 specific to each 
indicator that minimized the root mean squared error (RMSE) for the time period 2008-2016; the weights 
selected by this process are summarized below.  
We then use that weight function to determine the median annualised rate of change for each of the 
1,000 draws of a given indicator. In addition, for each of the draws we allow for year-to-year deviation 
from the median rate of change based on the variance across all draws. This resulted in 1,000 rate of 
change draws by country for each year from 2017-2030, which are then applied in a stepwise manner to 
produce the projected time series. Lastly, we scaled the 1,000 draws such that the mean of the draws for 
each country-year was equal to the value projected using the mean alone. 
The exception to the above was for natural disasters given the stochastic nature of the cause we used the 
long-term average over the 1990 to 2016 period to project the rate to 2030.  
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Table 1. Weights selected with out-of-sample validity testing for projecting the health-related SDGs. 
Disaster mort=Mortality due to exposure to forces of nature. MMR=Maternal mortality ratio. SBA=Skilled 
birth attendance. Under-5 mort=Under-5 mortality. Neonatal mort=Neonatal mortality. HIV incid=HIV 
incidence. Tuberculosis incid=Tuberculosis incidence. Malaria incid=Malaria incidence. Hep B 
incid=Hepatitis B incidence. NTD prev=Prevalence of 15 neglected tropical diseases. NCD mort=Mortality 
due to a subset of non-communicable diseases (cardiovascular disease, cancer, diabetes, and chronic 
respiratory diseases). Suicide mort=Mortality due to self-harm. Road injury mort=Mortality due to road 
injuries. FP need met, mod=Met need for family planning with modern contraception methods. Adol birth 
rate=Adolescent birth rate. UHC index=universal health coverage index. Air poll mort=Mortality 
attributable to household air pollution and ambient air pollution. WaSH mort=Mortality attributable to 
unsafe water, sanitation, and hygiene. Poisoning mort=mortality due to unintentional poisonings. 
Smoking prev=prevalence of daily smoking. Vaccine cov=Vaccine coverage of target populations based on 
national vaccine schedules. Int partner viol=Intimate partner violence. HH air poll=Household air 
pollution. Occ burden=Disease burden attributable to occupational risks. Mean PM2.5=Mean particulate 
matter smaller than 2.5 microns in diameter. Homicide=Mortality due to interpersonal violence. Conflict 
mort=Mortality due to conflict and terrorism. Violence prev=Prevalence of physical or sexual violence. 
Child sex abuse=Childhood sexual abuse. Cert death reg=Well-certified death registration. 
SDG indicator Weight function SDG indicator Weight function 
Disaster mort N/A UHC index 2.0 
Child stunting 0.4 Air Poll mort 1.6 
Child wasting 0.4 WaSH mort 1.6 
Child overweight 0.4 Poisoning mort 2.0 
MMR 2.0 Smoking prev 0.4 
SBA 2.0 Vaccine cov 2.0 
Under-5 mort 2.0 Int partner viol 1.6 
Neonatal mort 2.0 Water 1.8 
HIV incid N/A Sanitation 1.4 
Tuberculosis Incid 1.6 Hygiene 0.4 
Malaria incid 0.4 HH air poll 1.8 
Hep B incid 1.6 Occ burden 2.0 
NTD prev 2.0 Mean PM2.5 0.0 
NCD mort 1.8 Homicide 1.8 
Suicide mort 2.0 Conflict mort 0.8 
Alcohol use 2.0 Violence prev 2.0 
Road injury mort 2.0 Child sex abuse 0.6 
FP need met, mod 0.6 Cert death reg 0.4 
Adol birth rate 1.4 
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Section 2. Projecting HIV and ART coverage for the health-related SDGs 
Producing ART Coverage Caps 
In recent years, we have seen a massive scale up of ART treatment among low-income nations, who 
through large internal investments and substantial development assistance have been able to scale up 
ART access considerably. For that reason, if the past trends in ART coverage for each country are simply 
scaled up in projections using a logistic curve, all countries would be projected to achieve 100% coverage 
by 2040. Given limitations on coverage by health system capacity, and due to the cost of treatment, we 
bound ART projections with a frontier by income level to reflect resource availability. 
Cross-walking Cross-Sectional and Spectrum CD4 Definitions 
In order to model the relationship between income and ART coverage, we must also consider CD4 count 
as a major stratifying variable. As CD4 count defines eligibility for ART treatment in many locations, and 
individuals who are sicker (with lower ART counts) are more likely to have received a diagnosis and 
receive treatment, taking CD4 count into account is essential. Survey data provides cross-sectional CD4 
count information. However, the Spectrum modeling framework tracks individuals by categorical CD4 
count at the initiation of treatment, for individuals who are currently receiving ART. Therefore, in order to 
model the relationship between ART coverage and income in a CD4 specific fashion usable in Spectrum, 
we developed a method to crosswalk cross-sectional CD4 values to CD4 at treatment initiation, using 
information regarding the years each individual has been on treatment, and cohort information about the 
average CD4 progression pattern on treatment.  
We extracted information on the average CD4 progression over time after the initiation of ART treatment 
from a number of cohort studies (figure 1). We used a natural spline model to find the average 
Figure 1. Cohort data used to fit the CD4 count progression model 
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progression rate over time. Our outcome variable 𝑌𝑌𝑔𝑔,𝑡𝑡𝑡𝑡was the difference in the average CD4 count for a 
cohort I at time t from the value at the beginning of treatment, time s:  
𝑌𝑌𝑖𝑖,𝑡𝑡 = 𝐶𝐶𝐶𝐶4𝑖𝑖,𝑡𝑡 −  𝐶𝐶𝐶𝐶4𝑖𝑖,𝑡𝑡 
We model this change over time using the following model: 
𝑌𝑌𝑔𝑔,𝑡𝑡𝑡𝑡 = (𝑆𝑆1𝑇𝑇𝑤𝑤𝑇𝑇𝑤𝑤 ∗ 𝐶𝐶𝐶𝐶4𝑖𝑖,𝑡𝑡) + 𝑆𝑆2𝑇𝑇𝑤𝑤𝑇𝑇𝑤𝑤  
Where 𝑆𝑆2𝑇𝑇𝑤𝑤𝑇𝑇𝑤𝑤 is a natural spline on the number of months since treatment initiation, and (𝑆𝑆1𝑇𝑇𝑤𝑤𝑇𝑇𝑤𝑤 ∗
𝐶𝐶𝐶𝐶4𝑖𝑖,𝑡𝑡) is a natural spline on the number of months interacted with the starting average CD4 count of 
the cohort.  Both spline bases use knots at 3,12,24, and 36 months. The natural spline term captures the 
overall growth over time in CD4 count with ART treatment, while the interaction term captures the slow 
convergence effect that occurs over time as all individuals tend to stabilize at similar values regardless of 
starting CD4 counts.  Figure 2 shows the model fit, for each of the CD4 cutpoints used to define 
compartmental categories in the Spectrum modeling framework (0-49,50-99,100-199,200-249,250-349, 
350-500, and 500+) alongside the model input data.  
We then use the progression curves from this model to categorically backcast each individual observed in 
our cross-sectional survey data sources to one of the aforementioned categories (figure 3).  
Figure 2. Model fit for each categorical cutpoint used in the Spectrum modeling framework. 
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Modeling Coverage Frontier as a Function of Income and CD4 Count 
We identified two publically available survey datasets that provide person-level information regarding the 
distribution of ART coverage by CD4 count. We used data from the 2011 Uganda and 2012 Kenya Aids 
Indicator Surveys, subsetting the analysis to only individuals who were determined to be HIV positive 
from laboratory tests. ART coverage is defined as a binary variable, representing if the surveyed individual 
was currently taking ART medication at the time of the survey. CD4 information for each participant was 
obtained from laboratory test values, and crosswalked to the Spectrum definition as described in the 
previous section. As a proxy for income, we used a household asset index based on assets present in the 
respondent’s home. This asset-based index is converted to international dollars income (cite Nick’s work). 
A logistic curve describing the relationship between ART coverage probability and income is then fit, 
controlling for CD4 count, age and sex, using a logistic regression: 
𝑃𝑃𝑐𝑐𝑐𝑐𝑐𝑐𝑦𝑦𝑦𝑦𝑦𝑦𝑔𝑔𝑦𝑦 = 𝛽𝛽1𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑇𝑇𝑤𝑤 + 𝛽𝛽2𝐶𝐶𝐶𝐶4 +  𝛽𝛽3𝐴𝐴𝑤𝑤𝑤𝑤 + 𝛽𝛽4𝐹𝐹𝑤𝑤𝑇𝑇𝑦𝑦𝐹𝐹𝑤𝑤 
The predicted probabilities from this model are the used to fit a stochastic frontier analysis, which 
estimates the maximum possible coverage for a given degree of income and CD4 count. The probability of 
coverage values from the first model are logit transformed to ensure the final frontier predictions cannot 
exceed one. An offset is added to each value to bring each logit-transformed value above zero, and then 
the values are logged for the stochastic frontier analysis. Formally, we estimate: log (𝐹𝐹𝐼𝐼𝑤𝑤𝑤𝑤𝑡𝑡�𝑃𝑃𝑐𝑐𝑐𝑐𝑐𝑐𝑦𝑦𝑦𝑦𝑦𝑦𝑔𝑔𝑦𝑦� + 𝐼𝐼𝑜𝑜𝑜𝑜𝑜𝑜𝑤𝑤𝑡𝑡) = 𝛽𝛽1𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑇𝑇𝑤𝑤 + 𝛽𝛽2𝐶𝐶𝐶𝐶4 
Figure 3. Categorical backcast of survey microdata using modelled progression curves.  
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The stochastic frontier analysis assumes that inefficiencies are distributed according to a truncated 
normal distribution. Figure 4 shows the predicted probabilities and model fit for each CD4 group from the 
stochastic frontier analysis, after the frontiers have been transformed back to probability space using the 
reverse of the aforementioned transformation.  
ART Price Projects 
Projecting ART Prices 
In order to project ART coverage, an understanding of the cost of ART treatment over time is necessary. 
We created estimates and projections of the average cost of ART treatment using data from the Global 
Price Reporting Mechanism (GPRM)1. From the GPRM we obtained 1,175 country-years of data 
representing the average cost of ART in dollars per person per year, covering 130 countries and spanning 
2004-2016.  We used a stochastic frontier analysis and Gaussian process regression modelling framework 
to complete the timeseries and project the estimates through 2040 
Stochastic Frontier Analysis 
In order to bound the future minimum cost plausibly, we use a stochastic frontier analysis to model the 
minimum ART price possible over time. In this case, the secular trend should be viewed as representing 
the inherent decrease in cost of ART with improved technology. First we create our outcome variable by 
transforming cost, by rescaling to an inverse zero to one scale, where 0 is the lowest observed cost and 1 
is the highest. This is necessary as the stochastic frontier analysis function is used to find a maximum 
value, and therefore the outcome must be rescaled to find a minimum cost frontier. We then take the 
logit of this transformed cost variable, which creates our outcome variable: 
𝑌𝑌𝑐𝑐,𝑡𝑡 = 𝐹𝐹𝐼𝐼𝑤𝑤𝑤𝑤𝑡𝑡 �𝐶𝐶𝐼𝐼𝑜𝑜𝑡𝑡𝑖𝑖,𝑡𝑡 −  min (𝐶𝐶𝐼𝐼𝑜𝑜𝑡𝑡𝑖𝑖,𝑡𝑡)𝑦𝑦𝑦𝑦𝐼𝐼𝑤𝑤𝑤𝑤(𝐶𝐶𝐼𝐼𝑜𝑜𝑡𝑡𝑖𝑖,𝑡𝑡) + 𝐼𝐼𝑜𝑜𝑜𝑜𝑜𝑜𝑤𝑤𝑡𝑡� 
Figure 4. Predicted probabilities of coverage for each individual shown as points. Frontier of coverage as a function of 
income shown with lines. Color indicates categorical CD4 count. 
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We use an offset value of .000001 to prevent true zero values, which cannot be logit transformed. We 
then fit a stochastic frontier analysis, with time as the independent variable, assuming a truncated normal 
distribution for the inefficiencies: 
𝑌𝑌𝑐𝑐,𝑡𝑡 =  𝛽𝛽1𝑌𝑌𝑤𝑤𝑦𝑦𝑦𝑦 
Figure 5. illustrates the transformation used to create the outcome variable, as well as the stochastic 
frontier analysis fit.  
Gaussian Process Regression 
We used Gaussian process regression (GPR) to complete the timeseries and make projections through the 
year 2040, ensuring that the estimates fit the data well. GPR has been used extensively in the Global 
Burden of Disease estimation framework as a data synthesis tool 2,3. GPR uses a covariance function to 
smooth the residuals from a linear model prior. GPR also synthesizes both data and model uncertainty, in 
order to produce estimate uncertainty intervals. GPR assumes that the trend in the underlying data 
Figure 5. Illustrations of the transformed cost of ART prices, and the frontier model fit and final estimates. 
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follows a Gaussian process, which is defined using a mean function 𝑇𝑇(∙) and a covariance function 𝐶𝐶𝐼𝐼𝐶𝐶(∙). The mean function is a linear model which models the log of the difference between the cost frontier 
and the current cost, as a function of lag-distributed GDP per capita (LDI) 4 and super-region secular 
trends: log�𝐶𝐶𝐼𝐼𝑜𝑜𝑡𝑡𝑐𝑐,𝑡𝑡 − 𝑜𝑜𝑦𝑦𝐼𝐼𝐼𝐼𝑡𝑡𝑤𝑤𝑤𝑤𝑦𝑦𝑡𝑡� = 𝛽𝛽1𝐿𝐿𝐶𝐶𝐼𝐼 + 𝛽𝛽𝑦𝑦𝑌𝑌𝑤𝑤𝑦𝑦𝑦𝑦 
Consistent with prior implementations of GPR, A matern covariance function was used to smooth the 
residuals from the first stage mean function, and produce complete time series with uncertainty3. Figure 
6 shows the median and IQR of ART cost globally, as well as the cost frontier.  
Projecting Scenarios of Exogenous Inputs 
A number of inputs to the ART projecting, incidence hazard projecting, and Spectrum HIV modeling 
systems are treated as exogenous inputs. Projection scenarios for these inputs were created using a rate 
of change approach, consistent with that used across the projecting platform. These inputs include: 
• ART Price
• Lag Distributed GDP per capita
• HIV-specific development assistance for health
• Government Health Expenditure per capita
• Child ART coverage
• Cotrimoxazole coverage among children
Figure 6. Median and IQR of ART price over time globally, alongside the cost frontier as a dashed line. All series are shown in USD. 
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• Coverage of medication used to prevent mother-to-child transmission of HIV (PMTCT) prenatally
and postnatally
For each indicator, the distribution of the rate of change across countries was calculated. The timeseries 
in each indicator was projected for three scenarios. The ‘reference’ scenario assumed each country grows 
in the future at the 50th percentile of the rate of change across countries, the ‘worse’ scenario assumes 
growth at the 15th percentile, and the ‘better’ scenario assumed growth at the 85th percentile. For ART 
price, the ‘better’ and ‘worse’ scenarios are flipped, since decreases in price should be considered ‘better’ 
for health outcomes. Therefore, the ‘better’ scenario uses the 15th percentile of the rate of change and 
the ‘worse’ scenario uses the 85th.  
Some of the series had previously existing ‘reference’ projections, such as ART price (described above), or 
LDI (published separately). For these indicators, the projections for each scenario were scaled so that the 
original ‘reference’ scenario projections were used, and the ‘better’ and ‘worse’ projections fall on either 
side of the ‘reference.’ This was accomplished by simply calculating a single country-specific scaling factor 
for each year from 2016 through 2040 to adjust the rate of change based ‘reference’ scenario to be 
identical to the previously existing ‘reference’ scenario, and using this factor for all 3 scenarios. Inputs 
that represent a coverage indicator, including PMTCT, Cotrimoxazole, and ART, were projected in logit 
space, while the remaining indicators were modeled in log space. Figure 7 shows an example of projected 
exogenous inputs for Zambia.  
Figure 7. Scenarios of exogenous input projections for Zambia 
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Projecting ART Coverage 
ART coverage is projected using the ART caps described above, as well as the HIV-specific development 
assistance for health (DAH) and Government Health Expenditure per capita (GHES) exogenous inputs, 
which are projected as described in the previous section. In order to account for the changing costs of 
ART over time, the DAH and GHES covariates are rescaled to “dose equivalents,” by dividing by ART cost. 
The relationship between country-year specific ART coverage is then modelled with a slope on dose-
equivalents of GHES, a slope on dose-equivalents of DAH (using an indicator variable to remove the 
countries that are never recipients of DAH), and fixed intercepts for each CD4 group.  
𝐹𝐹𝐼𝐼𝑤𝑤𝑤𝑤𝑡𝑡(𝐴𝐴𝐴𝐴𝑇𝑇𝑐𝑐,𝑡𝑡) = 𝛽𝛽1𝐺𝐺𝐺𝐺𝐺𝐺𝑆𝑆𝐺𝐺𝐼𝐼𝑜𝑜𝑤𝑤𝑜𝑜 + (𝛽𝛽2𝐶𝐶𝐴𝐴𝐺𝐺𝐺𝐺𝐼𝐼𝑜𝑜𝑤𝑤𝑜𝑜 ∗ 𝐼𝐼𝐷𝐷𝐷𝐷𝐷𝐷𝑦𝑦𝑦𝑦𝑐𝑐𝑖𝑖𝐷𝐷𝑖𝑖𝑦𝑦𝐷𝐷𝑡𝑡) + (𝛽𝛽3𝐶𝐶𝐶𝐶40−49 ∗ 𝐼𝐼0−49) … (𝛽𝛽9𝐶𝐶𝐶𝐶4500+ ∗ 𝐼𝐼500+) 
Projected ART values are capped using the frontiers estimated as described above, or the largest value 
observed in the past for the timeseries in question, whichever is larger. Scenarios of ART coverage are 
created by using scenario specific ART caps, as well as scenario specific DAH, GHES, and ART price series. 
ART caps are estimated as a function of income, and we use scenarios of LDI as a proxy for income at the 
national level. DAH, GHES, LDI, and ART price scenarios are created as detailed in the previous section. 
We then project ART coverage at the granularity it is used in Spectrum, specific to single-year age and sex 
groups, as well as draws used in Spectrum to propagate uncertainty: 
𝐹𝐹𝐼𝐼𝑤𝑤𝑤𝑤𝑡𝑡(𝐴𝐴𝐴𝐴𝑇𝑇𝑐𝑐,𝑦𝑦,𝑡𝑡,𝑡𝑡,𝑑𝑑 = 𝛽𝛽1𝐺𝐺𝐺𝐺𝐺𝐺𝑆𝑆𝐺𝐺𝐼𝐼𝑜𝑜𝑤𝑤𝑜𝑜 + (𝛽𝛽2𝐶𝐶𝐴𝐴𝐺𝐺𝐺𝐺𝐼𝐼𝑜𝑜𝑤𝑤𝑜𝑜 ∗ 𝐼𝐼𝐷𝐷𝐷𝐷𝐷𝐷𝑦𝑦𝑦𝑦𝑐𝑐𝑖𝑖𝐷𝐷𝑖𝑖𝑦𝑦𝐷𝐷𝑡𝑡) +  (𝛽𝛽3𝐶𝐶𝐶𝐶40−49 ∗
𝐼𝐼0−49) … (𝛽𝛽9𝐶𝐶𝐶𝐶4500+ ∗ 𝐼𝐼500+) +  ∅𝑐𝑐,𝑦𝑦,𝑡𝑡,𝑡𝑡,𝑑𝑑 
where ∅𝑐𝑐,𝑦𝑦,𝑡𝑡,𝑡𝑡,𝑑𝑑is a country-year-age-sex-draw specific intercept shift term, used to ensure no disjunctions 
in the first year of the projects by removing the difference from year 2015 to year 2016 from all projected 
estimates for each timeseries. The intercept shift term also preserves draw-level uncertainty from past 
ART coverage estimates from the GBD.  
Project Incidence Hazard 
Incidence hazard is a key input to the Spectrum modeling process, which is projected using ART 
projections, as well as a rate of change approach, similar to those described above, with respect to the 
trend in the counterfactual incidence hazard. First the hazard counterfactual is calculated as: 
𝐺𝐺𝑦𝑦𝐻𝐻𝑦𝑦𝑦𝑦𝐺𝐺 𝐶𝐶𝐼𝐼𝐶𝐶𝐼𝐼𝑡𝑡𝑤𝑤𝑦𝑦𝑜𝑜𝑦𝑦𝐼𝐼𝑡𝑡𝐶𝐶𝑦𝑦𝐹𝐹𝑐𝑐,𝑦𝑦,𝑡𝑡,𝑡𝑡,𝑖𝑖 = 𝐺𝐺𝑦𝑦𝐻𝐻𝑦𝑦𝑦𝑦𝐺𝐺𝑐𝑐,𝑦𝑦,𝑡𝑡,𝑡𝑡,𝑖𝑖1 − (𝐴𝐴𝐴𝐴𝑇𝑇𝑐𝑐,𝑦𝑦,𝑡𝑡,𝑡𝑡,𝑖𝑖  ∗  𝑉𝑉𝑤𝑤𝑦𝑦𝑦𝑦𝐹𝐹 𝑆𝑆𝐶𝐶𝑆𝑆𝑆𝑆𝑦𝑦𝑤𝑤𝑜𝑜𝑜𝑜𝑤𝑤𝐼𝐼𝐼𝐼𝑐𝑐,𝑦𝑦,𝑡𝑡,𝑡𝑡,𝑖𝑖  )
Where: ART is the proportion of HIV+ individuals receiving ART, hazard is the number of new HIV 
infections over population at risk, hazard counterfactual is the estimated hazard if ART coverage were 
zero and viral Suppression is the proportion of individuals taking ART who achieve viral suppression, 
which is assumed to be uniformly distributed with a mean of 70%: 
𝑉𝑉𝑤𝑤𝑦𝑦𝑦𝑦𝐹𝐹 𝑆𝑆𝐶𝐶𝑆𝑆𝑆𝑆𝑦𝑦𝑤𝑤𝑜𝑜𝑜𝑜𝑤𝑤𝐼𝐼𝐼𝐼 ~ 𝑈𝑈(.6, .8) 
Consistent with the approach taken to project the independent drivers, projections scenarios for the 
secular trend in the counterfactual hazard are created by calculating the rate of change across 
countries in the past, and applying the 15th,50th,and 85th percentile to each country to create the 
‘worse,’ ‘reference,’ and ‘better’ scenarios respectively. The final projected hazard rates therefore 
decreases in response to improvements in ART coverage, as well as change due to the underlying 
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secular trend in the counterfactual hazard. Scenarios of ART coverage and the secular trend are both 
reflected in the final incidence hazard scenarios.  
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Part 4. Online tools and abbreviations 
Part 1. Online tools 
Further results are presented as dynamic visualizations at https://vizhub.healthdata.org/sdg/ 
GBD data sources are available at http://ghdx.healthdata.org/gbd-data-tool 
Part 2. List of abbreviations 
Adol: adolescent 
Air poll mort: mortality attributable to air pollution 
ANC: Antenatal care 
ART: antiretroviral therapy 
DAH: development assistance for health 
DALY: disability-adjusted life-year 
DHS: Demographic and Health Survey 
DPT: diphtheria-pertussis-tetanus 
GATHER: Guidelines for Accurate and Transparent Health Estimates Reporting 
GBD: Global Burden of Diseases, Injuries, and Risk Factors Study 
GPRM: Global Price Reporting Mechanism  
HAQ: Healthcare Access and Quality 
HH air poll: household air pollution 
Hib: Haemophilus influenzae type B 
IAEG-SDGs: Inter-Agency and Expert Group on Sustainable Development Goal Indicators 
IHR: International Health Regulations 
IOTF: International Obesity Task Force 
ISIC: International Standard Industrial Classification 
JMP: Joint Monitoring Programme 
MDG: Millennium Development Goal 
MMR: maternal mortality ratio 
Mort: mortality 
NCDs: non-communicable diseases 
NTDs: neglected tropical diseases 
OECD: Organisation for Economic Co-operation and Development 
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Occ burden: disease burden attributable to occupational risks 
ODA: Official development assistance 
PCV3: Three-dose pneumococcal conjugate vaccine 
PM2.5: particulate matter <2.5μm in diameter 
SBA: skilled birth attendance 
SD: standard deviation 
SDG: Sustainable Development Goal 
SDI: Socio-demographic Index 
SDSN: Sustainable Development Solutions Network 
SEV: summary exposure value 
TB: tuberculosis 
TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights 
UHC: universal health coverage 
UIs: uncertainty intervals 
UN: United Nations 
UNICEF: United Nations Children’s Fund 
VR: vital registration 
WaSH: water, sanitation, and hygiene 


































































































































































































































































































































































Methods Appendix Figure 1. Comparison of health−related SDG index values using the arithmetic 
 mean of targets versus the geometric mean, by country, 2016. The black line shows the equivalence 
 line, such that values that fall on this line are the same for each construction of the health−related 
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Methods Appendix Figure 2. Comparison of health−related SDG index ranks using the arithmetic 
 mean of targets versus the geometric mean, by country, 2016. The black line shows the 
 equivalence line, such that values that fall on this line are the same for each construction of the 
 health−related SDG index. Countries are abbreviated according to the ISO3 code. 



















































































































































































































































































































Methods Appendix Figure 3. Comparison of health−related SDG index values using geometric 
 mean of the minimums across each target versus the standard geometric mean, by country, 2016. 
 The black line shows the equivalence line, such that values that fall on this line are the same 
 for each construction of the health−related SDG index. Countries are abbreviated according 
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Methods Appendix Figure 4. Comparison of health−related SDG index ranks using geometric mean 
 of the minimums across each target versus the standard geometric mean, by country, 2016. 
 The black line shows the equivalence line, such that values that fall on this line are the same for 
 each construction of the health−related SDG index. Countries are abbreviated according to 

































































































































































































































































Methods Appendix Figure 5. Comparing the absolute change in the health-related SDG index from 2016 to 2030 using the geometric versus arithmetic mean
4 341
